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1.	Summary	
	
The maintenance of correct chromosome number (euploidy) during cell 
division is essential for health. Loss of euploidy is observed in most cancers and is 
linked to tumorigenesis. During mitosis, a highly conserved surveillance 
mechanism termed ‚spindle assembly checkpoint’ safeguards correct chromosome 
segregation by delaying anaphase onset until all chromosomes are properly bi-
oriented on the spindle apparatus. The kinase Bub1 functions in the spindle 
assembly checkpoint and in chromosome congression, but the impact of its 
catalytic activity on these function remains controversial. 
Here we present a thorough characterization of two novel small-molecule 
ATP-competitive inhibitors of Bub1 kinase, BAY-320 and BAY-524, to demonstrate 
potent Bub1 kinase inhibition both in vitro and in intact cells. We compared the 
cellular phenotypes of Bub1 kinase inhibition in HeLa and RPE-1 cells with those 
of protein depletion, indicative of catalytic or scaffolding functions, respectively. 
We demonstrate that Bub1 inhibition resulted in the persistence of chromosome 
arm cohesion. Furthermore, Bub1 inhibition affected chromosome association of 
Shugoshin and the chromosomal passenger complex, without abolishing global 
Aurora B function. Bub1 cooperates with Haspin on CPC localization, as inhibition 
of both kinases showed an additive effect. But for all that, Bub1 kinase inhibition 
exerted only minor effects on mitotic progression, chromosome alignment or 
spindle checkpoint function. In striking contrast, Bub1 depletion impaired all the 
mentioned mitotic processes, arguing that Bub1 largely operates as a scaffolding 
protein. 
Although, Bub1 inhibition seems to have little influence in mitotic fidelity, 
BAY-320 and BAY-524 treatment sensitized cells to low doses of Paclitaxel, 
resulting in remarkable impairment of chromosome segregation and cell 
proliferation.  
These findings are relevant to our understanding of Bub1 kinase function 
and the prospects of targeting Bub1 for therapeutic applications. 
 
 	 4	
  
 	 5	
 
 
 
 
 
 
 
 
2. Introduction 
 
 
  
2. Introduction 
	 6	
Cancer is characterized by an alteration in the strict regulation of cell 
division. Cancer cells reproduce at a much higher rate than their normal 
counterparts.  A deregulated cell cycle results in the failure to repair DNA damage 
before the cell progresses to mitosis or in the failure to segregate chromosomes 
faithfully. Furthermore these cells do not respond correctly to internal and 
external signals that regulate cell cycle progression.  
So far, the most effective cancer treatment strategies aim at the induction of 
aberrant mitoses leading to a controlled cell death of highly proliferative cancer 
cells. These treatments very often have deleterious side effects. 
Protein phosphorylation controls many aspects of cell cycle regulation or 
more precisely cell division. The specific inhibition of mitotic protein kinases 
marks a new attempt to tackle aberrant cell division. Thus, the development of 
specific small molecule inhibitors along with the further understanding of the 
complex regulation processes involved in cell division mark new opportunities to 
improve cancer therapies. 
 
 
2.1 The Cell Cycle 
 
Cells have the remarkable attribute to create copies of themselves, defining 
them as the smallest and simplest form of solitary life, like unicellular bacteria and 
yeasts. Multi-cellular organisms arise from one single founder cell. Countless 
complex sequences of cell divisions transform that single cell into diverse 
communities of cells, which form the various tissues and organs that comprise a 
fully developed and functional individual. The cell cycle is a highly regulated and 
coordinated process that consists of a series of events that take place in a cell, 
which eventually lead to its duplication and division into two equal daughter 
cells. 
In 2001, the identification of key molecules, which coordinate the cell cycle in 
all eukaryotic organisms, was awarded with the Noble Prize in Physiology or 
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Medicine to Leland Hartwell, Tim Hunt and Paul Nurse. The three scientists 
together have enabled an understanding at the molecular level of how the cell is 
driven from one phase to the next during division (Nasmyth, 2001). 
To produce two identical daughter cells, the DNA of each chromosome must 
be faithfully replicated and then carefully segregated into the two daughter cells. 
Ergo, each daughter cell contains the entire genome. In addition, cells also 
duplicate their macromolecules and organelles by simply dividing them and 
therefore grow in order to keep their original cell size after division. Hence, cells 
need to coordinate their growth and division. In eukaryotes this process is 
organized into four sequential stages: G1 (gap phase 1), S (synthesis phase) and G2 
(gap phase 2) that comprise together interphase and M (mitotic) phase consisting 
of mitosis and cytokinesis. During interphase, the cell continues to grow, 
accumulates nutrients, replicates its DNA and prepares for its division. The 
genetic material is replicated during S (synthesis) phase, resulting in duplicated 
chromosomes, called sister chromatids that must be equally segregated. DNA is 
allowed to duplicate once and only once per cell cycle. Additional time to grow is 
provided by the gap phases, G1 and G2. Here, the cell can decide whether the 
environmental conditions are suitable for propagation. G1 corresponds to the 
interval between mitosis and DNA replication, in which the cell is metabolically 
active and continuously grows. In G2, DNA replication is completed and the cell 
continues to grow and to synthesize proteins needed for mitosis. If the 
environment is unfavorable the cell may extend the time spend in G1 or enter a 
quiescent state, called G0. The cell does not proliferate unless appropriate 
extracellular signals trigger this process. Most proteins, RNAs, macromolecules 
even organelles are synthesized throughout interphase and their high-copy 
numbers allow their simple distribution, respectively their fragmentation 
(Morgan, 2007).  During M phase the cell segregates its genome and cytoplasmic 
content equally on to two daughter cells with cytokinesis as a final step. M phase 
is usually a very brief period in the cell cycle compared to interphase, which can 
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take up to 90-95 % of the cycle time (Cooper and Hausman, 2013). The protein 
machinery that governs the precise execution of cell cycle events is under strict 
control of a regulatory network. This system acts as a timer programming the 
molecular events in the right order and for the time until a preceding event is 
completed. Hence, all cell cycle events are ordered and directional, meaning it is 
impossible to reverse the cycle. The regulatory drivers of the cell cycle are cyclins 
and cyclin-dependent kinases (Cdks) (Figure 1). Cyclins are the regulatory or 
activating subunits of Cdks and once a cyclin/Cdk complex is activated, it 
phosphorylates target proteins and thereby changes their enzymatic activity, their 
location or their interaction with other proteins. Cdks are constitutively expressed 
whereas cyclin levels oscillate in a cyclical fashion throughout the cell cycle. Their 
expression is triggered by transcription and proteasome-dependent degradation in 
response to external and internal molecular signals, so that different cyclin/Cdk 
pairings are active at specific points. (Morgan, 2007; Lodish et al., 2012; Alberts et 
al., 2014). 
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Figure 1: Cyclin-Cdk complexes play a central role in cell cycle progression. The 
function of cyclin-Cdks is to run the cell cycle smoothly, and these are therefore called 
“cell cycle engines.” Cyclins are proteins that vary in quantity throughout the cell cycle. 
Each cyclin is rapidly synthesized during a specific phase of the cell cycle and is again 
promptly degraded down after it serves its purpose. Inactivation, activation of cyclin-
Cdk1 complexes allows the transition from one cell cycle phase to the other. Adapted 
from (CSLS, The University of Tokyo, 2011).  
 
 
Specifically, there are several types of G1/S-phase cyclins and G1/S-phase 
Cdks. Cyclin D-Cdk4/6 complex and the cyclin E-Cdk2 complex are representative 
examples of G1/S-phase cyclin-Cdk complexes, which function at the start of the S 
phase. G2/M-phase cyclin and G2/M-phase Cdk (cyclin B-Cdk1 complex) function 
at the start of M phase and induce nuclear membrane breakdown and 
chromosome formation when activated. 
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2.1.1 Mitosis 
 
“Where a cell arises, there must be a previous cell, 
just as animals can only arise from animals and plants from plants” 
Rudolf Virchow, 1858 
 
Mitosis is usually referred to as the last stage of the mammalian cell cycle 
and also visually the most spectacular. In 1882, Walter Flemming was the first 
cytologist to describe chromosome behavior and their distribution during the cell 
cycle (Paweletz, 2001). A process he called mitosis, according to the Greek word for 
‘thread’. Surprisingly, already back then the process of cell division could be 
described in great detail and has since then been a source of great fascination.  
Mitosis encompasses the time in which sister chromatids are segregated 
equally on to two daughter cells. Regarding the regulation of mitosis by the 
oscillation of cyclin levels, mitosis can be divided in two major parts. During 
mitotic entry an abrupt increase in Cdk activity triggers the phosphorylation of a 
variety of proteins leading to the assembly of the mitotic spindle, the priming of 
the chromatin to sister chromatid pairs and their attachment to the mitotic spindle. 
In the second half of mitosis, Cdk activity decreases thereby initiating the 
separation of sister chromatids, the subsequent division into two daughter cells 
and hence exit from mitosis (Morgan, 2007).  
 
 
2. Introduction 
	11	
 
 
 
Figure 2: Events of mitosis. Depicted are the six morphologically distinct mitotic phases: 
Prophase, Prometaphase, Metaphase, Anaphase and Telophase. Mitosis is followed by 
cytokinesis. Adapted from (Morgan, 2007). 
 
 
The process of mammalian nuclear division is further split into six distinct 
phases that can be distinguished based on cell morphology (Figure 2) (Pines and 
Rieder, 2001; Scholey et al., 2003). During ‘prophase’, the replicated interphase 
chromatin condenses into chromosomes, each comprising two sister chromatids 
held together by a ring-like centromeric protein complex, called cohesin. The 
centrosomes (main microtubule organizing centers, MTOCs), which have been 
duplicated during S phase, begin to separate and move towards the opposite ends 
of the cell and start to nucleate highly dynamic microtubules (MTs) to initiate 
mitotic spindle assembly. Nuclear envelope breakdown (NEBD) signals the 
beginning of ‘prometaphase’. The biopolar spindle forms, and MTs are now able 
to invade nuclear space and make contact with chromosomes. Moreover, a 
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specialized proteinaceous structure situated on both sister chromatids, called 
kinetochore (KT), assembles adjacent to the centromeric region (Cheeseman and 
Desai, 2008). During a highly dynamic and stochastic process KTs are captured by 
MTs emanating from opposing spindle poles and serve as anchors. When all 
chromosomes have become stably attached by a biopolar attachment between KTs 
and MTs, they begin to congress at the center of the cell. ‘Metaphase’ is the state 
when all chromatids are bipolar attached and aligned at the cell equator, the so-
called metaphase plate (Walczak et al., 2010). The cells await the signal to separate. 
After a brief delay, during which the connection between sister-chromatids is 
resolved, ‘anaphase’ is initiated. Here, sister chromatids are pulled apart towards 
opposite spindle poles by the shortening of kinetochore MTs. Separation is further 
accelerated as the poles move further apart from each other towards the cell 
cortex. During ‘telophase’ the spindle disassembles and a new nuclear envelope 
reassembles around each set of decondensing chromatids, completing the 
formation of two daughter nuclei.  The cleavage furrow begins to ingress, 
constricting the spindle midzone. Cell division is completed as cytokinesis occurs 
(Barr and Gruneberg, 2007). The central spindle compresses to form a compact 
midbody and contraction of an actin-myosin II-based ring-like structure beneath 
the plasma membrane leads to furrow ingression. Finally abscission takes place 
resulting in the formation of two new genetically identical daughter cells (Pines 
and Rieder, 2001; Lodish et al., 2012; Cooper and Hausman, 2013; Alberts et al., 
2014).  
 
 
2.1.2 Cell Cycle Checkpoints 
 
“Normal cells obey strict rules. Divide only when told. Die rather than misbehave.” 
Dr. Andrew Murray, 2005 
Director of the Center of Genomic Research 
Havard University 
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The ultimate goal of the cell cycle is to produce duplicates of each cell’s DNA 
and to divide the cell and its content evenly between the two resulting daughter 
cells. Successful progression through the cell cycle requires control mechanisms. A 
tight network, including three major regulatory transitions or checkpoints, 
controls this cycle. These checkpoints function as molecular brakes to block 
progression, giving ‘STOP and GO’ signals, namely the G1/S- or restriction-point, 
the G2/M- or DNA damage checkpoint and the spindle assembly checkpoint (SAC) 
at the metaphase-to-anaphase transition. Accordingly, the control system monitors 
and dictates progression through the cycle. The next step is not triggered unless 
the cell is prepared and has met the needed requirements (Hartwell and Weinert, 
1989; Alberts et al., 2014). These checkpoints respond to feedback loops and 
information received from the processes they control.  Thus, they are able to sense 
defects that occur during essential processes like DNA replication. It is monitored 
if the environment is suitable and whether all cell cycle stages occur in the 
appropriate order. If a defect or a delay is sensed, a cell cycle arrest is induced and 
the cell gets more time to repair or to meet the needed prerequisites, respectively 
(Malumbres and Barbacid, 2009). To achieve this, eukaryotic cells have evolved 
molecular control mechanisms, involving post-translational modification and 
targeted degradation. The master regulator of the cell cycle control system is a 
family of kinases known as Cdks. They are associated with their regulatory 
subunits, cyclins. Different complexes are formed and activated at different stages 
of the cell cycle. Their activity oscillates during the cell cycle and cyclin levels are 
regulated by transcription and proteasome-dependent degradation throughout 
the cell cycle, so that different cyclin/Cdk pairings are active at specific points 
(Vermeulen et al., 2003). The activity of cyclin/Cdk complexes is most often 
deregulated in cancers, due to genetic or epigenetic changes in Cdks, their 
regulators or upstream mitogenic pathways (Vermeulen et al., 2003; Malumbres 
and Barbacid, 2009). 
The first checkpoint is located at the end of G1 phase, just before entry into S 
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phase (restriction point). During progression through G1 the cell senses internal 
and external conditions and decides whether it should divide, delay division, or 
enter a resting stage (G0). If the checkpoint is passed the cell is committed to a new 
round of the cell cycle and the cell activates cyclin/Cdk-dependent transcription 
which promotes entry into S phase (Bertoli et al., 2013). After the decision has been 
made to progress past the restriction point, cyclin D levels rise and form a 
complex with Cdk4 and Cdk6. Phosphorylation of target proteins and the 
transcriptional activation of downstream targets eventually activates cyclin 
E/Cdk2 that promote the G1/S transition eventually. The cyclin E/Cdk2 complex 
promotes an ‘all or nothing’ switch from which the cell cannot return (Skotheim et 
al., 2008). During S phase, DNA is being replicated and in G2 the cell undergoes 
rapid growth and gets prepared for mitosis. At the G2/M or DNA damage 
checkpoint, the cell ensures that all necessary prerequisites for cell division have 
been met and eventually triggers the G2-to-M phase transition. 
The G2/M transition is mediated by the activation of the cyclin B/Cdk1 
complex. Cyclin B/Cdk1 activity depends on the dephosphorylation of two 
residues in the ATP-binding site of Cdk1 (Thr 15 and Tyr 15) by the phosphatase 
Cdc25 that overcomes the inhibitory phosphorylation by the two kinases Wee1 
and Myt1 (Nigg, 2001; Donzelli and Draetta, 2003; Perdiguero and Nebreda, 2004).  
The activated cyclin B/Cdk1 complex as well as rising cyclin B levels guide the cell 
subsequently towards the entry of mitosis. 
The third checkpoint, called SAC, present at the metaphase-to-anaphase 
transition, monitors proper chromosome segregation. During mitosis sister 
chromatid cohesion must be maintained until all chromosomes are correctly 
aligned at the cell equator. Only then chromosome segregation can be initiated. 
Defects may provoke unequal inheritance of the genetic information that may 
facilitate tumor progression by accumulating numerical chromosomal aberrations 
(CIN). The SAC is dependent on cyclin B activity and Securin, an inhibitor of 
Separase, which is responsible for cleaving sister-chromatid cohesion prior to 
2. Introduction 
	15	
segregation (Musacchio and Salmon, 2007). 
The SAC and its regulation will be discussed in detail in the following 
chapter (2.2 The Spindle Assembly Checkpoint). 
 
 
2.2 The Spindle Assembly Checkpoint 
 
In 1991, two parallel screens in Saccharomyces cerevisiae first discovered the 
SAC and several of its signaling components (Hoyt et al., 1991; Li and Murray, 
1991). The key components were the MAD (mitotic-arrest deficient) genes for 
Mad1, Mad2 and Mad3 and the BUB (budding uninhibited by benzimidazole) 
genes for Bub1 and Bub3. If mutated, cells bypassed the ability to arrest in mitosis 
in response to spindle poisons. Later these genes were found to be conserved in 
eukaryotes (Musacchio and Salmon, 2007). With the exact mechanism being 
unknown at first, laser ablation and micromanipulation experiments 
demonstrated that a mitotic delay is mediated by an inhibitory signal capable of 
being generated by single unattached KT (Rieder et al., 1995; Li and Nicklas, 1995). 
Since then, the SAC has been identified as a surveillance mechanisms that delays 
anaphase onset until correct bipolar attachment of chromosomes to MTs 
emanating from opposing spindle poles has been achieved (Lara-Gonzalez and 
Taylor, 2012; Musacchio and Salmon, 2007; Vleugel et al., 2012). The KT represents 
the catalytic platform to generate the SAC signal. Thus most checkpoint proteins 
are highly enriched at unattached KTs to generate the ‘wait’ signal but are absent 
from properly attached KTs (Li and Nicklas, 1995; Musacchio and Hardwick, 2002; 
Cleveland et al., 2003; Pinsky and Biggins, 2005; Musacchio and Salmon, 2007). 
Cells, which have an altered or artificially inactivated checkpoint, undergo 
precocious mitotic exit in the presence of unattached or incorrectly attached 
chromosomes and are therefore prone to missegregation events. These errors can 
lead to aneuploidy (abnormal number of chromosomes) or genetic instability, 
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which are a hallmark of cancer (Weaver and Cleveland, 2006; Kolodner et al., 
2011).  
The downstream target of the SAC is the anaphase promoting 
complex/cyclosome (APC/C), an E3 ubiquitin ligase that targets proteins for 
proteolytic degradation (Chang and Barford, 2014; Pines, 2011). Activation of the 
APC/C is governed by its co-factor Cdc20. Active APC/CCdc20 triggers exit from 
mitosis and sister-chromatid segregation via degradation of Cyclin B and Securin, 
(Peters, 1999).  Cyclin B degradation inactivates Cdk1, the master mitotic kinase. 
Securin is a stoichiometric inhibitory binding partner of Separase, a cystein 
protease that cleaves cohesin complexes (Pines, 2006). The SAC itself catalyzes the 
formation of an inhibitory complex that prevents Cdc20 from activating the 
APC/C, thereby stabilizing Cyclin B and Securin and blocking the transition from 
meta- to anaphase (Lara-Gonzalez et al., 2012). 
 
 
2.2.1 Molecular basis of the mitotic checkpoint  
 
The SAC includes the core proteins Mad1, Mad2, Bub1, Bub1, BubR1 (human 
ortholog of yeast Mad3), Mps1, Aurora B (Lara-Gonzalez et al., 2012; Musacchio 
and Salmon, 2007), however the KT itself is comprised by more than 80 different 
proteins (Cheeseman and Desai, 2008; Santaguida and Musacchio, 2009). It is 
widely known that Bub1 is localizing to unattached KTs in early prophase and is 
there required to recruit the majority of downstream SAC effectors, including 
Mad1, Mad2, Bub3 and BubR1 (Meraldi et al., 2004; Perera et al., 2007; Johnson et 
al., 2004; Sharp-Baker and Chen, 2001). At the unattached KT the molecular 
inhibitor of the APC/C is formed, the so-called mitotic checkpoint complex (MCC) 
that is needed for the sequestration of Cdc20 and consists of BubR1, Bub3, Mad2 
and Cdc20 (Chao et al., 2012; Kulukian et al., 2009; Sudakin et al., 2001) (Figure 3).  
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Figure 3: Molecular basis of the SAC. During early mitosis (prometaphase) the 
unattached kinetochore (green) catalyzes the formation of the MCC, composed of BubR1, 
Bub3, Mad2 and Cdc20. This complex formation leads to the inhibition of the APC/C. 
Once bi-orientation is achieved, the generation of the MCC is stopped, releasing Cdc20 
that can now activate the APC/C. This leads to the ubiquitylation of cyclin B and Securin 
and thus their degradation.  Securin is an inhibitor of Separase, which in turn cleaves the 
Scc1 kleisin subunit of cohesin. This allows ring opening and sister-chromatid separation. 
Meanwhile, degradation of cyclin B1 inactivates Cdk1, leading to mitotic exit. Adapted 
from (Lara-Gonzalez and Taylor, 2012).  
 
 
The current model for the formation includes the ‘Mad2 template model’ (De 
Antoni et al., 2005; Mapelli et al., 2007). Mad2 can adopt two distinct 
conformations, an inactive ‘open’ conformer and an active ‘closed’ conformer that 
is able to bind Cdc20. According to the model, KT-bound Mad1 binds open-Mad2 
(o-Mad2) and catalyzes its conversion from the open to the closed state (c-Mad2) 
This conversion stabilizes the heterodimer and equips it with a prion-like activity, 
by further inducing the same conversion in soluble O-Mad2. This process is called 
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conformational dimerization (Mapelli et al., 2006). The formation an maintenance 
of the MCC is also dependent on the kinase Mps1. Mps1 phosphorylates so-called 
MELT motifs (Met-Glu-Leu-Thr) on the KT protein Knl1, which acts as an anchor 
for Bub3:Bub1 and Bub3:BubR1 complexes (Krenn et al., 2014; London et al., 2012; 
Overlack et al., 2015; Primorac et al., 2013; Shepperd et al., 2012; Vleugel et al., 
2013; Yamagishi et al., 2012). The cMad2:Cdc20 complex is then primed to bind 
BubR1:Bub3 and forms a heterotetramer (Fang, 2002; Davenport et al., 2006; 
Nilsson et al., 2008) that is bound to the APC/C and acts as a pseudosubstrate 
(Sudakin et al., 2001; Wang et al., 2011; Morrow et al., 2005). Although Mad2 is 
needed for the initial step of MCC generation, Mad2 might only play a 
subordinate role in APC/C inhibition as it is sometimes only a substoichiometric 
component of the MCC and is thought to rather promote the interaction between 
BubR1 and Cdc20 (Nilsson et al., 2008; Kulukian et al., 2009; Westhorpe et al., 
2011). New evidence is emerging that BubR1 interferes with substrate binding 
either by inducing a conformational change on the APC/C or by directly 
occupying the substrate/activator binding site (Lara-Gonzalez et al., 2012; 
Buschhorn et al., 2011; da Fonseca et al., 2011). 
 As a single KT is able to generate a stable wait signal even for several hours 
(Rieder et al., 1995), the question arises how SAC signaling of a single KT is 
amplified to levels that arrest cells in mitosis. A first notion was that the SAC 
signal is a all-or-nothing response in which a threshold for the initiation of the 
wait signal has to be met (Collin et al., 2013). However, it has been shown that the 
amount of MCC generated and thus the strength with which the APC/C is 
inhibited, correlates with the number of unattached KTs (Dick and Gerlich, 2013). 
The rapid establishment of the SAC signal depends on positive-feedback 
loops between several mitotic kinases. As already mentioned Mps1, localizes to 
unattached KTs and recruits Bub1/Bub3 dimers, which in turn recruit other SAC 
effectors like Mad1, Mad2 and BubR1 (Lara-Gonzalez and Taylor, 2012; Vleugel et 
al., 2012; Nijenhuis et al., 2013). Bub1 together with Haspin, triggers Aurora B 
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localization at the inner centromere by phosphorylating histones H2A and H3 
(Kawashima et al., 2007; Kelly et al., 2010; Yamagishi et al., 2010). Aurora B 
feedbacks to Mps1 and stimulates its further recruitment to KTs (Nijenhuis et al., 
2013; Saurin et al., 2011) whereas Mps1 further enforces its influence on Aurora B 
(Jelluma et al., 2008; van der Waal et al., 2012). This cascade ensures rapid and 
robust MCC activity. 
Despite its key function in mitosis, the SAC already operates during 
interphase. A recent study proposes that not only positive feedback-mechanisms 
fuel a rapid establishment of the SAC signal but that nuclear pore complexes 
(NPCs) can act as scaffolds for MCC generation instead of KTs (Rodriguez-Bravo 
et al., 2014). This premade wait signal allows the cell to initiate a wait signal before 
NEBD and thus before the KT is assembled to generate a KT-based SAC signal. 
Additionally this pre-mitotic wait signal allows correction of erroneous 
attachments that are not sensed by the SAC (Rodriguez-Bravo et al., 2014) 
(merotelic attachments, see chapter 2.3 The Mechanism of Chromosome Alignment). 
Stable bi-orientation of all sister-chromatids silences the SAC and the cell is 
able to initiate the metaphase to anaphase transition. This silencing is governed by 
several mechanisms. As the SAC signal is dependent on the enrichment of SAC 
effectors on the unattached KT, effectors get depleted from the KT as soon as 
stable attachment is sensed and tension increases between KTs (Lara-Gonzalez et 
al., 2012). This ‘stripping’ of SAC components, mostly Mad1:Mad2 complexes, is 
mediated via the minus-end directed microtubule motor dynein (Gassmann et al., 
2010; Howell et al., 2001). However, this pathway does not contribute directly to 
the disassembly of cytoplasmic inhibitors, which is required for the release of 
Cdc20. An antagonist of the SAC is p31comet. Overexpression of this protein causes 
a SAC override while its depletion delays anaphase onset (Westhorpe et al., 2011; 
Mapelli et al., 2006; Fava et al., 2011). p31comet binds Mad2 at the dimerization 
interface and thus prevents the recruitment and conversion of open-Mad2 
(Mapelli et al., 2006; Fava et al., 2011; Jia et al., 2011; Lara-Gonzalez et al., 2012). 
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Since phosphorylation is a key driver of mitotic events, it is reasonable to argue 
that also phosphatases contribute to SAC silencing and there is evidence that PP1 
(protein phosphatase 1) plays an important role in reverting phosphorylation at 
least in yeast (Vleugel et al., 2012).  
 
 
2.2.2 Cell fates after a SAC-mediated cell cycle arrest  
 
As previously mentioned, cell cycle checkpoints can arrest cells at different 
stages during progression, as response to DNA damage, spindle abnormalities or 
unfavorable environmental conditions. Usually a cell re-enters or continues the 
cycle after this stop-signal has been extinguished, e.g. after DNA damage repair or 
stable chromosome bi-orientation. However, if the damage cannot be repaired, the 
cell cannot stay in an infinite arrest. A variety of subsequent fates after a 
prolonged arrest are possible. One likely fate is cell death (apoptosis) that is 
marked by cell shrinkage, chromatin condensation, nuclear fragmentation and 
blebbing of the plasma membrane (Elmore, 2007). Apoptosis can be induced by 
the cell cycle control system in response to aberrant mitoses (Vitale et al., 2011). 
Apoptosis due to a prolonged mitotic arrest is mediated via Caspase-9, which is 
normally inhibited by cyclin B/Cdk1 (Allan and Clarke, 2007). During a prolonged 
arrest cyclin B is slowly degraded due to an unsatisfied SAC, thereby releasing the 
inhibition of Caspase-9 and leading towards an exit from mitosis via cell death 
(Gascoigne and Taylor, 2008). Another possible fate is the exit of mitosis with or 
without division and the return to interphase, a process known as ‘slippage’ (Brito 
and Rieder, 2006; Gascoigne and Taylor, 2008).  A model has been proposed, 
illustrating that the cell fate is determined by two competing networks that 
include cell death initiation pathways and cell exit from mitosis due to cyclin B 
degradation (Gascoigne and Taylor, 2008). Both networks have thresholds and 
depending on which threshold is reached first, either death or exit is induced. 
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However the rate of slippage or death can differ within and between populations 
(Gascoigne and Taylor, 2008). 
 
 
2.3 The Mechanism of Chromosome Alignment 
 
During mitosis, replicated sister chromatids are aligned at the cell equator in 
metaphase and are subsequently segregated into two daughter cells. This process 
requires the establishment of stable KT-MT attachments and a wide variety of 
proteins are needed for generating these connections and to induce dynamics that 
foster proper chromosome alignment. 
A simple but fundamental model, the ‘search and capture’ model described 
in 1986, tries to explain the complex mechanism of chromosome attachment and 
alignment (Kirschner and Mitchison, 1986). This model postulates that capture is 
initiated by MTs that are nucleated at MTOCs and that undergo growth and 
shortening (MT catastrophe) and search the cytoplasmic space for chromosomes. 
Those MTs get selectively stabilized once they reach their targets, the KT region. 
The mono-oriented chromosome oscillates close to the pole it is attached to, until it 
gets caught by the opposite pole. Since this process reflects a stochastic behavior, 
full capture of all chromosomes can take some time (Guo et al., 2013). However, 
this attractive model does not account sufficiently for a realistic timing of 
chromosome capture (Wollman et al., 2005). Since this model relies on the action 
of centrosomes that act as MTOCs, another model proposes an acentrosomal 
nucleation of MTs, which spontaneously adopt a spindle-like structure. This 
model is called the ‘self-assembly’ model (Heald et al., 1996; Guo et al., 2013). 
Here, nucleation is dependent on a RanGTP gradient around chromosomes that is 
generated by chromatin association with the guanine nucleotide exchange factor 
(GEF) RCC1 (Li et al., 2003). 
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Indeed, the SAC should only be silenced once all sister chromatids are 
attached in a bipolar fashion, an arrangement that is described as ‘amphitelic’ 
attachment (Figure 4). Since the generation of kinetochore-microtubule (KT-MT) 
attachments is a stochastic process, erroneous attachments can be formed. These 
incorrect attachments can generate lagging chromatids and chromosome 
missegregation in anaphase. ‘Monotelic’ attachments are characterized by the 
attachment of only a single KT to MTs and represents a normal condition in 
prometaphase. In addition, MTs emanating from one pole might become attached 
to both sister KTs of a single chromosome resulting in ‘syntelic’ attachment. 
‘Merotelic’ attachments are characterized by single KTs that are captured by MTs 
from opposite poles. Hence one chromatid gets pulled towards both directions 
and can create a lagging chromosome (Morgan, 2007; Gregan et al., 2011). 
 
 
    
 
Figure 4: Attachments states that occur during mitosis. Monotelic attachment is a normal 
condition during prometaphase before bi-orientation. In syntelic attachment, both sisters 
are connected to the same pole. Merotelic attachments occur when one KT is captured 
from both poles. Adapted from (Musacchio and Salmon, 2007). 
 
 
The SAC is activated by monotelic and syntelic attachments, as those KT-MT 
attachments are not fully stabilized due to low tension (Nezi and Musacchio, 2009; 
Pinsky and Biggins, 2005). In contrast, merotelic attachments produce sufficient 
tension and are not sensed by the SAC and can lead to chromosome 
missegregation and aneuploidy (Gregan et al., 2011). However, in both cases 
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Aurora B plays a central role in correcting these erroneous attachments (Hauf et 
al., 2003; Lampson et al., 2004; Knowlton et al., 2006; Lampson and Cheeseman, 
2011). This attachment error correction mechanism is executed via active 
destabilization in order to provide a new opportunity to reach bi-orientation 
(Lampson et al., 2004). Aurora B is a member of the chromosomal passenger 
complex (CPC), together with Borealin, INCENP and Survivin (Carmena et al., 
2012). The CPC is involved in several processes of mitosis due to its dynamic 
localization, including chromosome cohesion at chromosome arms, the regulation 
of KT-MT attachments, the SAC at the centromeric/KT region and cytokinesis at 
the spindle midzone and the midbody (Carmena et al., 2012). The centromeric 
localization of the CPC is dependent on two histone phosphorylations mediated 
by the kinases Haspin and Bub1 (Yamagishi et al., 2010). 
During prometaphase, the CPC corrects erroneous attachments by 
phosphorylating the positively charged N-terminal tail of the Ndc80-Hec1 
complex in the KMN network. The N-terminal tail interacts with the negatively 
charged C-terminal tail of tubulin, which weakens KT-MT interactions 
(Cheeseman et al., 2006; DeLuca et al., 2006; Ciferri et al., 2008; Guimaraes et al., 
2008). Moreover, Aurora B regulates the activity and the recruitment of the 
kinesin-13 microtubule depolymerase MCAK through phosphorylation (Lan et al., 
2004; Andrews et al., 2004; Zhang et al., 2007; Tanno et al., 2010). However, so far 
it is not completely known how inhibition of MCAK facilitates error-correction 
(Carmena et al., 2012). Bi-oriented chromosome pairs are exposed to pulling forces 
from both opposite poles. This generates tension and leads to an increase of the 
inter-kinetochore space. This spatial separation of Aurora B from its substrates at 
the outer KT reduces phosphorylation by Aurora B and thus increases stability of 
bi-oriented attachments (Liu et al., 2009). Hence, Aurora B is able to target KTs 
that are not under full tension and can destabilize erroneous KT-MT attachments 
until bi-orientation is achieved. 
 Alongside with attachment error correction, MT motor-mediated 
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movement of chromosomes during mitosis contributes to proper alignment 
(Cheeseman and Desai, 2008; Kops et al., 2010). KTs are able to bind MTs laterally 
and this facilitates chromosome alignment by rapid poleward movement.  This 
movement is mediated by the minus end-directed motor dynein (Yang et al., 2007) 
and the plus-end directed motor CENP-E (McEwen et al., 2001; Putkey et al., 
2002). Whereas dynein promotes poleward movement to increase the probability 
of end-on KT capture at a place where a lot of MTs are present, CENP-E moves 
chromosomes from the polar region to the cell equator, which is necessary for 
congression (Yang et al., 2007; Kapoor et al., 2006). 
 
 
2.4 Chromosome Cohesion – Hold and Release 
 
In bacteria, chromosome segregation occurs almost at the same time as DNA 
replication. However in eukaryotes, large genomes can only be segregated with a 
gap phase between S and M phase, to ensure chromosome condensation and 
proper preparation for cell division (Nasmyth et al., 2000). During S phase the 
genome of a cell is being replicated and sister chromatid cohesion is established, 
which permits delayed chromosome segregation. This connection between sister 
chromatids needs to be maintained until metaphase to ensure their bi-orientation. 
Only then sister chromatids are separated from each other. Sister chromatid 
cohesion allows sustaining this connection despite emerging pulling forces from 
spindle MTs that attach to KTs to achieve bi-orientation. Cohesion also gives 
information about which chromatids should be separated during cell division, 
making sure that each emerging daughter cell is genetically identical. Premature 
sister chromatid segregation either triggers the SAC, as no stable KT MT 
attachments can be formed, or leads to premature division and aneuploid 
daughter cells (Peters and Nishiyama, 2012). 
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Cohesion is mediated by ring complexes of cohesin that consist of Smc1 
(structural maintenance of chromosomes 1), Smc3, Scc1 (sister chromatid cohesion 
1) and Scc3/SA (stromal antigen) (Nasmyth and Haering, 2009; Anderson et al., 
2002; Haering et al., 2002). Interactions between Smc1, Smc3 and Scc1 from a 
tripartite ring structure that embraces chromatin (Gruber et al., 2003; Ivanov and 
Nasmyth, 2005; Haering et al., 2008). The forth cohesin subunit Scc3/SA directly 
binds Scc1, which is needed to recruit other proteins that stabilize sister chromatid 
cohesion (Peters and Nishiyama, 2012). 
Cohesin associates with chromatin during G1 phase and is dependent on 
ATP hydrolysis followed by a ring opening (Peters and Nishiyama, 2012). During 
G1, cohesin only wraps one single chromatid but during DNA replication the ring 
complexes encircle both chromatids and becomes cohesive (Losada, 2014). The 
establishment of cohesion requires the acetylation of Smc3 by Eco1 (Zhang et al., 
2008). It was suggested that this acetylation process stabilizes cohesin on DNA by 
blocking ATP hydrolysis and hence ring opening (Peters and Nishiyama, 2012). 
Furthermore, after acetylation of Smc3, Sororin is recruited via Pds5 (Nishiyama et 
al., 2010). Sororin stabilizes cohesion by antagonizing the cohesin release factor 
Wapl, as Sororin and Wapl compete for the binding with Pds5 (Schmitz et al., 
2007). In the absence of Sororin, Wapl-Pds5 dissociates cohesion from chromatin 
(Gandhi et al., 2006; Kueng et al., 2006). 
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Figure 5: Two distinct pathways remove Cohesin during mitosis. (A) The initial removal 
of cohesion is dependent on Cdk1, Plk1 and Aurora B activity.  The phosphorylation of 
various proteins allows removal of cohesin from chromosome arms. Centromeric 
cohesion is protected by Sgo1, which recruits phosphatase PP2A. PP2A counteracts 
phosphorylation that preserves the cohesin ring structure at the centromere. (B) When the 
SAC is silenced centromeric cohesion gets removed by Separase, thereby triggering sister 
chromatid separation. Adapted from (Haarhuis et al., 2014). 
 
 
In eukaryotes, two distinct pathways release cohesin from chromatin (Figure 
5). During prophase cohesin complexes are removed from sister chromatid arms, 
by a mechanism called the ‘prophase pathway’ (Waizenegger et al., 2000). This 
pathway is dependent on the action of three mitotic kinases. Cdk1 and Aurora B 
phosphorylate Sororin, which in turn drives its dissociation from Pds5. 
Subsequently Wapl is able to bind Pds5 and to unload cohesin (Nishiyama et al., 
2013). Additionally, Plk1 phosphorylates the Scc3/SA subunit and triggers the 
dissociation of the cohesin ring (Sumara et al., 2002; Lenart et al., 2007). However, 
a small portion of cohesion at centromeres is maintained. This protection of 
cohesion is executed by a protein called Shugoshin (Sgo). Sgo recruits the 
phosphatase PP2A and thereby counteracts the Plk1-mediated phosphorylation of 
Scc3/SA (Kitajima et al., 2006; Liu et al., 2013b). The remaining cohesion is only 
removed after bi-orientation has been achieved in metaphase. The Scc1 subunit is 
cleaved by Separase, a protease that is activated after the SAC is satisfied and the 
APC/C ubiquitylates its inhibitor Securin (Hauf et al., 2001). 
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2.5 Mitotic Kinases – Regulation by Phosphorylation 
 
The coordinated process that eventually leads to the irreversible separation 
of sister chromatids during mitosis needs a tightly regulated control and execution 
system. Several kinases are acting side by side during mitosis and sometimes even 
collaborate with each other, adding complexity to the system. 
The major mitotic kinase is Cdk1 in conjunction with its activator cyclin B 
(Morgan, 2007). Active Cdk1 mediates various cellular reorganizations at mitotic 
entry and is involved in almost all processes until metaphase, while at the same 
time prevents late mitotic events, through inhibitory phosphorylation. Substrates 
at early mitosis include proteins involved in the regulation of NEBD, centrosome 
separation, spindle assembly, chromosome condensation and Golgi dynamics 
(Lodish et al., 2012; Alberts et al., 2013; Morgan, 2007). To ensure the activity of 
Cdk1/cyclinB is maintained during early mitosis, Cdc25C phosphatase counteracts 
the inhibitory phosphorylation on Cdk1 (Sebastian et al., 1993). The timed 
activation of the APC/CCdc20 at metaphase results in the degradation of cyclin B 
and the shutdown of Cdk1 activity. Phosphatases like PP2A or Cdc14 seem to 
counteract Cdk1 function at the onset of anaphase (Wurzenberger and Gerlich, 
2011). The removal of the inhibitory impact of Cdk1 on late mitotic processes, 
allows for example the formation of the central spindle or furrow ingression, 
regulated by Prc1 or Mklp1 (Wurzenberger and Gerlich, 2011). Thus the transition 
from metaphase to anaphase and mitotic exit is mainly driven by the inactivation 
of cyclin B/Cdk1 and by the proteolysis of components required for Cdk1 activity. 
Mps1 (monopolar spindle 1) is a serine/threonine/tyrosine kinase located at 
the apex of mitotic checkpoint signaling. Several studies have shown the absolute 
requirement for Mps1 in the SAC (Liu et al., 2003; Stucke et al., 2002; Tighe et al., 
2008; Liu and Winey, 2012). Mps1 fosters directly or indirectly the recruitment of a 
vast number of checkpoint components, like Bub1, BubR1, Cdc20, Mad1, Mad1 
and Plk1 (Lan and Cleveland, 2010; Maciejowski et al., 2010; Santaguida et al., 
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2010; Sliedrecht et al., 2010). Cells lacking Mps1 exit mitosis prematurely with 
unaligned chromosomes, leading to aneuploid progeny. Moreover, it has been 
shown that the MCC is already formed in interphase to allow cells to arrest in 
early prophase before a functional KT is build to emit a stop signal. This initial 
interphase MCC formation is dependent on Mps1 (Rodriguez-Bravo et al., 2014; 
Maciejowski et al., 2010). Mps1 has additional functions in chromosome 
congression and error correction of KT-MT attachments that are dependent on 
Aurora B activity (Jelluma et al., 2010). Efficient Mps1 recruitment to KTs is fueled 
by Aurora B. Inhibition of Aurora B delays the activation of Mps1, however it is 
not needed to maintain Mps1 activity (Saurin et al., 2011). Despite its ubiquitous 
functions in the SAC, only few substrates of Mps1 have been identified, including 
Mps1 itself, Plk1, Borealin and Knl1 (Dou et al., 2011; Schubert et al., 2015b; 
Jelluma et al., 2008; Yamagishi et al., 2012). 
Aurora B kinase is a member of the CPC, which also contains three non 
enzymatic proteins Borealin, INCENP and Survivin (Carmena et al., 2012). Beside 
its function in chromosome alignment (see chapter 2.3 The Mechanism of 
Chromosome Alignment), Aurora B is also involved in the establishment of the SAC 
signal, chromosome cohesion, cleavage furrow ingression and cytokinesis. This 
reflects a very dynamic localization of this kinase. Inhibition of the kinase 
compromises the checkpoint and leads to exit from mitosis without cytokinesis 
(Ditchfield et al., 2003; Hauf et al., 2003). The spatiotemporal activity of Aurora B 
is tightly regulated by its main counteracting phosphatase PP1 via 
dephosphorylating Aurora B substrates as well as reducing the activating 
autophosphorylation on Aurora B (Liu et al., 2010; Emanuele et al., 2008; Honda et 
al., 2003) 
Plk1 (Polo-like kinase 1) is key a regulator of mitotic progression (Petronczki 
et al., 2008; Schubert and Nigg, 2013). The N-terminal domain of Plk1 contains a 
kinase domain, whereas the C-terminal domain features two highly conserved 
polo-box domains (PBD). These form a phosphopeptide binding pocket that 
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mediate the recruitment of Plk1 to proteins that have been primed by 
phosphorylation (Elia et al., 2003). This kinase supports amongst others the 
maturation of the centrosome and bipolar spindle formation (Petronczki et al., 
2008; Kishi et al., 2009). Furthermore, Plk1 is involved in the removal of cohesin 
from chromosome arms by phosphorylating Scc3/SA, in a process called the ‘the 
prophase pathway’ (Waizenegger et al., 2000). In prometaphase, levels of Plk1 are 
especially high on KTs. Later on Plk1 localizes to the central spindle in anaphase 
and to the midbody in telophase (Petronczki et al., 2008). KT-based function of 
Plk1 is most probably the formation of stable KT-MT attachments (Hanisch et al., 
2006a; Lenart et al., 2007; Santamaria et al., 2007) whereas Plk1 fuels spindle 
elongation and the execution of proper cytokinesis at the end of mitosis (Taylor 
and Peters, 2008). Cells devoid of Plk1 activity enter a robust checkpoint-mediated 
mitotic arrest and display monopolar spindles and KTs with normal levels of 
Mad2 (Lenart et al., 2007; Santamaria et al., 2007). This indicates dispensability for 
Plk1 in checkpoint signaling. Surprisingly, Plk1 shares a similar motif preference 
as Mps1 (Dou et al., 2011; Santamaria et al., 2011). It has been recently shown that 
Plk1 is able to strengthen the establishment of the SAC signal and to maintain it by 
acting synergistically with Mps1. However, this attribute is usually masked by its 
other function, mainly bipolar spindle formation (Schubert et al., 2015b; Espeut et 
al., 2015). 
BubR1 (Budding Uninhibited by Benzimidazoles Related 1) also contains a 
C-terminal kinase domain whereas its counterpart in yeast, Mad3, has lost this 
domain (Bolanos-Garcia and Blundell, 2011; Li and Murray, 1991). The protein has 
been proposed to be a pseudokinase, with its kinase domain acting as protein 
structure stabilizer but otherwise being dispensable in vertebrates (Suijkerbuijk et 
al., 2012b). Thus, the main function of BubR1 lies in the formation of the MCC 
(Lara-Gonzalez et al., 2012; Bolanos-Garcia and Blundell, 2011) and chromosome 
alignment via PP2A recruitment (Foley et al., 2011; Suijkerbuijk et al., 2012a; Kruse 
et al., 2013; Xu et al., 2013). 
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Those kinases are only a selection of enzymes active during mitosis. The next 
chapter will focus on a specific mitotic kinase, called Bub1. 
 
 
2.5.1 Budding uninhibited by benzimidazole (Bub1) 
 
Bub1 was one of the first initially identified and characterized components of 
the SAC (Farr and Hoyt, 1998; Taylor and McKeon, 1997; Musacchio and Salmon, 
2007). Bub1 is a serine-threonine protein kinase and is one of the first checkpoint 
proteins that binds to unattached KTs in early prophase (Jablonski et al., 1998). 
The protein structure can be generally divided into three distinct domains.  A N-
terminal domain that contains 3 tetratricopeptide repeats (TPR). Approximately 
the first 300 residues are sufficient for KT recruitment (Taylor and McKeon, 1997; 
Taylor et al., 1998). Then, a Bub3-binidng domain (or Gle2-binding domain, 
GLEBS, residues 240-280) that ensures binding to Bub3 throughout the cell cycle 
(Hardwick et al., 2000; Larsen et al., 2007; Roberts et al., 1994; Taylor et al., 1998) 
via binding to a 7-bladed β-propeller structural domain of Bub3 (Larsen and 
Harrison, 2004; Larsen et al., 2007). And a C-terminal kinase domain (residues 784-
1085) (Kang et al., 2008).  
 
Bub1 recruitment to unattached kinetochores 
Mutations in the Bub3-binding domain prevent KT localization of Bub1 
(Klebig et al., 2009) and it is suggested that this interaction might be necessary for 
efficient KT recruitment (Overlack et al., 2015). The recruitment of the Bub1:Bub3 
complex to the nascent KT is mediated via Knl1 and Mps1 kinase. Knl1 acts as a 
scaffold, with several MELT-based (Met-Glu-Leu-Thr) short sequences that serve 
as docking sites when phosphorylated by Mps1 (London and Biggins, 2014; 
Shepperd et al., 2012; Vleugel et al., 2013; Yamagishi et al., 2012; Zhang et al., 2014; 
Overlack et al., 2015; Primorac et al., 2013). Additionally, Bub1 directly interacts 
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with the KI1 (Lys-Ile) and KI2 motifs in the N-terminus of Knl1 via its TPR motifs 
(Krenn et al., 2014; Kiyomitsu et al., 2011; Bolanos-Garcia and Blundell, 2011). This 
interaction is supposed to enhance MELT-mediated recruitment of Bub1, however 
it was also shown that mutations in the TPR domain do not affect Bub1 
recruitment to KTs (Krenn et al., 2014; 2012; Lara-Gonzalez et al., 2012). Moreover, 
a recent study gives insight into the regulation of KT residency of Bub1.  It has 
been shown that Bub1 localization at KTs is dynamic and dependent on Bub1 
autophosphorylation (Asghar et al., 2015). 
 
Mitotic functions of Bub1 
Bub1 mediates several processes during mitosis. It gets recruited to 
unattached KTs, where the anaphase-wait-signal is generated and gets released 
once bi-orientation is achieved. At the KT, Bub1 mediates the recruitment of core 
checkpoint effectors, such as Mad1, Mad2, BubR1 and Bub3 and this recruitment 
marks an important step for all downstream signaling of the SAC (Boyarchuk et 
al., 2007; Johnson et al., 2004; Klebig et al., 2009; Meraldi and Sorger, 2005; 
Rischitor et al., 2007; Sharp-Baker and Chen, 2001; Overlack et al., 2015). Recent 
data in Caenorhabditis elegans even report a direct interaction between Bub1 and 
Mad1 (Moyle et al., 2014). Depletion of Bub1 by RNAi (Meraldi and Sorger, 2005) 
or BUB1 knock-out (Perera et al., 2007) leads to checkpoint malfunction. In 
addition, Bub1 has been shown to phosphorylate Cdc20, adding an extra level of 
APC/C inhibition (Kang et al., 2008; Tang et al., 2004a). However, this 
phosphorylation event remains controversial, since kinase-dead (KD) mutants are 
able to support the spindle checkpoint (Perera and Taylor, 2010; Klebig et al., 
2009). Thus, the molecular consequences of Cdc20 phosphorylation remain to be 
shown. While studies in yeast and frog show a requirement of Bub1 kinase activity 
in KT function, it is believed that Bub1 acts as a non-catalytic scaffold for the 
checkpoint in mammals (Fernius and Hardwick, 2007; Rischitor et al., 2007; Sharp-
Baker and Chen, 2001; Johnson et al., 2004; Boyarchuk et al., 2007; Overlack et al., 
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2015). In particular, in yeast, mouse and human cells Bub1 kinase activity was 
reported to be important for chromosome alignment but dispensable for SAC 
signaling (Fernius and Hardwick, 2007; Warren et al., 2002; Klebig et al., 2009; 
Perera and Taylor, 2010; Ricke et al., 2012). 
In addition to targeting SAC effectors to the unattached KT, Bub1 is also 
required for the KT targeting of the kinesin CENP-E (Johnson et al., 2004; Sharp-
Baker and Chen, 2001), which has been proposed to promote bi-orientation via 
various pathways (Kim et al., 2010; Schaar et al., 1997; Iemura and Tanaka, 2015). 
It has been shown that Bub1 is promoting stable KT-MT end-on attachment and 
thus chromosome bi-orientation (Johnson et al., 2004; Klebig et al., 2009; Meraldi 
and Sorger, 2005; Windecker et al., 2009).  This function can be either exerted via 
CENP-E or via Bub1-dependent phosphorylation of H2A. Phosphorylation of H2A 
at T120 provides a recruitment platform for Sgo1 and thus the CPC via a direct 
interaction with Borealin (Yamagishi et al., 2010; Kawashima et al., 2010; 
Tsukahara et al., 2010). It has been shown that interference with Bub1 leads to 
impaired PP2A and Aurora B recruitment to centromeres (Tang et al., 2006; Ricke 
et al., 2012), most presumably due to the lack of pT120-H2A and reduced CPC 
levels. Thus, the reported errors in chromosome alignment in Bub1-deficient cells 
(Johnson et al., 2004; Meraldi and Sorger, 2005; Perera et al., 2007; Jeganathan et 
al., 2007; Klebig et al., 2009) could be a result of dephosphorylated Aurora B 
substrates, since ectopic tethering of the CPC recues chromosome alignment 
(Ricke et al., 2012). This can also be underlined by the fact that Bub1 
overexpression results in Aurora B hyperactivation and increased numbers of 
chromosome segregation errors (Ricke and van Deursen, 2011). Taken together, 
although Bub1 kinase activity seems to be not directly involved in SAC signaling, 
a secondary impact via Aurora B, fueling into the Mps1-Aurora B feedback loop, 
might still be possible. 
As previously mentioned, the Bub1-dependent phosphorylation of T120-
H2A focuses Sgo proteins to the KT where it protects centromeric cohesin from 
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being cleaved prematurely (Kawashima et al., 2010; Tang et al., 2004b; 2006). In 
Bub1 depleted cells, Sgo is relocated to chromosome arms and causes a persistent 
cohesion of mitotic chromosomes in together with a loosening of centromeric 
cohesion (Kitajima et al., 2005). It is suggested that the decrease of centromeric 
cohesion could perturb chromosome bi-orientation due to insufficient tension 
between sister-chromatids. However, evidence is still missing (Kitajima et al., 
2005).  
 
 
2.5.2 Mitotic kinase inhibitors as anti-cancer agents 
 
Minor missegregation events can promote tumorigenesis, whereas severe 
aneuploidy is usually followed by cell death (Holland and Cleveland, 2009). 
Apoptosis, mitotic catastrophe and hyperploid progression are usually the desired 
outcomes of chemotherapy, as they eventually kill proliferating cancer cells. It has 
been shown that shutting down the SAC by RNAi causes apoptosis in cancer cells 
(Kops et al., 2004; Michel et al., 2004).  Therefore, tackling the SAC for cancer 
therapeutics seems plausible. Traditional anti-mitotic drugs include MT toxins. 
However, their side effects and toxicity limit their usage in clinics (Gascoigne and 
Taylor, 2008). A recent study showed that tumor cells are more sensitive to low 
doses of Paclitaxel if mild chromosome segregation errors are induced by the 
reduction of essential mitotic checkpoint proteins than normal human fibroblasts 
(Janssen et al., 2009). The combination of SAC inhibition and clinical doses of 
Paclitaxel increased the amount of cell death and shows a new path to selectively 
kill cancer cells by raising aneuploidy to intolerable levels. 
The development of small-molecule inhibitors for mitotic kinases for 
example bears a new advantage towards MT toxins, as those can also affect non-
dividing cells (Schmit and Ahmad, 2007; Figueroa-Masot et al., 2001). The 
advantages of targeting mitotic kinases are their active expression in proliferating 
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cells, thus quiescent cells should not be affected. Families of mitotic kinases have 
usually very specific target sites for chemical inhibition and most often their 
deregulation is linked to uncontrolled proliferation (Schmit and Ahmad, 2007).  
In the following, some of the most important mitotic kinase inhibitors are 
listed that are currently used in research (Table 1). 
 
 
Table 1: Selection of inhibitors that target mitotic kinases. 
 
Kinase Functions Inhibitor(s) References 
Cdk1 
mitotic entry, early spindle assembly, 
NEBD breakdown, chromosome 
condensation, chromosome cohesion, 
etc. 
RO-3306 (Vassilev et al., 2006) 
Mps1 
spindle checkpoint, interphase MCC 
formation, chromosome alignment 
Reversine (Santaguida et al., 2010) 
Aurora B 
chromosome cohesion, spindle 
checkpoint, chromosome alignment, 
central spindle assembly, cytokinesis 
ZM-447439, 
Hesperadin 
(Ditchfield et al., 2003; 
Hauf et al., 2003) 
Plk1 
centrosome maturation, mitotic spindle 
formation, SAC establishment, 
chromosome cohesion, central spindle 
elongation, cleavage furrow ingression, 
cytokinesis 
ZK-
Thiazolidinone 
(TAL), BI-2536 
(Santamaria et al., 2007; 
Lenart et al., 2007) 
Haspin 
CPC recruitment, chromosome 
alignment, chromosome cohesion, 
5-iodotubercidin 
(5-ITu) 
(De Antoni et al., 2012) 
Bub1 
spindle checkpoint, chromosome 
alignment, chromosome cohesion 
2OH-BNPP1, 
BAY-320, BAY-
524 
(Kang et al., 2008), this 
study 
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2.6 Phosphoproteomics 
 
Phosphorylation is one of the most prominent and wide spread post-
translational modifications (PTMs) of proteins and a key regulator of their 
function. Reversible phosphorylation regulates a huge variety of cellular processes 
and it is therefore crucial to gain a fundamental understanding of this process. For 
instance, protein phosphorylation can increase or decrease a protein’s biological 
activity, stabilize it or mark it for destruction, facilitate or inhibit subcellular 
translocations or initiate or disrupt protein-protein interactions (Cohen, 2002). 
Taking the constant availability of ATP into account, phosphorylation represents a 
simple, fast and flexible tool in eukaryotic cells for initiation of various processes. 
Hence, monitoring phosphorylation sites helps to elucidate regulation 
mechanisms and it is a prerequisite for characterizing upstream kinases according 
to their substrate specificities and substrate sequence motifs. 
Phosphorylation is often a substoichiometric event since not all copies of a 
given protein are usually present in the phosphorylated state. Therefore complete 
phosphorylation profiling remains a challenge. There are different approaches to 
determine phosphorylation sites. One can use computer algorithms (Trost and 
Kusalik, 2011) to predict potential phosphorylation sites based on the consensus 
recognition motif of known protein kinases, or based on known phosphorylation 
sites in a homologous protein. Also the use of phospho-specific antibodies with 
high sensitivity can give a hint on the time-point when a protein is 
phosphorylated, however the availability is a huge limitation factor. In the past, 2-
D phospho-peptide mapping with 32P labeling (van der Geer and Hunter, 1994; 
Nagahara et al., 1999) combined with site directed mutagenesis or Edman 
sequencing (Berg et al., 2015) has been most often the method of choice. 
Nowadays people move to a mass spectrometry (MS) based approach (Dephoure 
et al., 2013), which allows fast and sensitive identification of low abundant sites 
including peptide sequence analysis and the exact localization in the protein. 
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Due to their substoichiometric phosphorylation, phospho-peptides are 
usually under-represented in a peptide sample, due to an excess of 
unphosphorylated peptides. Therefore prior to LC-MS/MS analysis, 
phosphorylated peptides have to be enriched to increase the number of 
identifications (Fíla and Honys, 2012). To date, many different enrichment 
strategies exist like performing immunoprecipitation (IP) or more advanced 
techniques like the enrichment of phosphorylated peptides using TiO2-beads or 
immobilized metal affinity chromatography (IMAC). Metal oxides, like titanium 
dioxide (TiO2) beads have a high specific affinity to organic phosphates in solution 
and exhibit high mechanical, chemical, and thermal stability and are currently the 
most used resin material (Ozlu et al., 2010). Suitable modifiers should be able to 
exclude or compete with the binding of non-phosphorylated peptides to TiO2 
beads. 2,5-dihydroxy benzoic acid (DHB), phthalic acid, glycolic acid, and lactic 
acid have proven to be efficient additives (Larsen et al., 2005; Thingholm and 
Larsen, 2009).  
 
 
2.7 Quantification of Phosphorylated and Unphosphorylated Peptides 
 
It is not only important to identify proteins and their phosphorylation sites 
but also to give quantitative information about the extent and the dynamic 
changes in their abundance. This also simplifies the identification of possible up-
stream kinases. However, the precise quantification of low abundance proteins 
remains a challenging task (Domon and Aebersold, 2010). In the past conventional 
data-dependent acquisition (DDA) mass spectrometry (MS) workflows have been 
the method of choice for protein quantification, however they have become more 
and more outdated due to limits in sensitivity, sequencing speed and their 
dynamic range (Sandhu et al., 2008; Michalski et al., 2011). Protein quantification 
in combination with DDA workflows has been tackled by two main approaches. 
Stable isotope labeling by amino acids in cell culture (SILAC) (Ong et al., 2003; 
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Chen et al., 2015) or label-free quantification (Wong and Cagney, 2010; Bantscheff 
et al., 2007). SILAC uses the incorporation of ‘heavy’ labeled amino acids into one 
or more of the samples being studied. The differentially labeled samples are then 
cross-compared to each other. Unlabeled and labeled samples can be simply 
combined prior to mass spectrometric (LC-MS) analysis. Labeled proteins with 
stable isotopes have shifted mass-to-charge (m/z) ratios in mass spectra compared 
to their natural, non-labeled counterparts but are otherwise identical in all respects 
(Ong et al., 2003; Chen et al., 2015). A disadvantage of this method is inefficient 
labeling, the need for cultivable cells and high costs. Moreover, to monitor low 
abundant proteins or phosphorylation events it is still required to enrich the 
protein of interest and/or to perform phospho-peptide enrichment, respectively 
(Ibarrola et al., 2003). However, enrichment procedures on pull-down samples 
have proven to very difficult (data not shown). 
Label-free quantification also aims at the relative quantification of two or 
more samples on the basis of the assumption that conditions with sufficient data 
redundancy and identical peptides across different MS experiments can be 
compared (Wong and Cagney, 2010). This can be achieved either by comparing 
the mass spectrometric signal intensity of peptide precursor ions of a protein of 
interest or by comparing the number of acquired fragment spectra (spectral 
counts) that match to a peptide/protein (Wong and Cagney, 2010; Bantscheff et al., 
2007). 
In the last years ambitious efforts have been made in order to establish 
acquisition methods (directed and targeted work-flows) that allow the usage of 
labeled internal standards for the quantification of a selected set of proteins of 
interest and that overcome the limiting factors of DDA-driven workflows 
(Schmidt et al., 2008; Jaffe et al., 2008; Savitski et al., 2010; Picotti et al., 2009). 
In the following sections different MS approaches are shortly discussed that 
have been validated in regard of peptide and phospho-peptide quantification 
during this study (Figure 6). 
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Figure 6: Performance profiles of the discovery (shotgun) (a), directed (b) and targeted 
(c) proteomic method. ‘High’ and ‘Low’ refer to sample complexity. Adapted from 
(Domon and Aebersold, 2010). 
 
 
2.7.1 DDA – Data dependent acquisition 
 
A universally applicable proteomic method is generally described as data 
dependent acquisition (DDA), shotgun proteomics, or discovery-based strategy 
(Figure 7). Here, peptides are eluted form a liquid chromatography (LC) setup and 
are converted to gas phase ions by electrospray ionization. The masses of the ions 
produced in the ion source are recorded generating a full mass spectrum that 
comprises all precursors that elute at a given time. This spectrum is generally 
referred to as survey scan (MS1). In order to identify the peptide, information from 
parent masses and fragmented ions are needed. Those are generated by 
fragmentation of the parent ion (process is part of Tandem MS or MS/MS). During 
the DDA mode, a fixed number of precursor ions detected in the survey scan, are 
automatically selected according to pre-determined and user-defined criteria, 
usually on the basis of their signal intensity in the survey scan (data-dependent). 
These precursor ions are automatically selected, isolated and subjected to 
fragmentation by collision-induced dissociation (CID) and a full fragment-ion 
mass spectrum is generated (MS2) (Domon and Aebersold, 2010; Blackburn and 
Goshe, 2009). The interpretation of the MS2 spectra allows amino acid sequence 
identification and together with parent-ion data, peptide identification is possible 
(Gillette and Carr, 2013). 
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Figure 7: DDA – Data dependent acquisition. At any given point of the chromatic 
separation, hundreds of peptides are eluting. A full-scan MS spectrum is acquired but 
only a fixed number of precursor ions, usually with the highest intensities are selected for 
fragmentation. Adapted from (Gillette and Carr, 2013). 
 
 
DDA analysis is not suitable for characterizing whole proteomes, as one big 
limitation of this approach is the discrimination against peptides of low 
abundance (Schmidt et al., 2008). MS1 signals for low abundant peptides as for 
example post-translational modified peptides are most often not detected because 
of significant background noise (Sherrod et al., 2012). Also the amount of available 
precursor ions exceeds the number of product ion scans (Schmidt et al., 2009). 
Moreover, high intensity precursor ions are being oversampled in regard to the 
total number of peptides. Hence, directed and targeted approaches have been 
developed to overcome these sampling limitations.  
 
 
2.7.2 Directed Mass Spectrometry 
 
Directed proteomics circumvents the bias of automatically selecting high 
abundant and high intensity precursor ions, as it is the case for data dependent 
acquisition (DIA, data-independent acquisition) (see previous chapter). A 
predetermined set of peptide ions that are detected in a survey scan is selected for 
fragmentation, allowing the analysis of low intensity precursor ions. In a first 
analysis, survey scans are generated and features (mass-to-charge ratio, m/z; 
retention time tR) or peptides of interest are selected from this initial experiment 
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for an inclusion list. This information is then used for a second experiment during 
which the selected precursors of interest are chosen for fragmentation as soon as 
their mass (m/z) is detected in the survey scan. This means the MS2 acquisition 
mode is performed in DDA mode but the precursor mass selection takes into 
account the additional constraints of the inclusion list (Figure 8) (Domon and 
Aebersold, 2010). This hypothesis-driven MS technique is applied on rapidly 
scanning mass spectrometers with high accuracy precursor ion measurement 
(hybrid linear ion trap/Orbitrap) (Schmidt et al., 2009). This provides the 
advantage that MS2 analyses can be focused on non-redundant and information-
rich precursor ions, which provides increased depth of analysis (Schmidt et al., 
2008).  
 
 
 
 
 
Figure 8: Directed Mass Spectrometry. A full-scan MS spectrum is acquired, however, 
precursor ion fragmentation takes place by taking additional constraints of an inclusion 
list into account during precursor mass selection.  Hence full MS2 spectra of selected 
precursor ions are detected. Adapted from (Gillette and Carr, 2013). 
 
 
2.7.3 Targeted Mass Spectrometry  
 
Targeted experiments also take previously acquired data into account when 
generating MS2 spectra and are hence also a DIA strategy. In this case a set of 
predetermined product ions from precursor ions that are anticipated but not 
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necessarily detected in a survey scan, are being observed (Domon and Aebersold, 
2010). 
This workflow is generally used with selected reaction monitoring (SRM) 
and is based on a reference spectrum that allows the identification of an analyte 
using only a few selected fragment ions instead of the entire set of the MS2 
fragmentation spectrum (Gillette and Carr, 2013). These experiments are usually 
carried out on triple quadrupole instruments (QqQ) that have two mass filters. In 
a SRM experiment a precursor ion of a particular mass is selected in the first stage 
of a tandem mass spectrometer (Q1, mass filter). This precursor ion is then selected 
for fragmentation (q2). However, only selected fragment ions are then detected 
(Q3, mass filter)  (Figure 9) (Lange et al., 2008). A precursor ion and its specific 
fragment ion are referred to as transitions (precursor-fragment pairs). Relative 
quantification is achieved by relating the fragment ion intensities (peak areas) to 
the corresponding signals of isotopically labeled reference peptides of identical 
sequence that are spiked in as concentration standards (Domon and Aebersold, 
2010). SRM can therefore be used to generate a calibration curve for absolute 
quantification (Gillette and Carr, 2013). Pseudo-SRM (pSRM) does not focus on 
single selected fragment ions but records a full MS2 spectrum for each monitored 
peptide. 
 Both SRM and pSRM have become increasingly popular as they are suitable 
for quantification and due to the focused setup of these methods and their high 
resolution further increase in specificity is achieved (Gallien et al., 2012; Peterson 
et al., 2012).  
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Figure 9: Targeted Mass spectrometry. During targeted experiments first proteotypic 
peptides uniquely representing proteins of interest are predefined from a prior 
experiment together with their most informative fragment ions.  Those preselected 
peptides are selected for fragmentation (Q1 and Q2) and only fragment ions of interest are 
selected for detection (Q3). During pSRM all generated fragment ions of the targeted 
peptide are being detected.  Quantification is achieved via the usage of synthetic peptides 
containing stable-isotope labels can be spiked in as standards (asteriks). Comparison of 
labeled standards and unlabeled peaks provides relative and up to absolute quantification 
of the endogenous analyte. Adapted from (Gillette and Carr, 2013). 
 
 
2.7.4 Higher stage fragmentation of the neutral loss peaks 
 
A common feature of the fragmentation of phospho-peptides is the neutral 
loss of phosphoric acid during CID of phosphorylated precursor ions if 
phosphorylated at serine or threonine. This loss leads to information poor MS2 
spectra that are dominated by the neutral loss peak that is found 80 or 98 Da lower 
than the precursor mass (Boersema et al., 2009). These frequent loss peaks 
translate into reduced intensities of sequence informative ions and most often 
mask peptide-specific fragment ions that are required for identification and 
quantification of phospho-peptides (Villén et al., 2008; Ulintz et al., 2009; Palumbo 
et al., 2008). Hence, this causes a general decline in MS2 spectra quality. This 
limitation can be circumvented by isolation of the neutral loss fragment and a 
following second fragmentation step, called higher stage fragmentation or high-
resolution higher energy collision dissociation (HCD) (Schmidt et al., 2009; Olsen 
et al., 2007). Once these ions are detected, they get isolated and can be either 
automatically selected for MS3 (in non-targeted approaches), or be manually 
assigned (targeted analysis) for MS3 on a subsequent LC/MS analysis (Steen et al., 
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2006). This leads to a highly more selective and efficient backbone-fragmentation 
and therefore results in more sequence informative fragments. Another extension 
of MS3 acquisition is multi stage activation (MSA). This method is also used for the 
further analysis of neutral phospho loss peaks, however this is done without an 
additional isolation cycle. Hence, the initial MS2 ions are trapped together with the 
product ions of the neutral loss fragment thereby generating a composite 
spectrum (Ulintz et al., 2009) (Figure 10). 
 
 
 
 
 
Figure 10: Neutral loss of phospho-peptides during fragmentation. (A) During MS2 
analysis of phospho-peptides very often the resulting fragments display a dominant 
neutral 2loss peak that corresponds to the loss of phosphoric acid and that only provide 
poorMS2 spectra quality.  If a neutral loss peak is detected, it gets isolated and is 
reselected for a second round of fragmentation yielding information-rich MS3 data. (B) 
During multistage activation a dominant neutral loss peak has been detected and gets 
reselected for a second round of fragmentation but retains the informative fragments from 
the precursor ion. Hereby the isolation step between MS2 and MS3 is eliminated, 
producing structurally informative ion spectra with fragments from both collision events. 
Adapted from (Rogers and Foster, 2009). 
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3.1 Probing the catalytic functions of Bub1 kinase using small molecule 
inhibitors BAY-320 and BAY-524  
 
 
3.1.1 Aim of the project 
 
Bub1 is a dual function kinase in mitosis: it is part of the SAC signaling 
network that monitors the metaphase-to-anaphase transition and it contributes to 
the mechanism of chromosome alignment. Despite of vast evidence on Bub1 
specific function during mitosis, the role of its kinase activity function is still 
under debate.  
While studies in yeast and Xenopus laevis share no consensus on whether kinase 
activity of Bub1 is needed (Fernius and Hardwick, 2007; Rischitor et al., 2007; 
Sharp-Baker and Chen, 2001) or not (Yamaguchi et al., 2003), the common 
comprehension of Bub1 function in SAC signaling in mammals goes without its 
kinase activity (Ricke et al., 2012; Perera and Taylor, 2010; Klebig et al., 2009). Still, 
studies propose a direct involvement of Bub1 catalytic activity on APC/C 
inhibition. 
The ultimate aim of this study was to examine the role of Bub1 kinase 
activity during mitotic progression, and by doing so to shed more light upon the 
requirement of Bub1 kinase activity for SAC signaling. 
The foundation and starting point of the presented work was the recent 
availability of two Bub1 inhibitors designed and synthesized by BAYER Pharma 
AG. BAY-320 and BAY-523, two small molecule inhibitors, allowed the specific 
inhibition of Bub1 in vitro and in vivo and thus gave the advantage to distinguish 
scaffold and catalytic functions with temporal resolution. 
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3.1.2 Introduction 
 
The maintenance of euploidy during cell division is important for survival 
and development of all organisms. During mitosis of higher eukaryotes, a highly 
conserved surveillance mechanism termed SAC, safeguards correct chromosome 
segregation by delaying anaphase onset. The attachment and orientation of 
chromosomes within the mitotic spindle is sensed at kinetochores (KTs), 
proteinaceous structures located at mitotic centromeres. Until full chromosomal 
alignment is achieved, KTs relay a ‘wait signal’ through the generation of a 
diffusible inhibitor of the ubiquitin ligase APC/C, termed MCC (Musacchio, 2011; 
Foley and Kapoor, 2013; Sacristan and Kops, 2015). The formation of MCC 
critically depends on the assembly of several protein kinases at KTs, including 
Aurora B, Monopolar spindle 1 (Mps1) and Budding uninhibited by 
benzimidazoles 1 (Bub1) (Santaguida et al., 2011; Jelluma et al., 2010; Meraldi and 
Sorger, 2005). These in turn regulate both correct KT-MT attachment and SAC 
activity. Once chromosome bi-orientation is achieved through stable KT-MT 
attachments, the SAC is silenced through MT-dependent removal of checkpoint 
components as well as local phosphatase activity; this allows APC/C-driven 
degradation of several mitotic proteins, including Securin and Cyclin B, and 
results in the onset of chromatid separation and mitotic exit (Funabiki and Wynne, 
2013).  
The serine/threonine kinase Bub1, along with Bub3, is one of the first 
proteins to accumulate at unattached KTs (Jablonski et al., 1998), governed by 
Mps1-dependent phosphorylation of MELT motifs on the KMN complex member 
KNL-1 (Yamagishi et al., 2012; London et al., 2012; Shepperd et al., 2012; Vleugel et 
al., 2013; Overlack et al., 2015). At KTs, Bub1 is then thought to regulate a variety 
of processes, including chromosome cohesion, KT-MT interactions and SAC 
function through the recruitment of additional factors, notably Sgo1, CENP-E, 
CENP-F, BubR1, Aurora B kinase, Mad1 and Mad2 (Kitajima et al., 2005; Liu et al., 
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2013a; Taylor and McKeon, 1997; Meraldi and Sorger, 2005; Perera et al., 2007; 
Klebig et al., 2009). In particular, depletion of Bub1 was reported to interfere with 
chromosome alignment as well as mitotic arrest (Meraldi and Sorger, 2005; Perera 
et al., 2007; Klebig et al., 2009), but the importance of Bub1 catalytic activity for 
mitotic progression remains controversial. While studies in yeast and frog show a 
requirement of Bub1 kinase activity for KT function, it is believed that in 
mammals Bub1 primarily acts as a non-catalytic scaffold (Fernius and Hardwick, 
2007; Rischitor et al., 2007; Sharp-Baker and Chen, 2001; Johnson et al., 2004; 
Boyarchuk et al., 2007; Overlack et al., 2015). In particular, Bub1 kinase activity 
was reported to be important for chromosome alignment but dispensable for SAC 
signaling (Ricke et al., 2012; Perera and Taylor, 2010; Klebig et al., 2009).  
Here we present a thorough characterization of two novel small-molecule 
ATP-competitive inhibitors of Bub1 kinase. We show that BAY-320 and BAY-524 
act as potent inhibitors of human Bub1 in vitro and in vivo. By comparing 
phenotypes provoked by Bub1 kinase inhibition and Bub1 protein depletion we 
are able to differentiate between catalytic and non-catalytic functions of Bub1. We 
demonstrate that Bub1 catalytic activity is required for chromosome arm 
resolution and the establishment of centromeric Sgo pools. Moreover, Bub1 kinase 
activity regulates the chromosomal localization of Aurora B and the CPC. In this 
function, Bub1 cooperates with Haspin, and chemical inhibition of both Bub1 and 
Haspin kinases show an additive effect. In striking contrast, Bub1 catalytic activity 
is largely dispensable for chromosome alignment and SAC function, arguing that 
Bub1 largely operates as a scaffolding protein. However, even though Bub1 
inhibition per se exerts only minor effects on mitotic fidelity, BAY-320 and BAY-
524 treatment sensitizes cells to low doses of Paclitaxel, resulting in remarkable 
impairment of chromosome segregation and cell proliferation. 
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3.1.3 The inhibitors BAY-320 and BAY-524 specifically inhibit Bub1 kinase in 
vitro and in vivo  
 
The chemical synthesis of small molecule inhibitors against Bub1 has 
recently been described (Hitchcock et al., 2013). In this study we used the two 
compounds 2-[5-cyclopropyl-1-(4-ethoxy-2,6-difluorobenzyl)-4-methyl-1H-
pyrazol-3-yl]-5-methoxy-N-(pyridin-4-yl)- pyrimidin-4-amine and 2-[1-(4-ethoxy-
2,6-difluorobenzyl)-5-methoxy-4-methyl-1H-pyrazol-3-yl]-5-methoxy-N-(pyridin-
4-yl)pyrimidin-4-amine, abbreviated as BAY-320 and BAY-524, respectively 
(Figure 11).  
 
   
 
Figure 11: Chemical structures of ATP-competitive inhibitors BAY-320 and BAY-524.  
 
 
When assayed in vitro in presence of 2 mM ATP, both compounds inhibited 
the catalytic domain of recombinant human Bub1 (amino acids 704-1085) with an 
IC50 of 680 ± 280 nM and 450 ± 60 nM, respectively (Table 2).  
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Table 2: IC50 profile of BAY-320 and BAY-524. (Data by courtesy of BAYER Pharma AG) 
 
concentrations are depicted in M 
 
 
When tested against a panel of 222 protein kinases, BAY-320 showed only 
modest cross reactivity with other kinases, even when used at a concentration of 
10 µM (Table 3). In vitro inhibition of Bub1 by BAY-320 and BAY-524 was 
demonstrated by monitoring both Bub1 autophosphorylation and 
phosphorylation of human histone H2A on threonine 120 (Thr120), the best 
characterized physiological substrate (Kawashima et al., 2010) (Figure 12).  
 
 
Table 3: Kinase-selectivity profile of BAY-320. Percentage of residual kinase activity at 10 
µM BAY-320 is shown. (Data by courtesy of BAYER Pharma AG) 
 
Kinase  Activity*  
 
Kinase  Activity*  
 
Kinase  Activity*  
Abl(h) 98 
 
Flt4(h) 50 
 
PDK1(h) 124 
ACK1(h) 108 
 
Fms(h) 76 
 
PhKγ2(h) 38 
ALK(h) 60 
 
Fyn(h) 91 
 
Pim-1(h) 56 
ALK4(h) 82 
 
GCK(h) 79 
 
Pim-2(h) 119 
Arg(h) 78 
 
GRK5(h) 99 
 
Pim-3(h) 112 
ARK5(h) 85 
 
GRK6(h) 102 
 
PKA(h) 141 
ASK1(h) 86 
 
GRK7(h) 96 
 
PKBα(h) 93 
Aurora-A(h) 105 
 
GSK3α(h) 148 
 
PKBβ(h) 57 
Aurora-B(h) 99 
 
GSK3β(h) 209 
 
PKBγ(h) 47 
Axl(h) 91 
 
Haspin(h) 47 
 
PKCα(h) 102 
Blk(m) 48 
 
Hck(h) 110 
 
PKCβI(h) 97 
Bmx(h) 122 
 
HIPK1(h) 105 
 
PKCβII(h) 96 
BRK(h) 72 
 
HIPK2(h) 81 
 
PKCγ(h) 100 
BrSK1(h) 70 
 
HIPK3(h) 102 
 
PKCδ(h) 99 
BrSK2(h) 108 
 
IGF-1R(h) 50 
 
PKCε(h) 106 
BTK(h) 130 
 
IKKα(h) 115 
 
PKCη(h) 101 
CaMKI(h) 41 
 
IKKβ(h) 107 
 
PKCι(h) 100 
CaMKIIβ(h) 84 
 
IR(h) 84 
 
PKCµ(h) 107 
CaMKIIγ(h) 106 
 
IRR(h) 99 
 
PKCθ(h) 88 
CaMKIδ(h) 54 
 
IRAK1(h) 105 
 
PKD2(h) 90 
CaMKIIδ(h) 89 
 
IRAK4(h) 74 
 
PKG1α(h) 89 
CaMKIV(h) 77 
 
Itk(h) 103 
 
PKG1β(h) 82 
CDK1/cyclinB(h) 68 
 
JAK2(h) 206 
 
Plk1(h) 127 
CDK2/cyclinE(h) 76 
 
JAK3(h) 146 
 
Plk3(h) 112 
CDK3/cyclinE(h) 92 
 
JNK1α1(h) 89 
 
PRAK(h) 102 
  
 
MW 
[g/mol] 
Bub1 kinase 
inhibition           
(2 mM ATP) HeLa proliferation 
HeLa proliferation  
(3 nM  Paclitaxel) 
A375 pro- 
liferation 
A375 
proliferation (3 
nM  Paclitaxel) 
IC50 SD IC50 SD IC50 SD IC50 IC50 
BAY-320 492.5 6.8E-07 2.8E-07 4.0E-06 1.4E-06 6.7E-07 2.7E-07 3.6E-06 4.0E-07 
BAY-524 482.5 4.5E-07 6.0E-08 8.1E-06 1.2E-06 6.4E-07 5.9E-07 nd nd 
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CDK5/p35(h) 119 
 
JNK2α2(h) 92 
 
PRK2(h) 96 
CDK6/cyclinD3(h) 80 
 
JNK3(h) 46 
 
PrKX(h) 65 
CDK7/cyclinH/MAT1(h) 99 
 
KDR(h) 82 
 
PTK5(h) 224 
CDK9/cyclin T1(h) 104 
 
Lck(h) 32 
 
Pyk2(h) 113 
CHK1(h) 113 
 
LIMK1(h) 95 
 
Ret(h) 102 
CHK2(h) 56 
 
LKB1(h) 105 
 
RIPK2(h) 85 
CK1γ1(h) 114 
 
LOK(h) 76 
 
ROCK-I(h) 79 
CK1γ2(h) 120 
 
Lyn(h) 58 
 
ROCK-II(h) 93 
CK1γ3(h) 97 
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Figure 12: BAY-320 and BAY-524 inhibit Bub1 kinase in vitro. In vitro kinase assays 
showing dose-dependent inhibition of Bub1 kinase activity towards histone H2A. Assays 
were performed by mixing human wild-type (WT) or kinase-dead (KD) LAP-Bub1, 
ectopically expressed in and purified from mitotic HEK 293T cells, with recombinantly 
expressed histone H2A as a substrate, γ-32P-ATP and increasing doses of the Bub1 
inhibitors BAY-320 and BAY-524. After 30 min at 30°C, reactions were stopped and 
analyzed by gel electrophoresis. Bub1 autophosphorylation and H2A phosphorylation 
were visualized by autoradiography (32P) and protein levels were monitored by 
Coomassie brilliant blue staining (CBB). Histone H2A-T120 phosphorylation (pT120-H2A) 
was detected by phospho-antibody probing of Western blots (WB) and Bub1 was 
monitored as control. 
 
 
To test whether BAY-320 and BAY-524 also inhibit Bub1 in intact cells, 
increasing doses of inhibitors were applied to mitotically synchronized HeLa and 
hTERT-RPE1 (RPE1) cells, and phospho-histone H2A-Thr210 staining at KTs was 
monitored by immunofluorescence (Figure 13). These studies revealed that near-
maximal inhibition of Bub1 could be achieved by using BAY-320 at 3 µM and 
BAY-524 at 7 µM; these concentrations were therefore used for long-time 
treatment (>10 h) in all future experiments on intact cells. At concentrations of 10 
µM or above, both inhibitors increasingly caused inhibition of cell proliferation 
and cell death (data not shown).  
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Figure 13: BAY-320 and BAY-524 inhibit Bub1 kinase in vivo. (A, B) Inhibition of Bub1 
reduces histone H2A-T120 phosphorylation. Asynchronous cultures of HeLa S3 (left 
panels) and RPE1 cells (right panels) were treated with the proteasomal inhibitor MG132 
for 2h, followed by the addition of 3.3 mM nocodazole and increasing doses of BAY-320 
(A) or BAY-524 (B) for 1 h. Cells were fixed and analyzed by immunofluorescence 
microscopy (IFM). Scatter plots show centromeric levels of pT120-H2A (n=19-28 cells per 
condition). Bars represent mean values. (C) HeLa S3 cells were synchronized by 
thymidine block, released for 10 h in the presence of solvent (control), 3 µM BAY-320 or 7 
µM BAY-524 and analyzed by quantitative IF (top panels). Cells transfected with mock 
(Gl2) or Bub1 siRNA-oligonucleotides for 48 h were synchronized and analyzed in 
parallel (bottom panels) Cells were stained with antibodies raised against Bub1 and 
pT120-H2A. Human CREST serum was used to identify centromeres and DNA was 
stained with DAPI; scale bars represent 10 µm.  (D) Histograms showing the average 
signal intensities of centromeric pT120-H2A observed in the experiments described in (C); 
n=73-107 cells per condition. Error bars represent standard error of the mean (SEM).  
(Panel A and B by courtesy of Dr. Conrad von Schubert) 
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To corroborate the above immunofluorescence data, histones were purified 
from control and inhibitor-treated cells. Examination of histone H2A 
phosphorylation by Western blotting revealed that treatment of cells with either 
BAY-320 or BAY-524 drastically reduced Thr210 phosphorylation (Figure 14). 
Thus, BAY-320 and BAY-524 act as potent and selective inhibitors of Bub1 kinase 
in vitro and in vivo and thus constitute attractive tools to study Bub1 catalytic 
function during mitosis.  
 
 
       
 
 
 
Figure 14: BAY-320 and BAY-524 reduce T120-H2A phosphorylation in vivo. To monitor 
the efficiency of Bub1 kinase inhibition in vivo, HeLa S3 cells were synchronized by 
thymidine block and released for 14 h in the presence of 3.3 µM nocodazole as well as 
solvent or Bub1 inhibitors solvent as indicated. Prometaphase-arrested cells were 
harvested by shake-off and subsequently mitotic cell extracts were selectively treated with 
phosphatase inhibitor for 30 min at 30 °C. Histone isolation was followed by Western blot 
analysis of histone H2A T120 phosphorylation levels. Equal loading was monitored by 
Ponceau S staining. 
 
 
3.1.4 Inhibition of Bub1 kinase activity 
 
Next, we set out to directly compare the impact of Bub1 kinase inhibition 
with the previously reported consequences of siRNA-mediated Bub1 depletion 
(Johnson et al., 2004; Meraldi and Sorger, 2005; Boyarchuk et al., 2007) or genetic 
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Bub1 knock-out (Jeganathan et al., 2007; Perera et al., 2007). In a first series of 
experiments we used time-lapse imaging to compare progression through mitosis 
in asynchronously growing HeLa and RPE1 cells in response to either Bub1 
inhibition or siRNA-mediated Bub1 depletion. In line with previous results (Tang 
et al., 2004b; Kitajima et al., 2005), depletion of Bub1 from HeLa cells significantly 
prolonged duration of mitosis, due to delayed chromosome alignment and 
transient prometa- and metaphase arrest (Figure 15B, C and D). Efficiency of 
siRNA-mediated depletion was monitored by Western blotting (Figure 15A). 
 
 
 
 
 
Figure 15: Bub1 depletion prolongs mitotic timing. (A) Western blots showing 
representative Bub1 depletion efficiencies. Asynchronous cultures of HeLa S3 or RPE1 
cells were transfected with control (Gl2) or Bub1 siRNA-oligos for 48 h, harvested and 
analyzed by Western blotting. α-tubulin served as loading control. (B) (C) Graphs show 
the cumulative frequency of mitotic duration determined by cell rounding/flattening. 
Indicated averages represent the time spent in mitosis (n=100 cells per condition). (D) 
Representative stills from time-lapse recordings of asynchronously growing cultures of 
HeLa S3 cells stably expressing GFP-tagged histone H2B. Cells were transfected with 
control (Gl2) or Bub1 siRNA for 48 h prior to time-lapse microscopy. Scale bars represent 
10 µm. 
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In stark contrast, treatment with either BAY-320 or BAY-524 provoked at 
most minor effects on mitotic progression, marked by a short delay of anaphase 
onset (Figure 16). Furthermore, in contrast to aneuploid HeLa cells, diploid RPE1 
cells were not significantly affected by either Bub1 inhibition or depletion (Figure 
15C, Figure 16C and E).  
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Figure 16: Inhibition of Bub1 kinase activity does not affect mitotic progression. (A) 
Representative stills from time-lapse recordings of asynchronously growing cultures of 
HeLa S3 cells stably expressing GFP-tagged histone H2B. Cells were treated with Bub1 
inhibitors (3 µM BAY-320 and 7 µM BAY-524) prior to time-lapse microscopy. Scale bars 
represent 10 µm. (B, C) Graphs show the cumulative frequency of mitotic duration 
determined by cell rounding/flattening. Indicated averages represent the time spent in 
mitosis (n=100 cells per condition). (D, E) HeLa S3 (D) or RPE1 (E) cells stably expressing 
GFP-H2B were treated with solvent (control) or Bub1 inhibitors at indicated doses and 
monitored by fluorescence time-lapse imaging. Dot plots show the time from mitotic 
entry to anaphase onset; bars represent mean values (n=80 cells per condition). (Panel D 
and E by courtesy of Dr. Conrad von Schubert) 
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Flow-cytometric analyses confirmed that Bub1 depletion from HeLa cells 
causes an increase in the G2/M population of HeLa but not RPE-1 cells and that 
Bub1 inhibition by BAY-320 or BAY-524 did not detectably affect cell cycle profiles 
in either cell line (Figure 17). We conclude that inhibition of Bub1 kinase activity in 
either HeLa or RPE-1 cells produces at most subtle effects on mitotic progression, 
whereas Bub1 depletion exerts more profound effects, at least in HeLa cells.  These 
results are consistent with the demonstration that Bub1 kinase activity is not 
required for the development and viability of mice (Ricke et al., 2012). 
3. Results 
	60	
 
Figure 17: Bub1 depletion but not inhibition affects cell cycle distribution. (A, B) Cell 
cycle distribution of exponentially growing HeLa S3 (A) and RPE1 (B) cells upon 
treatment with solvent (control), 3 µM BAY-320, 7 µM BAY-524 or after Bub1 protein 
depletion (siGl2 served as control). After 48 h of treatment or siRNA oligo transfection 
cells were permeabilized and DNA was stained with propidium iodide. Cellular DNA 
content was determined using flow cytometry and frequencies in percentage of G1, S and 
G2/M phases determined. 
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3.1.5 Catalytic activity of Bub1 regulates Shugoshin localization and chromatid 
cohesion   
 
One of the most interesting effects of Bub1 depletion described so far relates 
to sister chromatid cohesion (Tang et al., 2004b; Kitajima et al., 2005; Perera and 
Taylor, 2010; Fernius and Hardwick, 2007; Boyarchuk et al., 2007). In particular, 
depletion of Bub1 was shown to cause persistent arm cohesion and a 
redistribution of Sgo proteins from centromeres to chromosome arms (Kitajima et 
al., 2005). Moreover, Bub1 has been implicated in Sgo recruitment to centromeres 
through phosphorylation of histone H2A Thr120 (Kawashima et al., 2010; Liu et 
al., 2013a).  
To directly demonstrate a role for Bub1 kinase activity in sister chromatid 
cohesion, we analyzed chromosome spreads prepared from mitotic HeLa cells or 
RPE1 cells after treatment with Bub1 inhibitors (Figure 18A, B and E) or Bub1-
specific siRNA for comparison (Figure 18C-E). While mitotic chromosomes 
spreads from nocodazole-treated control cells showed the expected X-shape 
structure, indicative of centromere cohesion, most cells treated with either Bub1 
inhibitors or Bub1 siRNA showed sister chromatids whose arms remained paired 
(Figure 18).  
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Figure 18: Catalytic activity of Bub1 defines chromatid cohesion. (A) (B) HeLa S3 (A) or 
RPE1 (B) cells were synchronized by thymidine block (4 mM in case of RPE1) and 
released for 12 h or 3 h respectively, in the presence of 3.3 mM nocodazole as well as 
solvent (control), 3 µM BAY-320 or 7 µM BAY-524. (C) (D) HeLa S3 (C) or RPE1 (D) cells 
were transfected with mock (Gl2) or Bub1 siRNA-oligos for 48 h were synchronized and 
analyzed in parallel as (A) and (B). Micrographs show representative chromosome 
spreads prepared from mitotic cells. Scale bars represent 10 µm. (E) Quantitative results of 
the experiment described in (A) (B) (C) and (D). n= 200 cells per condition. 
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Moreover, centromeric levels of Sgo1 and Sgo2 were reduced to about 20% of 
control values in BAY-320 or BAY-524 treated cells (Figure 19A and B) and 
concomitantly, a significant redistribution of Sgo2 to chromosome arms could be 
observed (Figure 19C and D). We thus conclude that Bub1 catalytic activity 
contributes to the regulation of sister chromatid cohesion and the localization of 
Sgo proteins.  
 
 
Figure 19: Catalytic activity of Bub1 defines Sgo1 and Sgo2 localization. (A) HeLa S3 
cells were released from a thymidine arrest into solvent, 3 µM BAY-320 or 7 µM BAY-524. 
Cells were fixed and stained for Sgo1, Sgo2, CREST and DNA (DAPI) and analyzed by 
IFM. Scale bars represent 10 µm. (B) Histogram showing average centromeric Sgo levels 
observed in the experiments described in (A); n=43-120 cells per condition. Error bars 
represent SEM. (C) Asynchronous cultures of RPE1 cells were treated with indicated 
doses of Bub1 inhibitors for 3 h, fixed and analyzed by IFM. Scale bar represents 5 µm. 
(D) Dot plot showing the quantitative results of the experiment shown in (C). Sgo2 levels 
at centromeres and chromosome arms were determined in metaphase cells (n=150 
centromere/arm regions from 15 different cells). Bars represent mean values. (Panel C and 
D by courtesy of Dr. Conrad von Schubert) 
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3.1.6 Bub1 inhibition affects the CPC 
 
In addition to preserving sister chromatid cohesion, Sgo1 and Sgo2 play 
important roles in the recruitment of the CPC, comprising Aurora B kinase, 
Borealin, INCENP and Survivin (Kawashima et al., 2007; Tsukahara et al., 2010). 
This prompted us to investigate the impact of Bub1 inhibition on Aurora B 
localization and activity. Centromere recruitment of the CPC is ensured by two 
complementary signaling branches, which are under the control of two kinases, 
Bub1 and Haspin, respectively. In the first branch, Bub1-dependent 
phosphorylation of histone H2A-T120 (Kawashima et al., 2010; Sharp-Baker and 
Chen, 2001; Lin et al., 2014)  triggers the centromere localization of Sgo1, which in 
turn recruits the CPC subunit Borealin (Kawashima et al., 2010; Tsukahara et al., 
2010; Yamagishi et al., 2010). In the second branch, Haspin-dependent 
phosphorylation of histone H3 at T3 triggers the centromere binding of the CPC 
component Survivin (Du et al., 2012; Kelly et al., 2010; Wang et al., 2010). 
Consistent with the marked effects on centromere localization of Sgo1/2, we also 
observed significant effects of Bub1 inhibition on Aurora B localization. After 
treatment of HeLa cells with BAY-320 or BAY-524, all CPC subunits examined 
were displaced from centromeres (Figure 20). While Bub1 inhibition reduced 
centromeric levels of Aurora B, Borealin and INCENP by ~50% (Figure 20A upper 
panel and B left panel), depletion of Bub1 lowered centromere levels of these CPC 
components by ~70% (Figure 20A lower panel, and B right panel).  
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Figure 20: Bub1 inhibition affects localization and activity of the CPC. (A) Untreated or 
siRNA transfected (siBub1, siGl2 for control) HeLa S3 cells were synchronized by 
thymidine block and released for 10 h, as indicated (BAY-320 was used at 3 µM, BAY-524 
at 7 µM). Cells were fixed and stained for Aurora B, Borealin, INCENP, CREST and DNA 
(DAPI) and analyzed by IFM. Scale bars represent 10 µm. (B) Histograms show 
quantitative results of the experiments described in (A). Measurements represent 
centromeric levels (n=63-113 cells per condition). Scale bars represent 10 µm. Error bars 
represent SEM. 
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To examine the impact of Bub1 inhibition on the catalytic activity of Aurora 
B at both centromeres and chromosome arms, we next monitored phosphorylation 
of CENP-A Ser7 (Zeitlin et al., 2001) and histone H3 Ser10 (Hsu et al., 2000; Hirota 
et al., 2005), respectively. Compared to control cells, both Bub1 inhibition and 
depletion reduced CENP-A and histone H3 phosphorylation by ~50% and ~10-
20%, respectively (Figure 21), suggesting that interference with Bub1 primarily 
affects Aurora B activity at centromeres. This conclusion was corroborated by 
showing that both inhibition and depletion of Bub1 reduced the centromere 
association of the Aurora B effector protein MCAK (Andrews et al., 2004) by ~50% 
(Figure 21).  
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Figure 21: Bub1 inhibition affects activity of Aurora B. (A) Untreated or siRNA 
transfected (siBub1, siGl2 for control) HeLa S3 cells were synchronized by thymidine 
block and released for 10 h, as indicated (BAY-320 was used at 3 µM, BAY-524 at 7 µM). 
Cells were fixed and stained for pS10-histone H3, pS7-CENP-A, MCAK, CREST and DNA 
(DAPI) and analyzed by IFM. Scale bars represent 10 µm. (B) Histograms show 
quantitative results of the experiments described in (A). Measurements represent 
centromeric levels except for pS10-histone H3 signals, which were monitored along 
chromosome arms (n=40-83 cells per condition). Scale bars represent 10 µm. Error bars 
represent SEM. 
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Furthermore, use of biosensors for Aurora B activity (Fuller et al., 2008; 
Wang et al., 2011) revealed a stronger reduction in fluorescence resonance energy 
transfer (FRET) ratios for a sensor tethered to centromeres (through fusion to 
histone CENP-B) than for a sensor tethered to chromosome arms (through fusion 
to H2B) (Figure 22). Collectively, these observations demonstrate that Bub1-
dependent phosphorylation plays a major role in the regulation of Aurora B 
localization and activity. However, neither Bub1 inhibition nor Bub1 depletion 
resulted in complete removal of Aurora B from centromeres, prompting us to 
examine the relative contributions of Bub1 and Haspin to the process of CPC 
recruitment.  
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Figure 22: Bub1 inhibition affects Aurora B activity at centromeres but not at 
chromosome arms. (A) FRET experiments were performed on HeLa Kyoto cells stably 
expressing chromatin (H2B)- or centromere (CENP-B)-fused FRET reporters for Aurora B 
activity. Cells were synchronized in mitosis by 6 h treatment with 3.3 µM nocodazole, 
before the indicated inhibitors and 10 µM MG132 were added prior to live fluorescence 
microscopy. (B) HeLa Kyoto cells stably expressing the chromatin-targeted Aurora B 
FRET reporter were transfected with control (Gl2) or Bub1 siRNA oligonucleotides for 48 
h and synchronized by 6 h treatment with 3.3 µM nocodazole, before 20 µM MG132 were 
added prior to live fluorescence microscopy. (A) (B) Heat-map represents the 
phosphorylation status of the reporter. Scale bar represents 10 µm. (C) Left panel: scatter 
plot depicts CFP/FRET emission ratios of reporter targeted to chromatin (H2B; n=23-52 
cells per condition). Right panel: scatter plot depicts TFP/FRET emission ratios of reporter 
targeted to centromeres (CENP-B, n=16-34 cells per condition). (D) Dot plot depicts 
CFP/FRET emission ratios of reporter targeted to chromatin (H2B, n=14-19 cells per 
condition).  
Bars represent mean values; ***p < 0.001 (from unpaired two-tailed Student’s t-test. (Panel 
C and D: Data analysis with help of Dr. Conrad von Schubert) 
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3.1.7 Bub1 and Haspin inhibition have an additive effect on CPC recruitment to 
centromeres  
 
While inhibition of Bub1 by BAY-320 or BAY-524 or inhibition of Haspin by 
5-Iodotubercidin (De Antoni et al., 2012) similarly reduced centromere levels of 
the CPC components Aurora B, Borealin and INCENP to ~40 %, combined 
inhibition of both kinases resulted in a ~80 % reduction in CPC levels at 
centromeres (Figure 23). As an important control, treatment of cells with only 
BAY-320 or BAY-524 did not detectably affect the phosphorylation of the Haspin 
substrate histone H3 (T3), attesting to the specificity of the two Bub1 inhibitors 
(Figure 23). These results indicate that Bub1 and Haspin contribute to a similar 
extent to the recruitment of the CPC to centromeres. 
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Figure 23: Bub1 and Haspin inhibition exert additive effect on centromere association 
of CPC. (A) HeLa S3 cells were released from a thymidine block into 3.3 µM nocodazole, 
before they were additionally treated for 2 h with the proteasomal inhibitor MG132 and 
indicated kinase inhibitors. The Haspin inhibitor 5-iodotubercidin (5-ITu (De Antoni et al., 
2012)) was used at a concentration of 2.5 µM, BAY-320 at 3 µM and BAY-524 at 7 µM. 
Cells were fixed, stained for pT3-H3, Aurora B, Borealin, INCENP, CREST and DNA 
(DAPI) and analyzed by IFM.  Anti-pT3-H3 antibody was used to monitor Haspin 
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inhibition. Scale bar represents 10 µm. (B) Histograms show average centromeric (AurB, 
Borealin, INCENP) or chromosome arm (pT3-H3) signal intensities observed in the 
experiments shown in (A); n=20-100 cells per condition. Error bars represent SEM, ***p < 
0.001 (from unpaired two-tailed Student’s t-test). 
 
  
To quantify CPC localization over chromosome arms, analysis of fixed cells 
proved inadequate. We therefore used an RPE1 cell line expressing one 
endogenous allele of Aurora B tagged with EGFP (Schubert et al., 2015b) to 
monitor the subcellular localization of this kinase in living cells. Following Bub1 
inhibition, Aurora B-EGFP levels at chromosome arms increased approximately 2-
fold, concomitant with the described reduction of Aurora B at centromeres (Figure 
24A and B) (Boyarchuk et al., 2007; Ricke et al., 2012). Interestingly, this change in 
localization showed a strong correlation with the redistribution of Sgo2 (Figure 
24C and D). In contrast, treatment of cells with the Haspin inhibitor 5-
Iodotubercidin did not induce any significant redistribution of Aurora B from 
centromeres to chromosome arms; instead, inhibition of Haspin caused an overall 
reduction of EGFP signals at both centromeres and chromosome arms (Figure 24A 
and B). Combined inhibition of Bub1 and Haspin displaced Aurora B from both 
centromeres and chromosome arms (Figure 24), in line with the analysis of fixed 
cells described above. Taken together, these data corroborate the notion that Bub1 
and Haspin cooperate in the recruitment of CPC to centromeres through 
phosphorylation of histone H2A-T120 and histone H3-T3, respectively. In 
addition, they reveal a role for Bub1 activity, but not Haspin, in the control of CPC 
localization to chromosome arms.  
  Considering the role of Aurora B kinase in the regulation of KT-MT 
interactions and SAC signaling, the above results raised the question of what 
contributions Bub1 activity might possibly make to chromosome congression 
and/or the SAC. Although our initial analyses had not revealed a major impact of 
BAY-320 or BAY-524 on the overall timing of mitotic progression (Figure 16), we 
considered the possibility that inhibition of Bub1 might provoke compensatory 
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effects on mitotic timing, notably a delay in congression and a concomitant 
acceleration of mitotic exit. 
 
 
 
Figure 24: Aurora B localizes to chromosome arms after Bub1 inhibition. (A) RPE1 cells 
expressing endogenously EGFP-tagged Aurora B were incubated with the indicated 
drugs for several hours before EGFP signals were recorded by live fluorescence imaging. 
Scale bar represents 5 µm. (B) Scatter plots depict Aurora B-EGFP signal intensities at 
centromeres or arms after treatment with indicated drugs (n=84-185 centromeres/arm 
regions from 5-6 cells per condition). Bars represent mean values. Measurements relate to 
the experiment shown in (A). (C) Asynchronous cultures of RPE1 cells expressing 
endogenously EGFP-tagged Aurora B were treated with indicated doses of Bub1 
inhibitors for 3 h, fixed and analyzed by IFM. Scale bar represents 5 µm. (D) Dot plots 
show the quantitative results of the experiment shown in (C). EGFP-Aurora B and Sgo2 
levels at centromeres and chromosome arms were determined in metaphase cells (n=100 
centromere/arm regions from 10 different cells). Bars represent mean values. (Data by 
courtesy of Dr. Conrad von Schubert) 
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According to such a scenario, effects on timing might conceivably cancel 
each other. In support of this possibility, we emphasize that inhibition of mitotic 
kinases with pleiotropic functions have previously been shown to provoke 
opposing phenotypes (Schubert et al., 2015b; Santaguida et al., 2011). To explore 
the possibility of compensatory effects of Bub1 inhibition, we thus carried out 
more detailed analyses of mitotic progression, notably SAC signaling and 
chromosome congression. 
 
 
3.1.8 Bub1 inhibition produces minor effects on SAC signaling in HeLa or RPE1 
cells 
 
Depletion of Bub1 is known to weaken SAC signaling in human cells 
(Meraldi and Sorger, 2005; Perera et al., 2007; Klebig et al., 2009). To test the 
impact of Bub catalytic activity on SAC function we first analyzed KT levels of 
Mad1, Mad2 and BubR1 in BAY-320 or BAY-524 treated cells. With the possible 
exception of a very minor effect on BubR1, the localization of none of these SAC 
proteins was significantly affected by Bub1 inhibition (Figure 25A and C left 
panel). In sharp contrast, and in agreement with previous reports (Sharp-Baker 
and Chen, 2001; Johnson et al., 2004; Boyarchuk et al., 2007; Overlack et al., 2015), 
Bub1 depletion decreased KT recruitment of all three proteins by 80-90 % (Figure 
25B and C right panel). Thus, the recruitment of several SAC components to KTs 
strongly depends on Bub1 protein, but not Bub1 kinase activity. 
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Figure 25: Inhibition of Bub1 kinase does not significantly affect recruitment of SAC 
effectors to unattached KTs. (A) (B).  HeLa S3 cells were synchronized by thymidine 
block and released for 10 h in the presence of solvent (control), 3 µM BAY-320 or 7 µM 
BAY-524 (A). Cells transfected with mock (Gl2) or Bub1 siRNA-oligonucleotides (B) for 48 
h were synchronized and analyzed in parallel. Cells were fixed and stained for Bub1, 
Mad1, closed Mad2 (C-Mad2), CREST and DNA (DAPI) and analyzed by IFM. (C) 
Histogram shows average KT levels of indicated proteins (n=20-50 cells per condition) 
observed in the experiment shown in (A) and (B). Error bars represent SEM. Scale bar 
represents 10 µm. 
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The association of Bub1 with unattached KTs is dynamic (Howell et al., 
2004), raising the question of how Bub1 turnover at KTs is regulated. In the case of 
the SAC kinase Mps1, autophosphorylation constitutes a major mechanism for 
controlling Mps1 levels at KTs (Hewitt et al., 2010; Jelluma et al., 2010; Schubert et 
al., 2015b), and a recent study suggests that Bub1 turnover at KTs is also regulated 
by autophosphorylation (Asghar et al., 2015). To determine whether Bub1 
dynamics at KTs is affected by inhibition of Bub1 activity, we made use of an 
RPE1 cell line harboring one allele of Bub1 tagged by EGFP at the endogenous 
locus (Figure 26A and B). After treatment of cells with nocodazole to assure 
complete MT depolymerization and full SAC activation (Yang et al., 2009; 
Santaguida et al., 2011), Bub1 levels and turnover at KTs were measured by 
immunofluorescence microscopy and fluorescence recovery after photobleaching 
(FRAP), respectively. In comparison to control cells, neither BAY-320 nor BAY-524 
detectably affected steady-state Bub1 levels at KTs (Figure 26B-D), in line with a 
recent independent report (Liu et al., 2015). More importantly, FRAP experiments 
revealed only minor effects of Bub1 inhibition on Bub1 dynamics at KTs (Figure 
26B). The extent of fluorescence recovery after FRAP was not significantly 
different in control cells and inhibitor treated cells, revealing an immobile fraction 
of ~42%, in excellent agreement with previous data (Howell et al., 2004; Asghar et 
al., 2015). The half-time of Bub1 recovery at KTs after FRAP was ~18 sec in 
controls, again in good agreement with previous data (Howell et al., 2004; Asghar 
et al., 2015). However, whereas Asghar and colleagues observed a ~50% reduction 
in the half-time of recovery of an exogenously expressed, catalytically inactive 
EGFP-Bub1 mutant, we found that recovery of endogenously tagged wild-type 
EFP-Bub1 was only marginally accelerated by Bub1 inhibition (half-time reduced 
from 18 seconds to 12-15 seconds) (Figure 26B). These experiments suggest that 
the effects of Bub1 activity on Bub1 turnover at KTs are minor, at least when 
compared to the striking effects of Mps1 activity on Mps1 dynamics at KTs 
(Hewitt et al., 2010; Jelluma et al., 2010; Schubert et al., 2015b). Since, Bub1 protein 
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levels at KTs remained stable in Bub1 inhibited cells, we analyzed general Bub1 
stability during mitosis.  Bub1 is degraded during mitotic exit via mediated 
APC/CCdh1 (Qi and Yu, 2007). We could not observe any difference in the 
degradation profile between untreated cells and cell treated with our Bub1 
inhibitors, respectively (Figure 26E). Thus, the catalytic activity of Bub1 does not 
influence Bub1 stability during mitosis. 
 
 
 
 
Figure 26: Bub1 inhibition does not affect protein dynamics at the unattached KT. (A) 
Schematic illustrating the targeting strategy used to introduce the EGFP open-reading 
frame into the indicated locus of RPE1 cells. The EGFP open reading frame was fused to 
the 3’ exon of one allele of the BUB1L gene. (B) RPE1 cells expressing endogenously 
tagged Bub1-EGFP (Suppl. Fig. S6A) were synchronized in mitosis by overnight treatment 
with the Eg5 inhibitor STLC (10 µM) and subsequently treated with 3.3 µM nocodazole 
and 20 µM MG132 as well as solvent (control), 10 mM BAY-320 or 10 mM BAY-524. Bub1-
EGFP KT levels were recorded by 1 sec time-lapse microscopy. After 5 sec, a single KT 
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pair was bleached and fluorescence recovery was monitored. Traces illustrate average 
fluorescence recovery at KT pairs (n = 10–16 KT pairs per condition); shaded areas 
represent standard deviation (SD). Half-times and plateaus were determined by non-
linear curve fitting based on a one-phase association. (C) HeLa cells were synchronized by 
thymidine block and released for 10 h in the presence of solvent (control), 3 µM BAY-320 
or 7 µM BAY-524. Cells were fixed and stained for Bub1, CREST and DNA (DAPI) and 
analyzed by IFM. Scale bar represents 10 µm. (D) Histogram shows average Bub1 KT 
levels as measured in the experiment shown in (B); n=20-22 cells per condition. (E) 
Western blots showing Bub1 stability and degradation during mitosis and mitotic exit. 
HeLa cells were synchronized by thymidine block and released for 12 h in the presence of 
3.3 µM Nocodazole.  Mitotic cells were subsequently harvested by mitotic shake-off and 
replated. Those were released into fresh medium with solvent (control), 3 µM BAY-320 or 
7 µM BAY-524.Cells were harvested at the indicated time points. Cell lysates were 
analyzed by Western blotting, probing for Bub1, cyclin B1 and tubulin as loading control. 
(Panel B: data analysis with the help of Dr. Conrad von Schubert) 
 
 
As a further read-out for the effects of Bub1 inhibition on SAC activity, we 
used live cell imaging to monitor the responses of nocodazole-arrested HeLa and 
RPE1 cells to BAY-320 or BAY-524 and compared these to the responses seen in 
Bub1-depleted cells (Figure 27).  
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Figure 27: Bub1 inhibition in contrast to depletion, only marginally affects the spindle 
checkpoint. (A, B) Asynchronously growing cultures of HeLa S3 (A) or RPE1 (B) cells 
stably expressing GFP-tagged histone H2B were either directly treated with 3.3 µM 
nocodazole and the kinase inhibitors BAY-320 (3 mM) and BAY-524 (7 mM) or transfected 
with control (Gl2) or Bub1 siRNA for 48 h prior to addition of nocodazole. Cell fates 
(continued arrest, apoptosis or slippage) and duration of mitotic arrest were determined 
by fluorescence time-lapse imaging (n=150 cells per condition, accumulated from 3 
independent experiments). Frequencies of observed cell fates as well as average times of 
arrest are indicated. 
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Over a 24 hour observation period, the percentage of HeLa cells 
maintaining a SAC arrest dropped from 17% in controls to 4% and 2% in response 
to Bub1 inhibition by BAY-320 and BAY-524, respectively. These shifts in cell fates 
were largely compensated by increases in the percentages of cells undergoing 
apoptosis, from 71% in controls to 93%-94% in Bub1-inhibited cells. In contrast, the 
extent of mitotic slippage remained at less than 10%, under all conditions. In RPE1 
cells, maintenance of SAC arrest over 24 hours was more pronounced, but again 
the percentage of arrested cells dropped from 61% in controls to 51%/44% in 
response to Bub1-inhibition, with increasing proportions of cells undergoing 
apoptosis or mitotic slippage (Figure 27). For comparison, depletion of Bub1 from 
either HeLa or RPE1 cells resulted in a 2-3 fold increase in mitotic slippage at the 
expense of apoptosis, while the proportion of cells sustaining an arrest remained 
roughly constant (Figure 27). Collectively, these results indicate that Bub1 activity 
contributes to maintenance of maximal SAC activity, but that Bub1 protein levels 
are more important, most likely reflecting the observed role of Bub1 in the KT 
recruitment of SAC components (Figure 25).  
Importantly, we also compared the requirements for Bub1 activity and 
Bub1 protein in a cellular background in which SAC activity was partially 
compromised by treatment of HeLa or RPE1 cells with a low dose of Reversine, a 
widely used inhibitor of the SAC kinase Mps1 (Santaguida et al., 2010). In 
agreement with the results described above, Bub1 inhibition marginally reduced 
the time that Reversine-treated cells remained arrested before overriding 
nocodazole-induced arrest (Figure 28A and B left and middle panels). Thus, we 
compared the impact of Bub1 inhibition on the mitotic progression of cells with a 
compromised SAC to cells in which a different mitotic kinase was inhibited. 
Addition of Aurora B or Plk1 inhibitors, used as positive controls, led to the 
expected shortening of the duration of mitotic arrest (Figure 28A and B middle 
panels) (Saurin et al., 2011; Schubert et al., 2015b). Similarly, Bub1 depletion also 
caused a drastic shortening of arrest (Figure 28A and B right panels). Taken 
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together, and considering previous studies (Perera et al., 2007; Klebig et al., 2009), 
these observations demonstrate that the presence of Bub1 protein is more 
important for SAC signaling than Bub1 catalytic activity. 
 
 
 
 
 
Figure 28: Bub1 inhibition marginally affects SAC signaling. (A) Asynchronously 
growing HeLa S3 cells or HeLa cells stably expressing GFP-tagged histone H2B were 
treated with 3.3 µM nocodazole and 0.5 µM of the Mps1 inhibitor Reversine as well as 
solvent (control), 3 and 10 µM BAY-320, 7 and 10 µM BAY-524 or 2.5 µM of the Aurora B 
inhibitor ZM-447439 (ZM) (left and middle panel). Alternatively, cells were transfected 
with control (Gl2) or Bub1 siRNA oligonucleotides for 48 h prior to addition of 3.3 µM 
nocodazole and 0.5 µM Reversine (right panel). Cells were monitored by fluorescence 
time-lapse microscopy and the time elapsed from NEBD to SAC override and mitotic 
slippage was determined. Traces illustrate the cumulative frequency of mitotic duration 
before slippage (n=50 cells per condition). (B) Asynchronously growing RPE1 cells stably 
expressing GFP-tagged histone H2B were treated and analyzed as described in (A). Scale 
bars represent 10 µm. (Middle panels by courtesy of Dr. Conrad von Schubert) 
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3.1.9 Bub1 inhibition does not significantly interfere with chromosome 
congression  
 
To analyze the impact of Bub1 inhibition on chromosome alignment we 
treated cells with the Eg5 inhibitor Monastrol (Kapoor et al., 2000) and then 
monitored the restoration of KT-MT attachments during spindle bipolarization in 
response to drug washout (Figure 29). While nearly 28% of Bub1 depleted cells 
failed to completely align all chromosomes, more than 90% of Bub1 inhibited cells 
showed complete alignment that was indistinguishable from control cells. 
Inhibition of Aurora B, analyzed for control, resulted in the expected impairment 
of alignment (Figure 29).  
 
 
3. Results 
	83	
 
 
 
Figure 29: Bub1 inhibition does not significantly affect chromosome congression. (A) 
HeLa S3 cells were transfected with control (Gl2) or Bub1 siRNA-oligonucleotides for 48 
h, synchronized by thymidine block and released for 12 h in the presence of the Eg5 
inhibitor Monastrol to induce the formation of monopolar spindles. The capacity of 
spindle bipolarization and metaphase plate formation was tested by Monastrol wash-out 
and addition of MG132 and indicated drugs for 2 h (n = 170-200 cells). Percentages 
indicate the frequencies of depicted spindle morphologies. (B) Histograms show the 
frequencies of full, partial (≤5 unaligned chromosomes) or failed metaphase chromosome 
alignments that were observed in the experiment shown in (A). 
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To complement these assays, we also used immunofluorescence microscopy 
to quantify the frequency of micronucleation, a read-out for chromosome 
segregation errors, in HeLa and RPE1 cells. While partial inhibition of Aurora B 
kinase provoked an increase in micronucleation in both cell lines, as expected 
(Gohard et al., 2014; Tao et al., 2009), Bub1 inhibition only marginally increased 
the frequency of micronucleation (Figure 30A). This result supports the view that 
Bub1 inhibition causes surprisingly mild defects in chromosome congression or 
segregation (Figure 16 and Figure 29). Further corroborating this conclusion, we 
found that BAY-320 or BAY-524 treatment exerted no significant effects on the KT 
recruitment of the motor protein CENP-E (Figure 30B and C, left panels). In 
contrast, Bub1 depletion reduced CENP-E levels at KTs by ~40 % (Figure 30B and 
C, right panels), in agreement with previous reports (Sharp-Baker and Chen, 2001; 
Johnson et al., 2004).  
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Figure 30: Bub1 inhibition does not produce micronucleation or CENP-E mis-
localization. (A) HeLa S3 and RPE1 cells were treated for 16 h with the indicated drugs, 
fixed and analyzed by IFM. Histograms show the frequency of micronucleation among 
interphase cells (n=300 cells per condition). (B) Depletion but not inhibition of Bub1 kinase 
affects recruitment of CENP-E to unattached KTs. Untreated HeLa S3 cells or cells 
transfected with control (Gl2) or Bub1 siRNA-oligonucleotides (for 48 h) were 
synchronized by thymidine block and released for 10 h in the presence or absence of 3 
mM BAY-320 or 7 mM BAY-524. Cells were fixed and stained for CENP-E, CREST, DNA 
(DAPI) and analyzed by IFM. (C) Histograms show average CENP-E KT levels observed 
in prometaphase cells. Data relate to micrographs shown in (B). Error bars represent SEM. 
Scale bars represent 10 µm. 
 
 
Taken together, these results show that Bub1 kinase activity is largely 
dispensable for chromosome congression and segregation. It follows that even 
though Bub1 inhibition results in a marked reduction of Aurora B levels at 
centromeres (Figure 20), these levels are still sufficient to ensure largely faithful 
chromosome segregation. Conversely, Bub1 protein is clearly important for 
efficient chromosome congression, presumably reflecting the role of Bub1 in 
CENP-E recruitment to KTs. 
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3.1.10 Bub1 inhibition sensitizes HeLa cells to clinically relevant doses of 
Paclitaxel  
 
Interference with the SAC proteins Mps1 or BubR1 was previously shown to 
exert synergistic effects with Paclitaxel treatment of tumor cells, significantly 
elevating the frequency of chromosome missegregation and lethality (Janssen et 
al., 2009; Lee et al., 2004). Thus, we asked how inhibition of Bub1 kinase activity by 
BAY-320 or BAY-524 would impact on cells in which MT dynamics was 
compromised by low doses of Paclitaxel. Importantly, when used at clinically 
relevant doses of 1-4 nM, Paclitaxel induces spindle defects and aneuploidy 
without delaying mitotic progression (Brito and Rieder, 2009; Janssen et al., 2009; 
Ikui et al., 2005; Chen and Horwitz, 2002). While single treatment with 1-4 nM 
Paclitaxel produced modest impairment of cell proliferation, the concomitant 
application of the Bub1 inhibitors, BAY-320 at 3 mM or BAY-524 at 7 or 10 mM, 
clearly exacerbated inhibition of proliferation. Effects were particularly drastic in 
aneuploid HeLa cells (Figure 31A and B, top panels), while diploid RPE1 cells 
were less affected (Figure 31A and B, bottom panels). For comparison, we also 
examined the effects of combining low dose Paclitaxel treatment with partial 
inhibition of Mps1 by Reversine (Janssen et al., 2009). This analysis shows that the 
combination of Paclitaxel with either Mps1 or Bub1 inhibition produced similar 
synergistic effects, albeit with cell-type specific differences (Figure 31A and B). To 
what extent SAC inhibition differentially affects aneuploid versus diploid cells will 
thus require further investigation (Janssen et al., 2009; Kops et al., 2004; Maia et al., 
2015).  
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Figure 31: BAY-320 and BAY-524 treatment sensitizes cells to low doses of Paclitaxel. 
(A) Micrographs show colony formation of HeLa (top panel) and RPE1 cells (bottom 
panel) treated for 7 days with solvent (control) or the indicated kinase inhibitors in the 
presence or absence of 4 nM Paclitaxel. (B) Histograms quantify colony formation in HeLa 
(top panels) and RPE1 cells (bottom panels) treated with the indicated kinase inhibitors in 
the presence or absence of 1-4 nM Paclitaxel for 7 days. (Panel B by courtesy of Dr. 
Conrad von Schubert) 
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To determine whether the observed impairment of proliferation results from 
errors in chromosome segregation (Kops et al., 2004), we scored HeLa and RPE1 
cells expressing GFP-H2B for mild and severe chromosomal defects, as illustrated 
in Figure 32A. Following application of the above Paclitaxel and Bub1/Mps1 
inhibitor treatments, the frequencies of chromosomal defects were monitored by 
fluorescence time-lapse imaging and quantified (Figure 32B). Consistent with the 
micronucleation data described above (Figure 30A) Bub1 inhibition alone did not 
significantly elevate the frequency of chromosome missegregation in either HeLa 
or RPE1 cells (Figure 32B). For comparison, interference with the SAC by 
inhibition of Mps1 led to a marked increase in segregation defects in both cell 
lines, as expected (Figure 32B). Most importantly, HeLa cells displayed an even 
higher frequency of severe chromosome segregation defects when Bub1 inhibition 
was combined with 1-4 nM Paclitaxel, comparable to the consequences of 
combined Mps1 inhibition and Paclitaxel treatment (Figure 32B). In contrast, Bub1 
inhibition only marginally elevated the rate of Paclitaxel -induced chromosome 
missegregation in RPE1 cells, while combinatorial treatment with Reversine still 
resulted in a high rate of mild segregation defects.  
Considering the strong correlation in the data shown in Figure 29 and Figure 
32, it is tempting to conclude that chromosome segregation errors constitute the 
most likely cause for the observed impairment of cell proliferation when Bub1 
inhibition is combined with low dose Paclitaxel treatment. Thus, although 
inhibition of Bub1 kinase activity per se exerts only minor effects on SAC 
functionality, chromosome segregation and mitotic progression, treatment with 
BAY-320 or BAY-524 sensitizes cells to low, clinically relevant doses of Paclitaxel. 
These findings are clearly relevant for the potential therapeutic use of Bub1 
inhibitors. 
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Figure 32: Bub1 inhibition in combination with Paclitaxel treatments elevates the 
frequency of chromosome segregation defects. (A) Time-lapse stills of HeLa cells 
expressing H2B-GFP illustrate chromosome segregation defects that were used to classify 
cell fates in the experiments described in (B); arrowheads point to chromosome bridges 
and lagging chromosomes. (B) HeLa (top panels) and RPE1 cells (bottom panels) stably 
expressing H2B-GFP were treated with solvent (control) or the indicated kinase inhibitors 
in the presence or absence of 1-4 nM Paclitaxel and monitored by fluorescence time-lapse 
imaging. Histograms show the frequencies of chromosome segregation defects, following 
the classification illustrated in (A) (n=100 cells per condition). (Data by courtesy of Dr. 
Conrad von Schubert) 
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3.2 Evaluation of data-dependent and –independent mass spectrometric 
workflows for sensitive quantification of proteins and 
phosphorylation sites 
 
 
3.2.1 Aim of the Project 
 
The analysis of low-abundance proteins in complex mixtures has been a 
long-standing challenge in the field of mass spectrometry. Proceedings in the past 
10 years allow nowadays sensitive, hypothesis-driven analyses by focusing on 
proteins of interest. In this study the goal was to identify and develop a robust MS 
approach that is most suitable for the detection, identification and quantification 
of low abundant phosphorylated/unphosphorylated peptides in complex samples. 
The reason that prompted us to address this topic was the availability of different 
methods while their detailed comparisons with each other were lacking. In this 
regard the most popular MS approaches, data-dependent acquisition (DDA), 
directed and targeted MS, were compared and evaluated on the basis of their 
performance by analyzing spiked dilution curves of unmodified and 
phosphorylated peptides, covering several orders of magnitude in concentrations.  
The chosen method was then further validated in regard of robust 
identification and quantification of low abundant and transient phosphorylation 
sites, taking the SAC protein Mad1 as a model protein.  
 
 
3.2.2 Author contributions 
 
I performed all the sample preparations, MS analyses and peptide 
quantifications for the modified peptides. In addition I generated the Mad1 
phosphorylation site catalogue with the help of Dr. Luca Fava, Dr. Anna 
Santamaria and Dr. Alex Schmidt and performed Mad1 phosphorylation site 
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monitoring. I prepared the text regarding these analyses together with Dr. 
Alexander Schmidt.  All sample preparations and MS analyses regarding 
unmodified peptides, were performed by Dr. Manuel Bauer. Dr. Erik Ahrné 
performed all data analyses. Dr. Manuel Bauer, Dr. Erik Ahrné and myself 
contributed equally to this work.  
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ABSTRACT: In recent years, directed and, particularly,
targeted mass spectrometric workflows have gained momen-
tum as alternative techniques to conventional data-dependent
acquisition (DDA) LC−MS/MS approaches. By focusing on
specific peptide species, these methods allow hypothesis-driven
analysis of selected proteins of interest, and they have been
shown to be suited to monitor low-abundance proteins within
complex mixtures. Despite their growing popularity, no study
has systematically evaluated these various MS strategies in
terms of quantification, detection, and identification limits
when they are applied to complex samples. Here, we systematically compared the performance of conventional DDA, directed,
and various targeted MS approaches on two different instruments, namely, a hybrid linear ion trap−Orbitrap and a triple
quadrupole instrument. We assessed the limits of identification, quantification, and detection for each method by analyzing a
dilution series of 20 unmodified and 10 phosphorylated synthetic heavy-labeled reference peptides, respectively, covering 6
orders of magnitude in peptide concentration with and without a complex human cell digest background. We found that all
methods performed similarly in the absence of background proteins; however, when analyzing whole-cell lysates, targeted
methods were at least 5−10 times more sensitive than that of the directed or DDA method. In particular, higher stage
fragmentation (MS3) of the neutral loss peak using a linear ion trap increased the dynamic quantification range of some
phosphopeptides up to 100-fold. We illustrate the power of this targeted MS3 approach for phosphopeptide monitoring by
successfully quantifying nine phosphorylation sites of the kinetochore and spindle assembly checkpoint component Mad1 over
different cell cycle states from nonenriched pull-down samples.
KEYWORDS: Targeted mass spectrometry, directed mass spectrometry, data-dependent acquisition, peptide quantification,
limit of detection, phosphorylation, MAD1, cell cycle
■ INTRODUCTION
The identification and precise quantification of low-abundance
proteins within whole proteomes is still one of the major
challenges of mass spectrometry-based proteomics.1−6 This can
be mainly ascribed to the limited sequencing speed, sensitivity,
and dynamic range of current MS instruments in combination
with data-dependent acquisition (DDA) LC−MS workflows.7,8
The recent implementation of directed9−11 and targeted9,12,13
LC−MS workflows has tackled some of these limitations and
improved the dynamic concentration range over which proteins
can be detected and quantified for a selected set of proteins of
interest.10,11,14−16
In general, the dynamic detection range of DDA-driven
workflows critically depends on the sequencing speed of the
LC−MS platform employed. This is a result of the stochastic
peak selection starting with the most intense precursor ions and
the insufficient sequencing capabilities of current LC−MS
platforms to acquire MS/MS spectra of all detectable precursor
ions in the MS1 survey scans; this, in turn, hampers the
identification of low-abundance peptide ion signals when
analyzing complex peptide mixtures.8,17,18 These problems
can be largely overcome by data-independent acquisition (DIA)
workflows like directed or inclusion list driven LC−MS that
allow focused MS sequencing of a specific, predefined set of
precursor ion masses independent of their signal intensities.
The increased capability to identify low-abundance peptides
and proteins of directed over DDA LC−MS has been recently
demonstrated on a large scale.15,19 A significant advantage of
directed over targeted MS approaches is the high number of
peptides (up to several thousand precursor ion masses) that can
be analyzed per run using current high-performance LC−MS
platforms.20,21 On the other hand, the precursor ions have to be
detected in the MS1 survey scans to trigger a MS sequencing
attempt. This is challenging for low-abundance peptide species
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within complex mixtures due to the limited intraspectral
dynamic detection range.22,23
Targeted LC−MS, another DIA strategy, goes one step
further and overcomes this limitation by directly monitoring
MS/MS product ions without the need to detect peptide
precursor ions. The most popular approach is selected reaction
monitoring (SRM), in which the precursor ion and fragment
ion mass-to-charge (m/z) ratios as well as optimized collision
energies are predefined to monitor peptides of interest.24,25
Once these SRM assays are set up, they can be exchanged
between laboratories and instruments26,27 and thus represent a
rich resource for the community.8,28 Recently, several large-
scale studies have been conducted that generated SRM assays
for virtually all open reading frames for a number of species and
demonstrated the ability of this technique to potentially
monitor any protein of a given organism.8,29,30 Nonetheless,
accurate quantification of many low-abundance proteins within
very complex protein mixtures still requires additional sample-
and time-consuming fractionation/enrichment steps using
current LC−MS platforms.2,20,22,31,32
Pseudo-selected reaction monitoring (pSRM, also termed
product ion monitoring or parallel reaction monitoring (PRM)
with high-resolution/accurate mass LC−MS instruments) is
another targeted MS approach, in which whole MS/MS spectra
are acquired for sets of peptide ion masses of interest.1,6,33
These spectra can be employed for identification and, by
focusing on peptide specific product ions, also quantification.
With the ever increasing sequencing speed and resolution of
modern Orbitrap and time-of-flight mass analyzers, high-
resolution/accurate mass (HR/AM) pSRM/PRM approaches
are becoming increasingly popular; because assay development
efforts are reduced, fragments suitable for quantification can be
selected postacquisition, and the high resolution further
increases specificity and quantification confidence.1,6,13 Recent
instruments even allow co-selection, simultaneous fragmenta-
tion, and analysis of multiple peptides per MS scan,
considerably increasing peptide throughput per LC−MS
analysis.1 Considering the high popularity of the various DIA
approaches, it is surprising that no systematic performance
assessment, demonstrating the strengths and drawbacks of the
individual approaches, has so far been reported.
Here, we present a systematic evaluation of detection,
identification, and quantification limits for DDA and several
popular DIA MS approaches by analyzing spiked dilution
curves covering several orders of magnitude in concentrations
of unmodified and phosphorylated peptides. To our knowledge,
this is the first study that compares the most popular DDA and
DIA approaches systematically and on a quantitative basis.
Thus far, this has been done only in a semiquantitative fashion.7
Our assessment revealed that the high selectivity of HR/AM
pSRM considerably improved analytical sensitivity for complex
samples and that very sensitive phosphopeptide assays could be
established using higher stage fragmentation in linear ion trap
instruments. We illustrate the performance of these approaches
by monitoring multiple phosphorylation sites of the mitotic
spindle assembly checkpoint (SAC) protein Mad1 during
different cell cycle stages.
■ EXPERIMENTAL PROCEDURES
Cell Culture and Sample Preparation of Human Cell Digest
HeLa S3 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen, Carlsbad, CA) supplemented
with 10% heat-inactivated fetal calf serum (FCS) and penicillin-
streptomycin (100 IU/mL and 100 μg/mL, respectively,
GIBCO) at 37 °C in a 5% CO2 atm in a humidified incubator.
Cells (107) were collected by centrifugation, and cell pellets
were washed twice with PBS. Cells were lysed in 200 μL of lysis
buffer (8 M urea, 0.1% RapiGest, 0.1 M ammoniumbicar-
bonate) using strong ultrasonication, and total protein
concentration was determined by BCA assay (Thermo
Scientific) according to the manufacturer’s instructions. Then,
proteins were reduced with 5 mM TCEP for 60 min at 37 °C
and alkylated with 10 mM iodoacetamide for 30 min in the
dark at 25 °C. After quenching the reactions with 12 mM N-
acetyl-cysteine, protein samples were digested by incubation
with sequencing-grade Lys-C (1:200, w/w; Wako) for 4 h at 37
°C. Samples were diluted 1:4 with 0.1 M ammoniumbicar-
bonate buffer to reduce urea concentration to 1.6 M, and
digestion was continued by adding modified trypsin (1:50, w/
w; Promega, Madison, WI) overnight at 37 °C. Subsequently,
peptides were desalted on C18 reversed-phase columns
according to the manufacturer’s instructions (SEP-PAK Vac 3
cc 500 mg, Waters), dried under vacuum, and stored at −80 °C
until further use.
Generation of Serial Dilution Mixtures
We took advantage of an ongoing parallel study aimed at the
absolute quantification of centrosomal proteins and employed
the chemically synthesized 20 heavy-labeled reference peptides
(AQUA grade, Thermo Scientific, Table S1) as spike-in
standards for our systematic quantitative evaluation of different
MS approaches. In this study, for each of the 10 centrosomal
proteins of interest, the two full tryptic peptides with the
highest MS intensities lacking any missed cleavages were
selected as reference peptides. Subsequently, a mixture
comprising equal concentrations of all peptides was prepared,
and a dilution series was generated using 10-fold steps starting
from 0.5 pmol/μL to 0.5 amol/μL. To minimize peptide losses
during pipetting and storage, low binding tips (Axygen) and
glass vials (VWR International) were applied for all sample
preparation steps. Next, the same dilution series was prepared
adding the human cell digest sample at a concentration of 0.5
μg/μL to all samples.
In a second dilution experiment, we employed a standard
mixture containing 10 singly and doubly phosphorylated
peptides in equal amounts (MS PhosphoMix 1 Heavy, Sigma-
Aldrich, Table S1) and prepared the same two dilution series
(with and without a human cell digest) as described above,
starting from 50 fmol/μL to 0.5 amol/μL. Two microliters of
each sample was subjected to LC−MS analysis.
Data-Dependent Acquisition (DDA) LC−MS/MS
Peptides were separated on a RP-LC column (75 μm × 20 cm)
packed in-house with C18 resin (Magic C18 AQ 3 μm;
Michrom BioResources, Auburn, CA, USA) using a linear
gradient from 95% solvent A (98% water, 2% acetonitrile,
0.15% formic acid) and 5% solvent B (98% acetonitrile, 2%
water, 0.15% formic acid) to 30% solvent B over 40 min at a
flow rate of 0.2 μL/min. Each survey scan acquired in the
Orbitrap at 60 000 fwhm was followed by 20 MS/MS scans of
the most intense precursor ions in the linear ion trap with
enabled dynamic exclusion for 20 s. Charge state screening was
employed to select for ions with at least two charges and
rejecting ions with undetermined charge state. The normalized
collision energy was set to 32%, and one microscan was
acquired for each spectrum. Collision induced dissociation was
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triggered when the precursor exceeded 100 ion counts. The ion
accumulation time was set to 300 ms (MS) and 50 ms (MS/
MS). All samples were measured in triplicate. Phosphopeptide
analysis was carried out as described above with the following
modification: each survey scan was followed by 10 MS/MS
scans of the most intense precursor ions in the linear ion trap
with enabled multistage activation.
Directed (INL) LC−MS/MS
For directed LC−MS/MS, two inclusion mass lists comprising
the calculated ion masses of the observed precursor ions of
either 20 unmodified (Table S2) or 10 phosphorylated (Table
S3) peptides were generated and imported as mass lists to the
instrument software. LC−MS analysis was carried out using the
same settings as those for DDA analysis with a few
modifications: monoisotopic precursor selection was disabled,
and peaks with unassigned charge states were not rejected. This
helped to trigger more MS sequencing attempts. Furthermore,
the ion accumulation time for MS2 scans was set to 100 ms.
Pseudo-selected Reaction Monitoring (pSRM) LC−MS/MS
PRM was carried out in the linear ion trap (LIT) (CID) and
Orbitrap (HCD). For both experiments, the peptides and their
modifications were imported into Skyline software (version
2.4) (https://skyline.gs.washington.edu/labkey/wiki/home/
software/Skyline/page.view?name=default).17 The precursor
ion masses were automatically calculated, and the masses of
all observed precursor ions were exported as an instrument
method file (Tables S2 and S3). For pSRM-CID-MS2, ion
accumulation time was set to 10 ms, and the mass selection
window was set to 1 Da. The collision energy was set to 35%,
and the activation time was 10 ms. Fragment ions were scanned
from the lowest possible m/z to 2000 Th. For pSRM-HCD,
MS2 spectra were acquired at a resolution of 7500 (fwhm at
400 m/z), the ion accumulation time was 50 ms, the mass
selection window was set to 2 Da, the collision energy was 35%,
the activation time was 100 ms, and the measured mass range
was from 100 Th to 2 times the precursor mass. Additionally,
corresponding charge states were set in the instrument HCD
fragmentation method. For pSRM-CID-MS3 analysis, the
neutral loss masses were manually calculated and added to
the pSRM-CID-MS2 instrument method. Here, to increase
sensitivity, the mass selection window was set to 2 Da for MS2/
MS3 ion isolation, and an ion accumulation time of 50 ms was
applied.
SRM LC−MS/MS (Triple Quadrupole Instrument)
Data derived from a spectral library generated on the basis of
acquired HCD spectra of the standard peptide mix from the
PRM-HCD experiment were imported into the Skyline
program (version 2.4) to extract the corresponding fragment
ion masses and precursor ion masses (transitions). After
collision energy optimization, the five most suited transitions
per peptide were selected according to ref 9 and traced on a
triple quadrupole mass spectrometer (QqQ, TSQ Vantage,
Thermo Scientific) connected to an electrospray nano ion
source and easy nano-LC system (both Thermo Scientific)
using the same settings as those used for DDA LC−MS
analysis. The cycle time was set to 2 s, resulting in a dwell time
of 20 ms per transition. The transition lists with optimized
collision energies comprising the 20 unmodified and 10
phosphopeptides are provided as Supporting Information
Tables S4 and S5, respectively.
Peptide Quantification
All raw files were loaded into the Skyline software tool (version
2.4) to generate extracted ion chromatograms of the precursor
(up to 5) or fragment (up to 10) ions. The mass windows were
adjusted to the resolution applied in the corresponding MS
method. For PRM-CID methods, a mass window of 0.4 Da was
applied. To make the PRM-CID-MS3 data files readable for the
Skyline software, we converted the raw files to mzXML format
using MM-conversion tool (version 3.9, www.massmatrix.org)
and replaced the neutral loss masses used for MS3 by the
corresponding original precursor ion masses using an in-house
Perl script (available upon request). All integrated peak/
transitions were manually inspected and corrected or removed,
if required. The integrated and quantified peak/transitions
obtained for the different methods and samples are listed in
Tables S6−14. Finally, we generated dilution profile
correlations and applied an established algorithm19 to
determine LOQ and LOD values as well as linear correlations
(Pearson’s correlation coefficient (R2) from highest concen-
tration to LOQ) for each MS method and peptide analyzed
(Figures S3−S11).
Determination of Identification Limits
All raw files acquired by DDA, INL, and pSRM for the dilution
curve samples of unmodified peptides were converted to mgf
format using the MM-conversion tool (version 3.9, www.
massmatrix.org) and searched against a decoy (consisting of
forward and reverse protein sequences) human Swiss-Prot
database (download date 16/05/2012) containing known
contaminants, resulting in a total of 41 250 protein sequences
using Mascot (Matrix Science, version 2.4). The search
parameters were set as follows: full tryptic specificity was
required (cleavage after lysine or arginine residues unless
followed by proline); up to two missed cleavages were allowed;
carbamidomethyl (C) was set as fixed modification; oxidation
(M), label 13C(6)15N(2) (K), and label 13C(6)15N(4) (R) were
set as variable modifications; 10 ppm precursor mass tolerance;
and 0.6 (0.02) Da fragment mass tolerance for CID (HCD)
tandem mass spectra. After importing the data to Scaffold
software (http://www.proteomesoftware.com, version 4.2.1),
the FDR rate was set to <1% for MS/MS spectra identifications
by the Scaffold Local FDR algorithm based on the number of
decoy hits. All identified MS/MS spectra in the dilution curve
experiment for DDA, INL, and pSRM are available as Tables
S15−S17.
Monitoring of Mad1 Phosphorylation Sites
Cell Culture, Synchronization, and Kinase Inhibitors.
HeLa S3 cells were cultured as described above. Cell cycle
arrest in S-phase was induced by thymidine (2 mM, Sigma-
Aldrich) treatment for 24 h. For MS analysis of mitotic cell
cycle stages, cells were released from thymidine and arrested in
mitosis before harvesting. Mitotic arrest in prometaphase was
induced by nocodazole (0.5 μg/mL, Sigma-Aldrich) treatment
for 14 h after thymidine release. Mitotic cells were collected by
mitotic shake-off. Mitotic arrest in metaphase was induced by
addition of the proteasome inhibitor MG132 (10 μM,
Calbiochem) for 2 h, which was added 10 h after thymidine
release.
Cell Extracts and Immunoprecipitations. For preparing
extracts, HeLa S3 cells were washed once with ice-cold PBS and
resuspended in ice-cold lysis buffer (20 mM Tris, pH 7.4, 150
mM NaCl, 0.5% IGEPAL CA-630, 1 mM DTT, 30 μg/mL
RNase, 30 μg/mL DNase, protease inhibitor cocktail (Roche, 1
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EDTA-free tablet for 10 mL of lysis buffer) and phosphatase
inhibitors cocktail (cocktails 2 and 3; Sigma-Aldrich)) and
incubated for 30 min on ice. After cell lysis, suspensions were
cleared by centrifugation at 14 000 rpm for 15 min.
Immunopurification of endogenous Mad1 was performed
using 50 μL of solid Affi-Prep protein G matrix beads (Bio-
Rad Laboratories) chemically cross-linked to 1 μg/μL of
antibody12 against 1 to 2 mg of clarified cell lysate for 2 h at 4
°C. Afterward, the resin was washed with lysis buffer followed
by washing with HNN buffer (50 mM Hepes, pH 7.5, 150 mM
NaCl, 5 mM EDTA, 50 mM NaF). Proteins were eluted with
100 mM glycine, pH 2.8, neutralized by the addition of Tris
buffer (pH 8.0), reduced, alkylated, enzymatically cleaved, and
prepared for MS analysis as described above. For generating a
comprehensive phosphorylation site map of Mad1, immune-
purified proteins obtained from 10 (S-phase) and 15
(prometaphase and metaphase) 15 cm dishes were pooled,
divided in two aliquots, and subjected to the two different
phosphopeptide enrichment strategies described below. For
monitoring of Mad1 phosphorylation sites, sufficient protein
amounts could be obtained from one (S-phase) and two
(prometaphase and metaphase) 15 cm dishes. After sample
preparation, the peptide samples were dissolved in 40 μL of
0.1% formic acid containing 125 fmol/μL of each heavy-labeled
phosphopeptide.
Western Blot. HeLa S3 cells were synchronized with
thymidine and subsequently released into nocodazole for 14 h.
Cells were collected by mitotic shake-off, and Mad1 and
associated proteins were immunopurified from mitotic extracts.
The following antibodies were used for western blot: mouse
anti-Mad1,12 rabbit anti-Mad2 (Bethyl Laboratories, cat. no.
A300-301A, 1 μg/mL), and mouse anti-α-tubulin (Sigma-
Aldrich, cat. no. T9026, 0.2 μg/mL).
Phosphopeptide Enrichment (TiO2). Thirty microliters
of titanium dioxide beads (100 mg/mL, Titansphere, GL
Sciences Inc., Japan) was placed on self-made GELoader tips
(Eppendorf) plugged with a piece of C8 material (Empore, 3M,
3 M Empore C8 and C18 disks, 2214-C8, Bioanalytical
Technologies, St. Paul, MN). The columns were washed with
water (HPLC grade, Sigma-Aldrich), methanol, and a solution
of 80% ACN (Acetonitrile) and 2.5% TFA (trifluoroacetic acid)
saturated with phthalic acid. Digested and dried peptides were
reconstituted in 80% ACN and 2.5% TFA saturated with
phtalic acid and loaded on the microcolumns. To allow
maximal binding of phosphorylated peptides to the titanium
dioxide beads, the peptide−bead mixture was incubated for 10
min and then slowly passed through and applied two additional
times. The microcolumns were subsequently washed with a
mixture of 80% ACN and 2.5% TFA saturated with phthalic
acid, a mixture of 80% ACN, 20% water, and 0.1% TFA, and,
finally, with 0.1% TFA. Phosphorylated peptides bound on the
TiO2 were eluted with a 0.3 M ammonium hydroxide solution.
Phosphopeptide-enriched eluates were immediately acidified
with 2 M HCl and 5% TFA, desalted, purified on C18
microspin columns (Harvard Apparatus), and dried in a
SpeedVac concentrator.
Phosphopeptide Enrichment (IMAC). PHOS-select iron
affinity gel beads (Sigma-Aldrich) and dried peptides were
resuspended in 30% acetonitrile/250 mM ethanol. IMAC beads
and peptides were shaken at room temperature at 1400 rpm for
2 h. Subsequently, samples were loaded three times in a
constricted GELoader tip and washed four times with 30%
acetonitrile/250 mM ethanol. Phosphorylated peptides were
eluted using 50 mM Na2HPO4/NH3 (pH 10.0), acidified with
100% ethanol and 10% TFA (pH < 3.5), desalted, and passed
to LC−MS/MS analysis.
Generation of a Mad1 Phosphorylation Site Cata-
logue from Phosphopeptide-Enriched Samples. One
microgram of total phosphopeptides was subjected to DDA
LC−MS/MS using HCD and CID with enabled multistage
activation fragmentation, as specified above. Acquired raw files
were database-searched using Mascot and Scaffold software, as
described above, with the following parameter modification:
oxidation (M), label 13C(6)15N(2) (K), label 13C(6)15N(4)
(R), and phosphorylation (S, T, Y) were set as variable
modifications. The identified proteins, peptides, and MS/MS-
spectra (Tables S18−S20) were filtered to a FDR of 1%
according to the Scaffold Local FDR algorithm based on the
number of decoy hits. A list of all MS/MS spectra assigned to
Mad1 phosphopeptides is shown in Table S21, and a summary
list comprising all identified Mad1 phosphorylation sites is
illustrated in Table 1. Protein probabilities were assigned by the
ProteinProphet program.34 Proteins that contained similar
peptides and could not be differentiated on the basis of MS/MS
analysis alone were grouped to satisfy the principles of
parsimony. Proteins sharing significant peptide evidence were
grouped into clusters. The location of the phosphorylated
residues was automatically assigned by Mascot (score >10). All
annotated spectra, MS raw files, and search parameters
employed have been deposited to the ProteomeXchange
Consortium (http://proteomecentral.proteomexchange.org)
via the PRIDE partner repository35 with the data set identifier
PXD000964 and DOI 10.6019/PXD000964.
Mad1 Phosphorylation Site Monitoring. Heavy-labeled
reference peptides were synthesized for all identified
phosphopeptides of Mad1. For precise quantitation of the
single-serine phosphorylation sites at positions S484, S485,
S486, and S490, we ordered all possible monophosphorylated
versions of the corresponding heavy reference peptide
(SQSSSAEQSFLFSR, Table 1). All different phosphopeptide
sequences and modifications together with the identified MS/
MS spectra from the previous phosphorylation catalogue
experiment were imported into Skyline software (version 2.4)
to set up a pSRM method to monitor all phosphopeptides. In
an initial analysis, we carried out MS2- and MS3-based PRM
analysis to select for the best transitions for each peptide.
Because of their higher selectivity and lower noise levels,
transitions originating from MS3 scans were preferred, if
available. Phosphopeptides were quantified using the Skyline
tool and the same parameters as described above. The
quantitative results, including normalization, ratio determina-
tion, and statistical analysis, are summarized in Tables S22 and
S23.
For the determination of phosphorylation site stoichiome-
tries and to compensate variations in Mad1 concentrations,
additional label-free quantification experiments of the same
samples were carried out as described recently.36 In brief, 1 μg
of peptides was subjected to DDA LC−MS/MS analysis using
CID with enabled multistage activation fragmentation and the
same LC and MS settings as specified above. LC−MS
Progenesis software (version 4.1.4832.42146) in combination
with the Mascot database search tool (version 2.4) was
employed to identify and quantify unmodified and modified
Mad1 peptides using the same database search parameters for
phosphopeptides as described above. Importantly, the Pro-
genesis software was set such that only nonconflicting peptides
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with specific sequences for single proteins in the database were
employed for quantification. The results were further statically
validated by our in-house software tool SafeQuant (available
upon request), as recently shown.36 All identified and
quantified peptides are listed in Table S24. Differences in
Mad1 concentrations in the samples were normalized using the
sum of all MS intensities generated from Mad1 peptides. The
corresponding normalization factors using the first sample as
base are displayed in Table S23. The data file names of LC−MS
runs of all samples analyzed in this study are shown in Table
S25.
■ RESULTS AND DISCUSSION
Experimental Overview
The general aim of this study was to assess the capabilities of
three recently established LC−MS strategies in terms of
sensitivity and linear relative quantification range for a variety of
different peptides in the presence and absence of a complex
analytical background (Figure 1). Therefore, we prepared serial
dilutions of two different peptide mixtures consisting of 20
unmodified and 10 phosphorylated chemically synthesized
heavy peptides (for selection criteria, see Experimental
Procedures) covering a concentration range of 6 and 5 orders
of magnitude, respectively (referred to as neat samples). To
assess analytical performance under a more realistic scenario,
we prepared the same dilution series with a complex human
digest spiked into each sample (referred to as complex
samples). This allowed us to precisely determine the impact
of the analytical background on limit of detection (LOD),
quantification (LOQ), and identification (LOI) for each
peptide and MS approach applied in this study. The four
dilution series were analyzed in duplicate using the following
data-dependent (DDA) and -independent acquisition (DIA)
MS approaches. (i) In DDA, only peptides of the highest
intensities in the acquired survey scans are selected for MS
sequencing, whereas many other peptides of sufficient intensity
for identification pass through the instrument to remain
unidentified. (ii) A directed LC−MS/MS strategy (also termed
inclusion mass list driven, INL) that attempts to overcome this
limitation by directing MS sequencing to the precursors of
interest independent of their MS intensities using an inclusion
mass list.10,11,14,15 Although several thousand peptides can be
analyzed by this approach, a drawback is the necessity to detect
the precursor ions in the MS1 survey scans to trigger
fragmentation. (iii) Targeted LC−MS/MS methods (selected
reaction monitoring (SRM) and pseudo-selected reaction
monitoring (pSRM, like SRM, but a full MS/MS scan is
acquired) that directly fragment selected peptide ions and use
the corresponding fragment ions for identification and
quantification. We analyzed each sample by SRM using a triple
quadrupole (QqQ) MS and by pSRM using collision induced
dissociation (CID, ion detection in the linear ion trap (LIT))
based fragmentation. For phosphopeptide analysis, we addi-
tionally carried out higher energy collision dissociation (HCD,
ion detection in the orbitrap) and neutral loss MS2/MS3 CID
fragmentation in the LIT. All peptides were quantified using
Skyline,17 and fragment spectra were identified by database
searching. Finally, we generated dilution profile correlations for
each peptide and MS method and applied an established
algorithm19 to determine linear quantification ranges as well as
identification, quantification, and detection limits.
Impact of Analytical Background on Limit of
Detection/Quantification of Unmodified Peptides
First, we assessed the effect of the analytical background on the
dynamic detection and quantification range of the four popular
MS approaches. This included data-dependent acquisition
(DDA); directed, inclusion mass list driven peak selection
(INL); selected reaction monitoring (SRM) on a QqQ; and
pSRM (pSRM-CID) on a LIT LC−MS platform. We
determined LODs and LOQs for all peptides and every MS
strategy in the presence and absence of a complex human cell
digest. In general, we found a very high and linear correlation of
peak intensity and analyzed peptide amounts for all MS
approaches employed down to the low attomole level (Figures
S3−S6). A typical example is illustrated in Figure 2A. For this
peptide, LOD/LOQ were found to be in the low attomole
range when analyzed by SRM (Figure 2A). However, LOD/
LOQ increased by a factor of 10 when analyzing this peptide in
the context of a complex human digest (Figure 2B). The
observed trend of elevated LOD/LOQ values with increased
Figure 1. Experimental overview. Two dilution series were generated
from two mixtures containing equal amounts of (i) 20 unmodified and
(ii) 10 monophosphorylated, respectively, heavy-labeled reference
peptides. Additionally, a HeLa whole-cell extract was prepared,
digested with trypsin, and spiked into each dilution series sample.
The mixtures were analyzed by liquid chromatography−tandem mass
spectrometry using three distinct methods to quantify the peptides of
interest: data-dependent acquisition (DDA), directed or inclusion list
driven (INL) LC−MS, and various targeted LC−MS workflows.
These include selected reaction monitoring (SRM) on a triple
quadrupole instrument, pSRM on a linear ion trap (LIT) and Orbitrap
instrument, and higher stage fragmentation for phosphopeptides on a
LIT instrument. For all methods, peak integration and quantification
were carried out using the Skyline software suite,17,29,30 and full MS/
MS spectra were database-searched by the Mascot search engine for
identification.2,20,22,54 From this data, limits of detection, quantifica-
tion, and identification were determined for each LC−MS method and
dilution series using recently established algorithms.1,6,19,33
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sample complexity was confirmed for all peptides (Figure 2C).
Although all four methods achieved similarly low LODs/LOQs
with neat samples, LODs/LOQs increased in the complex
samples to the mid attomole range for the targeted MS
approaches and high attomole range for MS1-based quantifi-
cation approaches (DDA and INL, Figure 2C). The lesser
increase in LOD/LOQ of the targeted MS methods is expected,
as these approaches do not need to detect the precursor ions in
the MS1 survey scans and have a higher selectively due to the
double mass filtering applied. Nonetheless, the performance of
targeted approaches is also affected by the analytical back-
ground present in the sample and considerably decreases the
sensitivity of peptide assays by 10-fold for pSRM-CID and 20-
fold for SRM. Therefore, like DDA-based analysis, reduction of
complexity (e.g., by sample fractionation,20 immune purifica-
tion/depletion,22 or use of longer LC columns24) is an efficient
way to increase the sensitivity of targeted MS assays in complex
mixtures. An advantage of the pSRM approach over SRM is
that less prior information is required to set up the assays
(basically, the peptide ion masses are sufficient) and transition
selection can be carried out after the LC−MS analysis.1,6 This
allowed us to remove outliers and pick the most intense
fragment ions for quantification postanalysis. By contrast,
fragment ion masses and their fragmentation parameters have
to be defined before SRM-based analysis. In line with previous
studies,26 popular and ubiquitous LIT−MS achieved very good
sensitivities, making them a suitable alternative for targeted MS
analysis in the event that QqQ instruments are not available.
However, the current sequencing speed of LIT does not match
the number of transitions monitored by SRM on a QqQ
Figure 2. Defining detection and quantification limits for unmodified peptides. The peak intensities and peptide concentrations were plotted for each
peptide and LC−MS method to compute linear regression (squared Pearson correlation (R2) from highest concentration to LOQ) as well as limit of
detection (LOD) and limit of quantification (LOQ). (A) Plot of the peptide INEVLAAAK analyzed by SRM in the neat dilution series. The R2,
LOD (red), and LOQ (blue) are indicated. (B) Similar to panel A for the same peptide analyzed in the context of complex human cell digest. (C)
Box plot showing the LOD values obtained for the four different LC−MS methods applied for the neat (−) and complex (+) dilution series. The box
covers the lower and higher quartiles. The median LODs are indicated as a black bar. The whiskers correspond to the maximum and the minimum
values, excluding outliers. Outliers that exceed 1.5 times the lower or upper quartile were not considered and are shown as black circles. (D) Similar
to panel C, showing the impact of the complex analytical background on the individual LOD values of each MS method.
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instrument and therefore fewer peptides can be monitored by
pSRM than by SRM. In our study, around 2.5 (5) times more
peptides could be quantified by SRM (5 transitions per
peptide) compared to that by pSRM-CID (HCD) in a single
LC−MS run.
Naturally, since DDA and INL differed only in the way the
precursor ions were picked for MS/MS analysis, both
approaches showed similar LOD/LOQ values determined
from the MS1 spectra (Figure 2C). The smaller LOD/LOQ
loss and the slightly lower LOD/LOQ values observed for the
DDA method in the complex samples (Figure 2C,D) could be
explained by the higher resolution applied for the DDA
approach (60 000 at 400 m/z (fwhm)) compared to that for
INL (30 000 at 400 m/z (fwhm)). Because, in a normal DDA/
Figure 3. Defining limits of identification for unmodified peptides. (A) The graph shows the number of peptides correctly assigned by the database
search tool dependent on their concentration for three different LC−MS approaches and the neat dilution series. (B) Similar to panel A, but for the
complex dilution series samples. (C) MS/MS spectrum acquired by pSRM-CID having the highest Mascot ion score (46.3) for the heavy (*Lys-8)
peptide SQGLDVQEPPVK* at 1 fmol concentration in the complex sample. (D) Similar to panel C, obtained by directed (INL) LC−MS at 1 fmol
concentration in the complex sample. (E) Similar to panel C, but at 100 amol concentration acquired from the neat sample. (F) Similar to panel C,
but acquired in the complex sample at a 10-fold lower concentration (100 amol).
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INL LC−MS experiment, each peak has to be identified by MS
sequencing to be assigned for analysis, these LOD and LOQ
values do not represent the true dynamic range usually achieved
by these methods. Therefore, defining limits of identification
(LOI) will result in a more meaningful assessment and
comparison of these two approaches. This will be further
investigated below.
To conclude, all methods achieved similar LODs/LOQs in
the low-complexity samples, and these values increased
considerably with higher sample complexity. As expected,
targeted methods are less affected by analytical background
than that of the DDA and INL approaches. Nonetheless, the
sensitivity of SRM assays will also benefit considerably from a
reduction of sample complexity. On average, for complex
samples, LODs/LOQs of targeted approaches were 5−10-fold
lower than those of DDA/INL approaches for the peptides
analyzed in this study.
Determining Limit of Identification for Unmodified
Peptides
As mentioned above, LOI is a better indicator to assess the
performance of the INL and DDA methods. To define LOIs,
we searched all MS/MS spectra acquired with the DDA, INL,
and pSRM-CID approaches against a human database and
applied a peptide false discovery rate of 1% to all samples (see
Experimental Procedures). When analyzing low-complexity
samples, more peptides were identified at low concentrations
using the INL approach compared to that using DDA (Figure
3A). In particular, in the mid concentration range at 1000 amol,
almost all peptides were identified by INL, whereas DDA
identified only 6 out of 20. Further zooming in on this issue, we
found that, at low concentrations, many peptides were not
fragmented by DDA and therefore were not identified.
Apparently, disabling most peptide ion detection filters of the
instrument software (see Experimental Procedures) resulted in
more identifiable peptide specific MS/MS scans from the
inclusion mass list for very low-intensity signals. This suggests
that implementing more sophisticated peak detection algo-
rithms for peptide ions could increase the overall sensitivity of
DDA LC−MS. The lowest LOIs could be achieved by pSRM-
CID, indicating that meaningful MS/MS spectra could be
generated in the highly sensitive LIT even if no precursor ion
was detectable in the survey scan acquired in the less sensitive
Orbitrap. Therefore, to exploit the full sensitivity of an LIT in
the hybrid LC−MS platform employed, a more sensitive
Orbitrap would be beneficial to further improve LOIs for
DDA/INL in low-complexity samples.
Compared to neat samples, LOIs increased significantly for
all approaches upon higher sample complexity, and only minor
differences in identification limits were observed across the
three methods (Figure 3B). This indicates that limited MS/MS
scan speed (tackled by the INL approach) and triggering of
MS/MS spectra (overcome by the pSRM-CID approach) had
only a minor impact on identification rates when analyzing
complex samples. Interestingly, LOIs were, on average, 10−
100-fold higher than the corresponding LODs, suggesting that
many precursor ions that were easily detectable in the MS1
scan and consequently fragmented remain unidentified by
database searching (Figure 2C). Therefore, we next investigated
if the interpretation of these MS/MS spectra by the database
search software was hampered at low peptide concentrations. A
typical example is shown in Figure 3C. At a concentration of 1
fmol, the peptide could be unambiguously identified by pSRM
and INL in the complex sample with the corresponding
fragment ions dominating the MS/MS spectrum (Figure
3C,D). After reducing the concentration by 10-fold, the
fragment ions, albeit present, were masked by interfering
peaks, which complicated the interpretation of this MS/MS
spectrum and resulted in an insignificant Mascot ion score
(Figure 3E). Without background, high-quality MS2 scans are
obtained at this low concentration (Figure 3F). From this, one
can conclude that the ratio of precursor-specific fragments to all
fragment ions present in the MS/MS spectra is a far more
critical parameter for the successful identification of low-
abundance peptide species within complex samples than is MS/
MS scan speed or dynamic detection range within the MS1
scan. As a result, the increasing prevalence of interfering peaks
ultimately defines LOIs for the DDA and INL approaches
evaluated in this study. This is in line with a recent publication
showing that MS/MS spectra become progressively more
difficult to identify if precursor ion intensity is lower than the
sum of all other co-fragmenting ions within the mass selection
window. The authors further report that this was the case for
the large majority of MS/MS spectra acquired in a single-shot
LC−MS/MS analysis.8 Consequently, reducing the amount of
co-fragmenting peptides by applying smaller mass selection
windows,8 using software that can identify multiple co-
fragmenting peptides from the same MS2 spectra,31,32
extracting co-eluting peptides,8,37 or using fragment ion-specific
search tools10,11,38,39 are useful approaches to extract the
relevant fragment ions from noisy spectra and improve the
identification rate of low-abundance peptides for these types of
analyses. Furthermore, spiking in heavy reference peptides at
high concentrations that are amenable to database searching is
an effective way to assign the corresponding precursor/
fragment ions of the endogenous peptide and considerably
improve analytical sensitivity, as demonstrated for the INL
approach.40
To conclude, besides limited sequencing speed and dynamic
detection range, co-fragmentation of peptides with similar ion
masses and elution profiles contributed, to a large extent, to the
high LOIs observed when analyzing complex samples. Smaller
mass selection windows and adequate software tools that
extract relevant fragment ions will be useful to lower LOIs;
however, for very complex samples, co-fragmentation will
remain a major challenge for single-dimension LC−MS
analysis.8,15,16 Notably, because only correctly identified
peptides are amenable to quantification in standard DDA and
INL workflows, the LOIs actually define the LODs/LOQs
achieved in our experimental setup for these two MS methods.
With LOIs being in the low femtomole range, the actual
LODs/LOQs achieved by the DDA and INL methods were
therefore several fold higher than those determined solely from
the precursor ions in the MS1 scans.
Impact of Analytical Background on Limit of
Detection/Quantification of Phosphopeptides
Although the SRM and the corresponding pSRM methods
showed the highest sensitivity for monitoring unmodified
peptides within complex mixtures, we next asked if this was also
the case for modified peptide species with altered fragmentation
patterns. To evaluate this, we employed a commercial mix
comprising 10 absolutely quantified phosphopeptides carrying
single or multiple phosphorylations, as identified in a recent
large-scale study using LIT-based fragmentation.8,18,41 To
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minimize sample consumption and cost, we prepared a 10-fold
dilution series starting from 100 fmol down to 1 amol.
We added two more targeted MS analysis methods to our
evaluation that are specifically suited for phosphopeptide
analysis, namely, higher stage fragmentation (MS3)15,42 and
Figure 4. Defining detection and quantification limits for phosphorylated peptides. (A) MS/MS spectrum acquired by pSRM-CID-MS2 of the heavy
(*Arg-10) phosphopeptide RDSLGpTYSSR* in the neat sample and assigned with the highest Mascot ion score (45.1). The assigned b- (red) and
y-ions (blue) as well as the neutral loss peaks (green) are indicated. (B) Plot of the peak intensities and concentrations of the heavy (*Arg-10)
phosphopeptide RDSLGpTYSSR* using the pSRM-CID-MS2 approach. The computed linear regression (squared Pearson correlation (R2) from
highest concentration to LOQ) as well as limits of detection (LOD) and quantification (LOQ) are shown. (C) MS3 spectrum acquired from the
neutral loss peak of the same phosphopeptide having the highest ion score (66.0). The assigned b- (red) and y-ions (blue) as well as the neutral loss
peaks (green) are indicated. (D) Similar to panel B, but for the pSRM-CID-MS3 method. (E) Box plot showing the LOD values obtained for the 6
different LC−MS methods applied for the neat (−) and complex (+) dilution series. The box covers the lower and higher quartiles. The median
LODs are indicated as a black bar. The whiskers correspond to the maximum and the minimum values, excluding outliers. Outliers that exceed 1.5
times the lower or the upper quartile were not considered and are shown as black circles. (F) Similar to panel E, showing the impact of the complex
analytical background on the individual LOD values of each MS method.
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high-resolution higher energy collision dissociation
(HCD).21,43 We performed MS3 of neutral loss peaks that
frequently dominate CID spectra of serine and threonine
phosphorylated peptides and thereby mask peptide-specific
fragment ions required for identification and quantifica-
tion.23,42,44 This method has been recently demonstrated to
be well-suited for quantification of selected phosphopeptides by
targeted MS.25,45 We observed neutral loss peaks in 8 of the 11
MS/MS spectra identified and generated MS3-based pSRM
assays for the corresponding peptide ions. The higher
selectivity gained by the additional fragmentation step can be
nicely demonstrated in Figure 4. The phosphopeptide
RDSLGpTYSSR showed a strong neutral loss peak in the
MS2-CID spectra, which masked sequence-specific fragments
amenable for quantification (Figure 4A). Conversely, the MS3
spectra of the neutral loss peak generated a concert of fragment
ions suited for identification and quantification (Figure 4C).
Switching from pSRM-CID-MS2 to MS3-based analysis
decreased LOD/LOQ in the complex samples for this peptide
by almost 2 orders of magnitude, down to the low attomole
range (Figure 4C/D). As is apparent from Figure 4D, this
additional mass filter lowered LOQs without compromising the
linearity of quantification. The additional fragmentation step
only marginally increased the scan time of MS3 assays by 30 ms
and did not compromise peptide throughput. Additionally, we
quantified each phosphopeptide by high-resolution (7500
fwhm at 400 m/z (fwhm)) HCD fragmentation-based pSRM
assays. Unfortunately, the instrument software did not support
multistage activation-based pSRM-CID analysis27,42 and there-
fore we could not include this popular phosphopeptide analysis
technique in our comparison. Because only minor performance
differences were observed in the first experiments between the
DDA and INL approaches, we carried out only DDA analysis
for the phosphopeptide samples.
Compared to unmodified peptides, the phosphopeptides
analyzed generally showed a much higher variation, and higher
Figure 5. Dependence of peptide length on the limits of detection achieved for the different samples and best performing methods. For each peptide,
the number of amino acids against the LODs achieved in the complex (red) and the neat (black) dilution series samples is shown. The plots for 20
unmodified peptides analyzed by DDA (A), SRM (B), and pSRM-CID-MS2 (C) are shown. The same plots are illustrated for the phosphopeptide
dilution series analyzed by DDA (D), pSRM-HCD-MS2 (E), and pSRM-CID-MS3 (F). The trend lines and squared Pearson correlations (R2) as
well as the p-values are indicated for each plot and dilution series, respectively. We performed an ordinary least-squares regression, describing
log(LOD) as a function of log(peptides length) (formally, log(LOD) = k log(PepLength) + m). The calculated p-value is the probability that the
slope parameter k equals 0 given the observed data.
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LOD/LOQs were determined for all methods and samples
(Figure 4E). In line with the results obtained for unmodified
peptides, detection limits increased in the complex samples for
all methods, most dramatically by 30-fold for the DDA
approach and by 10-fold for SRM and pSRM-MS2-CID, and
only little impact on LOD/LOQ values was observed for HCD
(4-fold increase) and MS3 (2.5-fold increase) based pSRM
strategies (Figure 4F). This can be mainly ascribed to the much
smaller mass windows that could be applied for fragment ion
extraction with HCD/Orbitrap MS2 scans and the additional
isolation/fragmentation step for MS3 that considerably reduced
noise and interfering peaks in the MS spectra. Figure S1 shows
a typical phosphopeptide that was analyzed by all five methods
with and without the presence of a human cell digest. We
observed good linearity for all methods, with the MS3 method
covering the largest dynamic concentration range for analyzing
this phosphopeptide within a complex sample. The improved
selectivity of HCD and MS3 can be illustrated with the
transitions extracted for this peptide at 1 fmol concentration
within a complex analytical background. Although DDA, SRM,
and pSRM-CID-MS2 all showed very high noise levels and an
accumulation of interfering peaks, the small mass extraction
windows applied for pSRM-HCD-MS2 and the additional
fragmentation step for the pSRM-CID-MS3 method consid-
erably increased the selectivity and facilitated accurate peak
interpretation (Figure S1L,O). Because the pSRM-CID-MS3
approach was not applicable to all phosphopeptides, due to
missing neutral loss peaks, we set up a combined approach of
MS2 and MS3 pSRM-CID-MS2 and selected the most sensitive
assay for each peptide based on the complex sample series. This
hybrid pSRM-MS2/MS3 method showed the lowest decrease
in sensitivity upon increased sample complexity of only 2-fold
(Figure 4F) and therefore also the lowest LODs/LOQs in the
complex sample (Figure 4E).
To conclude, like that for unmodified peptides, the sensitivity
of phosphopeptide detection critically depends on sample
complexity for most approaches. High-resolution HCD
fragmentation and, in particular, higher stage fragmentation
(MS3) were found to be the most sensitive MS methods that
were least affected by the analytical background. To
demonstrate the power of this MS3 approach, we applied it
to directly monitor phosphorylation changes in the mitotic
spindle assembly checkpoint (SAC) protein Mad1 during cell
cycle progression (see below).
Impact of Peptide Size on Limit of
Detection/Quantification
Defining LODs/LOQs for 30 peptides allowed us to
additionally evaluate the impact of general peptide properties
on the sensitivity of the various MS methods tested.
Interestingly, we found a strong and significant correlation
between peptide length and LOD for all targeted, but not for
MS1-based, DDA/INL LC−MS/MS methods. This was
observed for the unmodified (Figure 5A−C) and phosphory-
lated (Figure 5D−F) peptides analyzed. Apparently, the higher
number of fragment ions produced by longer peptides diluted
the MS signal to many more ions compared to smaller peptides
that generated fewer product ions. Intriguingly, no significant
peptide length dependencies were found for precursor ion-
based quantification methods (Figure 5A,D). This observation
is further supported by a recent publication demonstrating a 3-
fold loss of sensitivity when analyzing the same peptide using
pSRM (fragment-based quantification) over single ion
monitoring (precursor ion-based quantitation).1 In this study,
the impact of peptide size on assay sensitivity was even stronger
for the peptides analyzed. On average, reducing peptide size by
8 amino acids lowered LOD for SRM and pSRM analysis by 1
order of magnitude for the unmodified and phosphorylated
peptides (Figure 5). Therefore, focusing on smaller peptides
could be an additional and easy to implement parameter to
improve the sensitivity of MS assays for protein quantification.
It is important to note that peptides selected for targeted
analysis should not be too small so that a sufficient number of
specific transitions is available for confident peak assignment,
particularly if larger mass selection windows are applied.46 Of
note, with their high selectivity and specificity, the new HR/AM
PRM approaches have demonstrated that confident peptide
assignment can be achieved with as few as 3 transitions.6 This
makes this promising MS technology particularly well suited for
the targeted analysis of shorter peptides.
Table 1. Phosphopeptides Identified for the Protein Mad1
1Best ion score determined by the Mascot search engine. A detailed list of all identified MS/MS spectra is shown in Tables S20 and S21. 2Obtained
from www.phosphosite.org (20/05/2014). 3Predicted consensus motifs for Mps1,55,56 Plk1,57,58 Cdk1,58,59 and ATM/ATR49,60 kinases.
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Application to Mad1 Phosphorylation Site Monitoring
To demonstrate the power of the pSRM-CID-MS3 approach
for sensitive phosphopeptide analysis, we applied it to monitor
phosphorylation changes of the SAC protein Mad1 during cell
cycle progression directly from pull-down experiments. Mad1 is
one of the core proteins of the SAC, a surveillance mechanism
that delays chromosome segregation until chromosome
biorientation is achieved. Mad1, in complex with Mad2,
transduces this wait anaphase signal at unattached kineto-
chores.47 During interphase, Mad1 is located at the
nucleoplasmic side of the nuclear envelope and then trans-
locates to kinetochores after nuclear envelope breakdown
(NEBD).47,48
Careful mapping of Mad1 phosphorylation sites at different
cell cycle stages proved to be challenging. Although
immunoprecipitation of Mad1 from mitotic cells was efficient
(Figure 6A), phosphorylation events on Mad1 proved to be
transient and/or of low stoichiometry. Thus, preliminary
experiments showed that Mad1 phosphorylation analysis was
not reproducible enough to consistently quantify all identified
phosphopeptides across all samples (unpublished data). In
addition, the high number of cells required for efficient
phosphopeptide enrichment further complicated these experi-
ments and increased the cost associated with sample
preparation. Therefore, we applied the sensitive pSRM-CID-
MS3 method to monitor all detectable Mad1 phosphorylation
sites directly from minimal amounts of immunopurified Mad1
without phosphopeptide enrichment.
In a first step, we carried out an in-depth DDA MS analysis
of phosphopeptides extracted from a pool of Mad1
immunopurifications obtained from each cell cycle state to
generate an extensive catalogue of Mad1 phosphorylation sites.
We identified a total of 17 unique phosphopeptide ions
corresponding to 13 different phosphorylation sites, of which
seven were previously unknown (Table 1). Subsequently,
heavy-labeled reference peptides were synthesized for all
identified phosphopeptides, and pSRM-CID-MS2/MS3 assays
were generated for all phosphorylation sites as described above.
No assay could be set up for S494 due to synthesis problems of
the corresponding heavy reference peptide, and only the doubly
charged precursor ion of the phosphopeptide AILGSYDSELT-
PAEYpSPQLTR covering S428 was included in the analysis.
Overall, sensitive MS3-based pSRM assays could be generated
for 13 of the 15 remaining phosphopeptide ions. Because
several possible modification sites were in direct proximity of
the peptide SQSSSAEQSFLFSR and high mascot scores were
Figure 6. Quantification of all identified Mad1 phosphorylation sites across three different cell cycle stages. (A) Western blot of HeLa S3 cells
synchronized with thymidine and subsequently released into nocodazole for 14 h. Cells were collected by mitotic shake-off, and Mad1 and associated
proteins were immunopurified from mitotic extracts. (B) Bar chart showing the mean fold changes with error bars determined for each
phosphopeptide quantified by pSRM-CID-MS2/MS3 of Mad1 immunopurified from thymidine (blue), nocodazole (red), and MG132 (green)
arrested HeLa S3 cells. (C) Bar chart showing the mean abundance changes for the unmodified counterparts of the phosphopeptides monitored
across the three different conditions. For clarity, the ratios for nocodazole were set to 1, and the other ratios were normalized accordingly. All
experiments were carried out in triplicate. Significant changes are indicated (*, p-value < 0.05; **, p-value < 0.01; nd, no peaks detected).
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obtained for four different sites, correct positioning of these
phosphorylation sites was challenging (S484−S486 and S490,
Table 1). Therefore, we first investigated whether we could
obtain specific assays for each of the four phosphorylation sites.
We selected specific and common fragments (Figure S2A) and
analyzed them using pSRM-CID-MS3. As is apparent from
Figure S2B−E, the four phosphopeptides showed different
elution times and could be nearly fully resolved by the reversed-
phase chromatography employed. Elution was the earlier the
closer the phosphorylation was positioned to the peptide C-
terminus, probably reflecting reduced interaction of the
hydrophobic amino acids located at this part of the peptide
with the stationary phase during LC. This allowed us to select,
besides the few specific fragments, additional unspecific
fragments with high MS intensities and generate sensitive,
specific pSRM-CID-MS3 assays for all four phosphorylation
sites (Figure S2B−E). In general, the pSRM method is
particularly well-suited for localizing modifications of a
particular peptide because, due to the same precursor ion
mass, all possible sites can be monitored with one single MS
assay.
Next, we employed these assays for extensive Mad1
phosphorylation site monitoring during three different cell
cycle stages: S phase (achieved by thymidine addition),
prometaphase (nocodazole treatment), where the SAC is
active, and metaphase (MG132 addition), where the SAC is
shut down. We could consistently detect and quantify 11 of the
15 targeted phosphopeptides (corresponding to 9 of the 13
identified phosphorylation sites) on endogenous Mad1 pulled-
downs from cells in the three stages and across all biological
replicates. We observed significant increases in phosphorylation
for most sites after nocodazole and MG132 treatment
compared to that after thymidine treatment (Figure 6B), in
agreement with Mad1 function during SAC activation.
According to the consensus motifs present on these
phosphopeptides, Plk1, Mps1, and Cdk1 are likely candidate
upstream kinases responsible for phosphorylating most of these
sites in mitosis (Table 1). Interestingly, the peptide
IQELQApSQEAR carrying a phosphorylation at serine 214
showed an opposite trend, namely, a clear increase during S
phase (Figure 6B). Recently, this site has been shown to be
phosphorylated by ATM kinase, and it has been suggested that
such phosphorylation contributes to activation of the SAC.49 In
the future, it will be interesting to explore a possible role of
serine 214 in the mitotic checkpoint complex assembly during
interphase.
In an additional experiment, we analyzed each sample by
shotgun DDA LC−MS/MS to quantify the unmodified
counterparts of the phosphopeptides and define phosphor-
ylation site stoichiometries. Here, we identified two phospho-
peptides that showed a strong increase in phosphorylation
occupancy of around 50% from S-phase to prometaphase and
thus represent the most affected phosphorylation sites for the
cell cycle stages analyzed (Figure 6C). It is important to note
that with conventional DDA LC−MS/MS analysis only two
phosphorylation sites of Mad1 could be identified and
quantified from these pull-down samples by label-free
quantification, whereas nine sites could be monitored by the
more sensitive pSRM-CID-MS2/MS3 approach, increasing the
coverage by 4.5-fold.
Knowing that Mad1 exerts its function mostly in the first half
of mitosis and that Mad1 relocalizes from the nuclear envelope
to unattached kinetochores,50−52 it is tempting to speculate that
such relocalization might depend on the phosphorylation status
of Mad1.53
■ CONCLUSIONS
This is the first study that systematically assesses the
performance of the most popular DDA and DIA MS
approaches currently used in proteomics. The results will
help users to select the most suitable LC−MS methods for their
studies, to improve their experimental design, and to define
reasonable expectations for future proteomics analyses. It is
important to note that different MS analyzers and detectors,
which were most suited for the individual MS workflows, were
used throughout this study. Because not all LC−MS platforms
were available for this study (e.g., fast scanning Orbitrap or
time-of-flight analyzers for parallel reaction monitoring
(PRM)1,6), users with a different LC−MS setup should carry
out a similar method evaluation to assess the performance of
their individual LC−MS platforms and workflows. Of note, a
thorough comparison of the SRM (on QqQ instruments, used
in this study) and PRM (on Orbitrap instruments) approaches
has been described recently.1,6
In our study, we observed large performance differences in
particular for phosphopeptide analyses in complex samples, and
high-resolution HCD and higher stage fragmentation-based
pSRM approaches were identified as the most sensitive
approaches. We are confident that with the increasing number
of known phosphorylation sites (or other PTMs) and the
relatively low cost of synthetic heavy reference peptides with
modification homologues, such extensive phosphorylation site
or PTM monitoring studies can be applied to any protein of
interest that can be enriched from a complex protein sample
without the need for modification-specific enrichment steps.
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Brusniak, M.-Y.; Hengartner, M. O.; Aebersold, R. mProphet:
automated data processing and statistical validation for large-scale
SRM experiments. Nat. Methods 2011, 8, 430−435.
(39) Gillet, L. C.; Navarro, P.; Tate, S.; Röst, H.; Selevsek, N.; Reiter,
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Figure S1. Defining linearity and detection and quantification limits for the 
phosphopeptide “RDSLGpTYSSR“. The peak intensities and peptide concentrations 
were plotted for each LC-MS method to compute linear regression (squared Pearson 
Correlation (R2) from highest concentration to LOQ) as well as limit of detection (LOD) 
and limit of quantification (LOQ), respectively. The plots for neat (A, D, G, J, M) and 
complex samples (B, E, H, K, N) are illustrated. (C, F, I, L, O) Extracted ion 
chromatograms (XICs) of precursor ions (DDA) and transitions (SRM+pSRM) obtained by 
the different MS-methods when analyzing 1 fmol of the phosphopeptide in the complex 
samples using Skyline. For clarification, the elution time of transition/precursor ion XICs 
for low intense peaks are indicated (blue arrow). (BG, background) 
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Figure S2. Generation of specific MS assays for the different phosphorylation sites 
identified for the peptide “SQSSSAEQSFLFSR”. Four heavy reference peptides carrying 
one phosphorylation at the identified serine residues, respectively, were synthesized and 
used for MS assay generation. (A) Sequence of the peptide indicating the location of four 
phosphorylation sites on serine residues with the corresponding b- and y-ions identified 
by discovery LC-MS/MS. (B-E) Most intense transitions obtained for (B) 
“SQSSSAEQpSFLFSR” (red arrow), (C) “SQSSpSAEQSFLFSR” (blue arrow), (D) 
“SQSpSSAEQSFLFSR” (green arrow) and (E) “SQpSSSAEQSFLFSR” (orange arrow). The 
peak displaying the most intense phosphorylation site-specific transition is indicated in 
red for each chromatogram and phosphorylation site, respectively. 
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4.1 BAY-320 and BAY-524: novel tools to probe Bub1 function 
 
Bub1 is a serine/threonine kinase that is recruited to unattached KTs at a very 
early stage during mitosis (Jablonski et al., 1998). Indeed, it has been shown that 
Bub1 plays a central role in chromosome congression and the fidelity of 
chromosome segregation in species from yeast to vertebrates (Elowe, 2011; 
Funabiki and Wynne, 2013). Ever since, Bub1 was identified, the requirement of its 
catalytic activity for all its functions has been a matter of debate. 
Here, we have characterized two novel small molecule ATP-competitive 
inhibitors of Bub1, BAY-320 and BAY-524. We have used these inhibitors to get 
further insight into the mitotic functions of Bub1 kinase activity and set out to 
differentiate between scaffolding and catalytic function of Bub1. In detail, we 
compared cell fates provoked by Bub1 inhibition with those that were due to 
siRNA-mediated Bub1 protein depletion. According to that we conclude that Bub1 
exerts its functions mostly through its ability to act as a scaffold. We show that 
Bub1 kinase inhibition influences chromosome arm cohesion and the localization 
of Sgo pools. Moreover, Bub1 inhibition seems to have minor effects on mitotic 
progression as well as the establishment of a SAC response due to spindle defects. 
Also the efficiency of chromosome alignment is not impaired by inhibition of 
Bub1. On the contrary, there is a striking synergy between Bub1 kinase inhibition 
and Paclitaxel-induced interference with MT dynamics. Bub1 inhibited cells are 
sensitized to clinically relevant doses of Paclitaxel, displayed by a marked increase 
in chromosome segregation errors and drastically reduced cell proliferation. The 
results of this study thus give insight into the role of Bub1 catalytic activity during 
mitotic progression and elaborate on the potential use of Bub1 inhibitors in 
therapeutic applications.   
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4.1.1 Validation of BAY-320 and BAY-524 as Bub1 inhibitors 
 
Elucidating the role of Bub1 catalytic activity in dividing cells has been a 
long standing question. So far, this question has been mostly addressed by 
introducing Bub1 kinase-dead mutants into cells (Klebig et al., 2009) or by the 
development of Bub1-KD mice (Ricke et al., 2012).  However, these approaches are 
most often accompanied by technical challenges, high variability and low 
temporal resolution. The availability of small-molecule inhibitors is a big 
advantage, since they can overcome the described drawbacks. However, no 
specific Bub1 inhibitor has been available so far. The only previously described 
inhibitor of Bub1 is the bulky ATP analog 2OH-BNPP1 (Kang et al., 2008; Krenn et 
al., 2012; Liu et al., 2015; Nyati et al., 2015), however a detailed characterization of 
its specificity and efficacy in intact cells has been missing. 
 Here, two novel small molecule inhibitors for Bub1 are introduced, BAY-
320 and BAY-524, developed at BAYER Pharma AG. BAY-320 and BAY-524 have 
proved to be useful tools as they both efficiently inhibit Bub1 kinase in intact cells 
and in vitro. Ideally, small molecule inhibitors should be both potent and selective, 
to enable complete inhibition of the target kinase and minimize the potential for 
off-target effects in cells. Both compounds were able to specifically inhibit T120-
H2A phosphorylation (Kawashima et al., 2010). In addition, BAY-320 and BAY-
524 caused a persistence of chromosome arm cohesion, a phenotype that has 
already been accounted to Bub1 (Kitajima et al., 2005; Kawashima et al., 2010; Liu 
et al., 2015). Moreover, in vitro assays performed on a large panel of kinases 
showed that inhibition of off-target substrates required at least 20x higher 
concentrations of BAY-320 than inhibition of Bub1. One potential and relevant off 
target identified is the kinase Haspin. However BAY-320 and BAY-524 failed to 
inhibit intracellular Haspin activity at concentrations used in our assays illustrated 
by the phosphorylation of histone H3 on threonine 3 (Figure 23, Table 3). Thus, we 
are confident that BAY-320 and BAY-524 constitute highly effective and specific 
tools to explore the role of Bub1 kinase activity during mitotic progression.  
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4.1.2 Impact of Bub1 inhibition on mitotic progression 
 
One striking phenotype that results from the inhibition of Bub1 is the 
persistent chromosome arm cohesion during prometaphase. Both Sgo2 and 
Aurora B are not focused at centromeres and relocalize to chromosome arms when 
Bub1 is inhibited, most likely due to the dephosphorylation of T120-H2A. 
Phosphorylation of Sgo2 by Aurora B promotes Sgo2 interaction with protein 
phosphatase 2A (PP2A) (Tanno et al., 2010), and PP2A in turn enforces the 
protection of cohesin proteins against phosphorylation from Plk1 (Kitajima et al., 
2006; Riedel et al., 2006). Thus, colocalization of Sgo2 and Aurora B in Bub1-
inhibited cells provides a straightforward explanation for the observed persistence 
of arm cohesion (Perera and Taylor, 2010; Perera et al., 2007; Kitajima et al., 2005). 
However, alternative mechanisms should not be excluded and it might be 
rewarding to explore a possible connection between Bub1 kinase and the Sororin-
Wapl pathway (Peters and Nishiyama, 2012). The establishment of cohesion 
during S phase and its maintenance throughout mitosis is governed by Sororin. 
Sororin mediates sister-chromatid cohesion by antagonizing Wapl and its ability 
to release DNA from cohesin (Nishiyama et al., 2010).  Moreover Aurora B and 
Cdk1 further promote the release of cohesion by phosphorylating Sororin and 
thereby disturbing the interaction with its binding partner Pds5 (Nishiyama et al., 
2013). Since we could show that the kinase activity of the chromatin-associated 
fraction of Aurora B was not affected after Bub1 inhibition, it is tempting to 
speculate whether Bub1 kinase contributes to Wapl localization at chromatid 
arms. 
Furthermore, inhibition of Bub1 results in the clear reduction of CPC levels 
from the centromeric region. Borealin gets recruited to the centromere via 
interaction with Sgo1 (Kawashima et al., 2010; Tsukahara et al., 2010; Yamagishi et 
al., 2010). Thus there is a direct relationship between pT20-H2A level reduction, 
followed by impaired Sgo recruitment and thus impaired CPC recruitment. With 
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at least Sgo2 being redistributed to chromosome arms, a relocalizaton of Sgos in 
general is likely to foster also the localization of the CPC to arms. Comparably, 
mutant mice that lack Bub1 kinase activity fail at localizing Aurora B at the 
centromere (Ricke et al., 2012). CPC levels at KTs are further reduced upon 
simultaneous inhibition of Bub1 and Haspin, in line with the established roles of 
these kinases in the phosphorylation of histones H2A-T120 and H3-T3, 
respectively (Yamagishi et al., 2010; Wang et al., 2011). 
Surprisingly, persistent chromosome arm cohesion, observed in Bub1 
inhibited cells did not markedly prolong mitotic timing (Figure 16). But it is very 
interesting to mention that depletion of Wapl also causes persistent cohesion 
without significantly affecting mitotic progression (Lara-Gonzalez and Taylor, 
2012). In contrast to Bub1 inhibition, depletion of Bub1 markedly extended mitotic 
timing (Figure 15). One straightforward explanation for this observation is that 
Bub1 depletion, but not Bub1 inhibition, caused the displacement of CENP-E from 
KTs, a motor protein required for efficient chromosome congression (Putkey et al., 
2002; Tanudji et al., 2004; Bancroft et al., 2015). A mechanism centered on CENP-E 
may also explain the observation that Bub1 depletion exerted a more extensive 
mitotic delay in the hypertriploid HeLa cells than in diploid RPE1 cells.    
Considering the important role of Aurora B in the regulation of KT-MT 
interactions (Carmena et al., 2012; Funabiki and Wynne, 2013), it is remarkable 
that the observed reduction of KT-associated CPC caused by Bub1 inhibition did 
not exert a more profound effect on the fidelity of chromosome segregation. Bub1 
inhibition using BAY-320 and BAY-524 also significantly reduced centromeric 
Aurora B activity however leaving Aurora B activity at chromosome arms 
unaffected. This suggests that the remaining levels of the CPC are sufficient for 
correct chromosome segregation. Moreover, partial impairment of CPC 
recruitment to centromeres did not abolish viability or trigger extensive defects in 
chromosome segregation in budding yeast or chicken DT40 cells (Campbell and 
Desai, 2013; Yue et al., 2008).  
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Further support for BAY-320 and BAY-524 validity as Bub1 inhibitors comes 
from the observation that inhibitor-treated cells behaved similar to cells in which 
endogenous Bub1 was replaced with an exogenous KD mutant form of the kinase 
or in studies using Bub1-KD mice in several important respects (Klebig et al., 2009; 
Ricke et al., 2012).  
Bub1 is an established member of the signaling network comprising the SAC 
(Lara-Gonzalez et al., 2012; Elowe, 2011).  Inhibition of Bub1 kinase activity did 
not significantly reduce the KT recruitment of Mad1, Mad2 and BubR1 and barely 
affected the ability of nocodazole-treated cells to maintain a SAC arrest. Even 
when SAC activity was compromised by partial inhibition of the SAC kinase 
Mps1, Bub1 inhibition triggered only minor weakening of SAC signaling. In 
striking contrast, Bub1 depletion produced a drastic weakening of the SAC in this 
sensitized background. For comparison, combined inhibition of Mps1 and either 
Plk1 or Aurora B resulted in a complete SAC shutdown and immediate mitotic 
exit, in line with previous results (Saurin et al., 2011; Schubert et al., 2015b). 
Recently it has been shown that Plk1 strengthens SAC establishment and 
maintenance during prolonged mitotic arrest (Schubert et al., 2015b). Collectively 
these findings confirm that mitotic functions of Bub1 depend primarily on Bub1 
protein rather than kinase activity. In the future, it will be interesting to explore 
whether Bub1 activity contributes to purported non-mitotic functions of Bub1 
(Yang et al., 2012; Nyati et al., 2015). 
The major conclusion emerging from the present study is that the overall 
impact of Bub1 inhibition on mitotic progression is surprisingly mild, clearly less 
severe than the impact of Bub1 depletion. This strengthens the notion that Bub1 is 
required during chromosome congression and segregation primarily via its 
scaffolding function (Sharp-Baker and Chen, 2001; Fernius and Hardwick, 2007; 
Rischitor et al., 2007; Klebig et al., 2009). It is difficult to say whether a small 
portion of Bub1 catalytic activity is not responsive to inhibition and hence able to 
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activity is compatible with mouse development in contrast to complete Bub1 
elimination (Ricke et al., 2012; Perera et al., 2007). This argues against a 
fundamental role of Bub1 kinase activity for mitotic progression. Thus, inhibitor 
studies and genetic data concur to indicate that lack of Bub1 kinase activity 
produces only mild disturbances of mitotic progression.  
 
 
4.1.3 Bub1 inhibition and its potential therapeutic influence 
 
The principle of cancer chemotherapy is the killing of cells that divide 
rapidly, usually by chemical substances that are thus cytotoxic (Malhotra and 
Perry, 2003). It is probably ironic that the most effective cancer fighting strategies 
involves the induction of abnormal mitoses, thereby triggering programmed cell 
death (apoptosis) and therefore the elimination of malignant cells. Anti-mitotic 
agents are a vastly used element in cancer chemotherapy, mostly MT poisons such 
as taxanes (Gascoigne and Taylor, 2009). The inhibition of SAC kinases has 
emerged as a potentially attractive strategy to kill tumor cells (Janssen et al., 2009; 
Salmela and Kallio, 2013). Several inhibitors of the SAC kinase Mps1 have shown 
to exert anti-tumor effects in mouse models (Colombo et al., 2010; Tardif et al., 
2011; Tannous et al., 2013; Kusakabe et al., 2015), but toxicity associated with 
single agent therapy remains a concern (Martinez et al., 2015). Paclitaxel is a 
widely used anti-mitotic drug, which induces a mitotic checkpoint-dependent 
delay at high dose by inhibiting MT dynamics (Gascoigne and Taylor, 2008; Brito 
and Rieder, 2006). The combination of SAC-inhibiting compounds together with 
MT poisons seems to represent a more advantageous policy (Maia et al., 2015; 
Jemaà et al., 2013; Janssen et al., 2009). Here, we have made use of the combination 
of Bub1 inhibitors BAY-320 and BAY-524 together with Paclitaxel. Our data 
suggests that this combinatorial treatment might be beneficial for cancer therapy. 
BAY-320 and BAY-524 had comparatively little effect on mitotic progression when 
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used as single agents. However, in combination with therapeutic doses of 
Paclitaxel, a substantial increase in anti-proliferative activity along with an 
increase in chromosome segregation errors could be observed. Paclitaxel increases 
KT-MT attachments errors at low doses that are usually corrected by Aurora 
B/CPC. However in this setting, the combination of Paclitaxel and Bub1 inhibition 
induces KT-MT attachment errors that cannot be efficiently corrected by Aurora 
B/CPC anymore, due to their displacement from the kinetochore/centromeric 
region. In our setup as well, these synergistic effects were substantially more 
pronounced in aneuploid HeLa cells than in near-diploid RPE1 cells. This result is 
very exciting in terms of cancer therapy. It shows a great potential in targeting 
specifically cancer cells while leaving healthy cells spared. Also another study, has 
shown that untransformed fibroblasts with reduced Mps1 levels were not 
sensitive to low doses of paclitaxel, compared to tumor cell with lowered Mps1 
levels (Janssen et al., 2009). Thus, targeting members of the SAC that are also 
involved in chromosome alignment, in combination with clinically relevant doses 
of Paclitaxel, might constitute a selective approach to fight uncontrolled cell 
proliferation. 
Whether Bub1 inhibitors will prove valuable for pharmacological 
intervention in anti-tumor therapy remains to be seen. The findings described in 
this thesis clearly encourage further exploration of the potential use of Bub1 
inhibitors for therapeutic applications. 
 
 
4.1.4 Future prospects 
 
According to this study, inhibition of Bub1 catalytic activity seems to have 
only a mild impact on mitotic progression. This is probably why it is not very 
surprising that only few substrates of Bub1 kinase have been described so far. The 
best characterized substrate of Bub1 is T120-H2A (Kawashima et al., 2010), as 
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already mentioned. Another substrate of Bub1 that has been described so far, is 
Cdc20 (Tang et al., 2004a). This phosphorylation is supposed to exert an inhibitory 
function on the APC/C. However, this phosphorylation event has only been 
shown to happen in vitro (Tang et al., 2004a; Kang et al., 2008). Thus, the 
identification of Cdc20 as a physiological substrate of Bub1 kinase is still awaited. 
However, considering the very mild effect of Bub1 kinase inhibition on SAC 
signaling, it is tempting to speculate that Bub1-mediated Cdc20 phosphorylation is 
an artifact or of very low significance. However, we can still not rule out that a 
small portion of Bub1 is not affected by BAY-320 and BAY-524. Besides, no further 
substrates of Bub1 are known. Hence it would be benefitial to investigate the 
Bub1-dependent phosphoproteome in mitotic cells, using the described Bub1 
inhibitors in combination with mass spectrometry. Considering the mild effects on 
mitotic progression by Bub1 inhibition, it is debatable whether and how many 
substrates are awaiting their identification. 
 
 
4.2 The evolution of phospho-peptide quantification 
 
Another major goal in this study was to evaluate the most popular MS 
approaches for quantification of proteins and for changes in PTMs.  
During our initial proof-of-principle experiments we analyzed several 
phospho-peptides spiked at increasing concentrations into a cell lysate digest. 
Especially for phospho-peptides analyses in complex samples, huge variations in 
terms of quantification, detection and identification limits were obtained. We were 
able to identify high-resolution HCD and higher stage fragmentation-based pSRM 
methods as the most sensitive approaches, since they allow in depth analysis of 
MS spectra that are usually poor of information, due to neutral loss peaks. 
However, phospho-proteomics in mass spectrometry is a fast evolving field 
with a constant development in more sensitive and specific LC-MS setups as well 
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as MS-workflows and quantification approaches. Hence, this kind of comparison 
that we have described in this thesis has to be repeated as new methods and 
devices are available. One of these newly emerging approaches is SWATH-MS 
(Gillet et al., 2012). 
SWATH-MS is a DIA strategy that combines advantages of DDA with those 
of SRM. This means that high throughput can be achieved together with high 
reproducibility and consistency. In detail, SWATH-MS enables quantitative 
MS/MS data for every peptide or protein in a sample, meaning unbiased, 
reproducible quantitation with no sample-specific method development. During 
data acquisition, all analytes within a given m/z precursor range, are detected by 
repeatedly cycling through a series of fixed precursor isolation windows (swaths) 
(Gillet et al., 2012; SCIEX, 2012). During each cycle, all precursors from the 
isolation window are fragmented and their complete and highly accurate 
fragment ion spectra are recorded. The same precursor isolation window is further 
fragmented during each cycle, thus generating a time-resolved recording of the 
fragment ions of all peptide precursors that elute on the LC.  The window size is 
chosen in such a way that the cycle time is short enough to allow each peptide to 
be fragmented ~8–10 times across its chromatographic elution profile (Schubert et 
al., 2015a). 
Post-acquisition, a data extraction strategy is applied that uses information 
from spectral ion libraries to identify proteins and peptides of interest.  The 
fragment ion signals, their relative intensities, chromatographic concurrence and 
other information accessible from spectral libraries help to search the acquired 
data for constellations of signals that precisely correlate with the known 
coordinates of a targeted peptide (Gillet et al., 2012).  Matching combinations 
allow specific identification. Only the increasing availability of proteome-wide 
spectral libraries allows this targeted data extraction analysis. However, the 
quality of the quantitative data is highly dependent on the quality of the spectral 
library (Zi et al., 2014). Moreover, this approach allows the generation of a 
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permanent digital archive for every sample. Those can retrospectively be 
reanalyzed when new hypothesis arise, without running the sample again.  
Taken together, SWATH-MS offers a new advantage of analyzing multiple 
samples in a global fashion, without the usual constraints and bias of DDA-MS, 
thereby combining high throughput with specificity and sensitivity. 
This MS approach is so far only applicable with the fast, high resolution 
quadrupole time-of-flight (triple TOF) instruments or qOrbitrap systems, which is 
why we did not include this approach in our comparison, since these instruments 
were not available to us at the time of our study. 
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5.1 Preparation of BAY-320 and BAY-524 inhibitors 
BAY-320 and BAY-524 were synthesized as described in (Hitchcock et al., 
2013). Synthesis was performed by Bayer Pharma AG, Global Drug Discovery, 
Muellerstrasse 178, Berlin, 13342 Germany. For in vitro and in vivo experiments 
BAY-320 and BAY-524 were used from stock solutions (5 mM) in dimethyl 
sulfoxide (DMSO). Working concentration of Bub1 inhibitors are depicted in 
Figures and Figure legends, respectively.  
 
5.2 Determination of IC50-concentrations 
Inhibitory activities BAY-320 and BAY-524 towards Bub1 in presence of 2 
mM ATP were quantified as previously published (Hitchcock et al., 2013). A time-
resolved fluorescence energy transfer (TR-FRET) kinase assay was used to 
measure phosphorylation of the synthetic peptide Biotin-Ahx-VLLPKKSFAEPG 
(C-terminus in amide form, Biosyntan, Berlin, Germany) by the recombinant 
catalytic domain of human Bub1 (amino acids 704-1085). Recombinant human 
Bub1 (704-1085) was expressed in Hi5 insect cells with an N-terminal His6-tag and 
purified by affinity- (Ni-NTA) and size exclusion chromatography. 
 
5.3 Kinase selectivity profiling 
BAY-320 was counter screened against a panel of 222 kinases using the 
Eurofins kinase profiler screen (Millipore) at 10 µM and 10 µM ATP. Screen was 
performed by Bayer Pharma AG, Global Drug Discovery, Muellerstrasse 178, 
Berlin, 13342 Germany. 
 
5.4 In vitro kinase assay 
HEK 293T cells were transfected with plasmids coding for LAP-tagged Bub1 
wild-type (WT) or the K821R kinase-dead (KD) mutant (kindly provided by G. 
Kops, Utrecht, Netherlands) (Suijkerbuijk et al., 2012b). After induction of mitotic 
arrest (18 hours incubation with 1 µg/ml of nocodazole), cells were harvested and 
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lysed in kinase lysis buffer (50mM HEPES pH7.5, 150mM NaCl, 5mM EDTA, 0.5% 
NP-40, 1mM Na3VO4, 1mM β-glycerophosphate, 1mM NaF and complete protease 
inhibitor (Roche)). Lysates were cleared by centrifugation for 15 minutes at 21,000 
g, 4°C, and LAP-Bub1 proteins isolated by a 2 hour incubation with S-protein-
agarose (Novagen, EMD Chemical, CA, USA). Beads were washed 6 times in lysis 
buffer containing increasing concentrations of NaCl (150 mM, 200 mM, 300 mM, 
400 mM, 500 mM and 600mM) and 3 times in kinase buffer (20 mM HEPES pH7.5, 
100 mM KCl, 10 mM MgCl, 1mM Na3VO4, 1mM -glycerophosphate, 1mM NaF, 
1mM DTT). The bead-bound LAP-Bub1 was then aliquoted and used for kinase 
assays in 30 µl reaction volumes. Kinase reactions were carried out at 30°C in 
kinase buffer in presence of 100 µM ATP, 5 µCi γ-32P-ATP, 1 µg recombinant 
histone H2A (NEB, Frankfurt am Main, Germany) as substrate, and serial 
dilutions of Bub1 inhibitors. Reactions were stopped after 30 min by addition of 
sample buffer and heating to 95°C. Samples were then resolved by SDS-PAGE and 
visualized by autoradiography and Western blotting. 
 
5.5 Cell Culture  
HeLa S3 cells, HeLa S3 cells expressing histone H2B-GFP (Silljé et al., 2006), 
HeLa Kyoto cells expressing a FRET reporter for Aurora B fused to histone H2B 
(van der Waal et al., 2012) and HEK293T cells were grown under standard 
conditions in DMEM-Glutamax medium (Invitrogen, CA, USA), supplemented 
with 10% heat-inactivated fetal calf serum (FCS) (PAN Biotech, Aidenbach, 
Germany) and penicillin-streptomycin (Pen-Strep; 100 IU/ml and 100 mg/ml 
respectively, Gibco Life Technologies, Zug, Switzerland). hTERT-RPE1 cells and 
hTERT-RPE1 cells expressing histone H2B-GFP (kind gift of Stephen Taylor, 
University of Manchester, UK) were cultured in F12 DMEM nutrient mixture F-12 
HAM (Sigma Aldrich, MO, USA) supplemented with 10% heat-inactivated FCS), , 
L-glutamine (2 mM;  PAN Biotech, Aidenbach, Germany), sodium bicarbonate 
(0.35 %; Sigma-Aldrich, MO, USA) and Pen-Strep. Thymidine arrest was 
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performed for 24h and cells were either released into fresh medium for 10 h or 
into medium supplemented with Nocodazole for 12-14 h. Thymidine (Sigma-
Aldrich, MO, USA) was used at 2 mM, Nocodazole (Sigma-Aldrich, MO, USA) at 
3.3 µM if not otherwise stated, RO-3306 at 10 µM (Calbiochem), Paclitaxel (Taxol, 
Merck Milipore) at 1-4 nM, Reversine (Enzo Life Sciences, Lausen, Switzerland) at 
0.25 and 0.5 µM, 5-Iodotubercidin (5’Itu, Santa Cruz, Biotechnology, TX, US) at 2.5 
µM, Monastrol (Enzo Life Sciences, Lausen, Switzerland) at 150 µM and MG132 
(Calbiochem, Darmstadt, Germany) at 10 µM. 
 
5.6 Transient plasmid transfection and siRNA-mediated protein 
depletion 
Transient transfections of HEK293T cells with plasmids and small interfering 
RNA (siRNA) duplexes were performed using TransIT-LT1 transfection reagent 
(Mirus Bio, Madison, WI) and Oligofectamine (Invitrogen, CA, USA), respectively, 
according to manufacturers protocols. The following siRNA duplex 
oligonucleotides were used: siGl2 CGTACGCGGAATACTTCGA (Elbashir et al., 
2001), siBub1  CCAGGCTGAACCCAGAGAGTT (Tang 2004). All siRNA duplex 
oligonucleotides were ordered from Qiagen, Hilden, Germany. 
 
5.7 Fluorescence-activated cell sorting  
HeLa S3 or RPE1 cells were incubated with kinase inhibitors or depleted of 
the indicated proteins for 48 h. Cell suspensions were then fixed with 70% ice cold 
ethanol and incubated with 0.2 mg/ml RNase (Sigma-Aldrich, MO, USA) and 5 
µg/ml propidium iodide (Sigma-Aldrich, MO, USA). Cellular DNA content was 
determined by flow cytometry using FACSCanto II (BD Biosciences Clontech, San 
Jose, CA, USA) and FlowJo (Treestar, Ashland, OR, USA) instruments. 
 
5.8 Cell extracts and sample preparation for Western blot analysis 
Cells extracts were prepared on ice for 30 min in Tris lysis buffer (20 mM 
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Tris, pH 7.4, 150 mM NaCl, 0.5 % IGEPAL CA-630, 30 µg/ml RNAse, 30 µg/ml 
DNAse, 1 mM DTT, protease inhibitors cocktail (Roche, Basel, Switzerland) and 
phosphatase inhibitor cocktails (cocktails 2 and 3, Sigma-Aldrich, MO, USA). 
Lysates were cleared by centrifugation for 15 minutes at 21,000 g, 4°C, and 
proteins were resolved by SDS-PAGE and analyzed by Western blotting.  
 
5.9 Histone Isolation 
HeLa S3 cells were as described above and mitotic cells were collected by 
shake-off. Cells were the washed with cold PBS and lysed at 4°C for 30 min using 
histone lysis buffer (50 mM Tris pH 7.8, 300 mM NaCl, 1% IGEPAL CA-630). 
Nuclei were collected by centrifugation (110 g, 4°C, 10 min) and washed three 
times with histone lysis buffer. After an additional wash with Tris-EDTA (100 mM 
Tris, 1 mM EDTA) the nuclear pellet was incubated for 2 h in 0.4 M HCl at 4°C. 
After high-speed centrifugation of the sample, 6 volumes of acetone were added 
to the supernatant, followed by overnight incubation at -20 °C. Histones were 
collected by centrifugation, washed with acetone, air-dried and resolved by SDS-
PAGE. 
 
5.10 Antibodies 
Antibodies used for Western blotting: anti-Bub1 ((Hanisch et al., 2006b) or 
ab9000, Abcam, Cambridge, UK), anti-pT120H2A (Active Motif, Carlsbad, CA, 
USA) , anti-cyclinB1 (Merck Millipore) and anti-α-tubulin (DM1A, Sigma-Aldrich, 
MO, USA). Antibodies used for immunofluorescence microscopy: anti-Mad1 
(clone 117-468 (Fava et al., 2011)), anti-cMad2 (clone 107-276 (Fava et al., 2011)) 
anti-Borealin (Klein et al., 2006), anti-INCENP (clone 58-217, ab23956, Abcam, 
Cambridge, UK), anti-Bub1 (antibody against Bub1 hybridoma (clone 62-406) was 
produced after mice were injected with Bub1 recombinant protein spanning 
residues 1-318,  anti-Bub1 (ab9000, Abcam), CREST anti-human auto-immune 
serum (Immunovision, Springdale, AR, USA), anti-Aurora B (AIM-1, BD 
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Biosciences, San Jose, CA, USA), anti-Bub1 (ab9000, Abcam, Cambridge, UK), anti-
CENP-E (1H12, Abcam, Cambridge, UK), anti-Mad2 (A300-301A, Bethyl 
Laboratories, Montgomery, TX, USA),) anti-Sgo1 (Abnova, Taipei, Taiwan), anti-
Sgo2 (Bethyl Laboratories, Montgomery, TX, USA), anti-pT120H2A (Active Motif, 
Carlsbad, CA, USA), anti-pS7CENP-A (clone NL41, Merck Millipore, Billerica, 
MA, USA), anti-pT3H3 (clone 9714, Cell Signaling Technology, Danvers, MA, 
USA) and anti-pS10H3 (Millipore, Billerica, MA, USA). The polyclonal MCAK 
(R120) antibody was raised in rabbits by immunization with bacterially expressed 
His-MCAKaa588-725. For immunofluorescence experiments, all primary antibodies 
were detected with AlexaRed-594-, AlexaRed-564-, and AlexaGreen-488-labeled 
secondary anti-mouse and anti-rabbit antibodies (Invitrogen, Carlsbad, CA, USA) 
or Cy5-conjugated donkey antibodies (Dianova, Hamburg, Germany). For 
Western blotting, signals were detected using HRP-conjugated anti-mouse or anti-
rabbit antibodies (Pierce, Rockford, IL, USA). 
 
5.11 Immunofluorescence microscopy, image processing, quantification 
and live cell imaging  
For fluorescence microscopy cells were grown on coverslips and fixed in 
PTEMF buffer (20 mM PIPES, pH 6.8, 0.2% Triton X-100, 10 mM EGTA, 1 mM 
MgCl2, 4% formaldehyde) or methanol at -20°C (for CENP-A pS7) respectively. 
Images of randomly selected cell were acquired as z-stacks using a DeltaVision 
microscope (GE Healthcare) on an Olympus IX71 base (Applied Precision, WA, 
USA), equipped with a Plan Apochromat N 60x/NA1.42 oil immersion objective 
(Olympus) and a CoolSNAP HQ2 camera (Photometrics). Serial optical sections 
were deconvolved and projected using SoftWorx software (GE Healthcare). 
Images were quantified as previously described (Schubert et al., 2015b) using 
automated pipelines run by Cell Profiler software (Carpenter et al., 2006). Results 
from 2-3 independent experiments were pooled and statistical analysis was done 
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with GraphPad Prism software. Error bars on histograms illustrate SEM. Scale 
bars represent 10 µM.  
For time-lapse imaging, cells were imaged using a Nikon ECLIPSE Ti 
microscope equipped with a CoolLED pE-1 illumination system and a 20x/NA0.75 
air Plan Apochromat objective (Nikon) in a climate-controlled environment. 
Images were acquired at multiple positions at indicated time intervals. 
MetaMorph 7.7 software (MDS Analytical Technologies, Sunnyvale, CA, USA) 
was used for acquisition and processing of data. FRET, FRAP and high sensitivity 
microscopy (monitoring endogenously EGFP-tagged proteins) experiments were 
carried out using a spinning disk confocal system (Intelligent Imaging 
Innovations) based on a Zeiss Axio Observer stand equipped with a Photometric 
Evolve 512 back-illuminated EMCCD camera, 63x/NA1.4 plan apochromat 
objective and diode lasers and run by SlideBook software. FRET analyses were 
carried out by excitation with a 440 nm diode laser and by recording of CFP (CFP 
signal) and YFP (FRET signal) fluorescence emission in z-stacks. Background-
corrected FRET ratios (CFP signal/FRET signal) were calculated in ImageJ using 
the Ratio Plus plugin. FRAP analysis of EGFP-Bub1 was performed with a 488 
diode laser on one KT pair per cell. Overall bleaching was corrected using the 
signal intensities at a cytoplasmic region not targeted for photobleaching (average 
of the first 4 frames). Fluorescence recovery half-times and plateaus were 
determined by non-linear curve fitting based on a one-phase association in Prism 
software (GraphPad).  
 
5.12 Colony Formation Assay 
Asynchronous cell cultures (50,000/well) were plated on 6-well plates 
(Falcon). After 7 days of growth in the presence of the indicated drugs, cells were 
fixed with ice-cold Methanol at -20°C and stained with 0.1 % cresyl violet dH2O 
according to standard procedures. Cell densities were measured using ImageJ 
after black-and-white-conversion and inversion of the images. 
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5.13 rAAV-mediated gene targeting 
For gene targeting, homology arms to human Bub1 (BUB1) gene were 
amplified from RPE1 cell genomic DNA. Targeting constructs allowing the 
insertion of an EGFP tag C-terminal to Bub1 were assembled by 4-piece ligation in 
a NotI-digested pAAV vector. Recombinant adenovirus-associated virus (rAAV) 
particles were generated as previously described (Berdougo et al., 2009). RPE1 
cells were infected with 3 ml of viral supernatant for 48h and then expanded into 
fresh medium for an additional 48h.  FACS sorting was used to select EGFP-
positive cells, as previously described (Collin et al., 2013). To facilitate detection of 
fluorescence at mitotic stages, cells were synchronized with RO-3306 (10mM) for 
18h and released into nocodazole (50nM) for 2 hours, before they were trypsinized 
and subjected to sorting in the continued presence of nocodazole (10nM). Infected 
or uninfected cells were filtered (30 mm, Partec) and EGFP-positive cells (488 
excitation, 514/30 emission filter) were isolated on an Aria IIIu (BD) cell sorter by 
selecting the 514/30 channel against a 585/42 filter detecting cellular 
autofluorescence. Single cells were sorted into 96-well plates filled with 
conditioned medium and positive clones screened for by fluorescence microscopy. 
Generation of the stable RPE1 EGFP-Bub1 cell line was performed by Dr. Fabien 
Cubizolles. 
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6.1 Abbreviations 
 
All units are abbreviated according to the International Unit System 
 
aa  amino acid 
APC/C anaphase promoting complex/cyclososme 
ATP  adenosine 5’-triphosphate 
Bub1  budding uninhibited by benzimidazole 1 
BubR1 budding uninhibited by benzimidazole related 1 
Cdk  cyclin-dependent kinase 
CID  collision-induced dissociation 
CIN  numerical chromosomal aberration 
CPC  chromosomal passenger complex 
Da  dalton 
DAPI  4’6’-diamidino-2-phenylindole 
DDA  data dependent acquisition 
DHB  2,5 dihydroxy benzoic acid 
DIA  data independent acquisition 
DMSO dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
EDTA  ethylenediaminetetraacetic acid 
FCS  fetal calf serum 
FRAP  fluorescence recovery after photobleaching 
FRET  fluorescence resonance energy transfer 
GEF  guanine nucleotid exchange factor 
GLEBS Gle2-binding domain 
HCD  higher-energy collisional dissociation 
HCl  hydrochloric acid 
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HEK  human embryonic kidney 
HEPES N-2-hydroxyethylpiperazine-N’-2-ethane sulfonic acid 
IFM  immunofluorescence microscopy 
IMAC  immobilized metal affinity chromatography 
IP  immunoprecipitation 
KD  kinase dead 
KT  kinetochore 
KT-MT kinetochore-microtubule 
LC  liquid chromatography 
LOD  limit of detection 
Mad  mitotic arrest deficiency  
MCC  mitotic checkpoint complex 
Mps1  monopolar-spindle 1 
MS  mass spectrometry 
MSA  multi stage activation 
MT  microtubule 
MTOC microtubule organizing center 
m/z  mass to charge ratio 
NEBD  nuclear envelope breakdown 
PBD  polo-box domain 
Plk1  Polo-like kinase 1 
PMSF  phenylmethylsulfonyl fluoride 
PTM  post-translational modification 
SA  stromal antigen 
SAC  spindle assembly checkpoint 
SD  standard deviation 
SDS-PAGE sodium dodecylsulfate polyacrylamide gelelectrophoresis 
SEM  standard error of the mean 
Sgo  Shugoshin 
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SILAC stable isotope labeling by/with amino acids in cell culture 
siRNA small interference ribonucleic acid 
SRM  selected reaction monitoring 
pSRM  pseudo selected reaction monitoring 
TAL  ZK-Thiazolidinone 
TPR  tetratricopeptide repeat 
WB  Western blot 
WT  wild type 
XIC  extracted ion chromatograph 
 
 
 
 	154	
 		155	
 
 
 
 
 
 
 
7. References
 		156	
7.References 
		157	
Alberts, B., A. Johnson, J. Lewis, D. Morgan, M. Raff, K. Roberts, and P. Walter. 
2014. Molecular Biology of the Cell, Sixth Edition. Garland Science. 1 pp. 
Alberts, B., D. Bray, K. Hopkin, A. Johnson, J. Lewis, M. Raff, K. Roberts, and P. 
Walter. 2013. Essential Cell Biology, Fourth Edition. Garland Science. 1 pp. 
Allan, L.A., and P.R. Clarke. 2007. Phosphorylation of caspase-9 by CDK1/cyclin 
B1 protects mitotic cells against apoptosis. Molecular Cell. 26:301–310. 
doi:10.1016/j.molcel.2007.03.019. 
Anderson, D.E., A. Losada, H.P. Erickson, and T. Hirano. 2002. Condensin and 
cohesin display different arm conformations with characteristic hinge angles. 
The Journal of Cell Biology. 156:419–424. doi:10.1083/jcb.200111002. 
Andrews, P.D., Y. Ovechkina, N. Morrice, M. Wagenbach, K. Duncan, L. 
Wordeman, and J.R. Swedlow. 2004. Aurora B regulates MCAK at the mitotic 
centromere. Developmental Cell. 6:253–268. 
Asghar, A., A. Lajeunesse, K. Dulla, G. Combes, P. Thebault, E.A. Nigg, and S. 
Elowe. 2015. Bub1 autophosphorylation feeds back to regulate kinetochore 
docking and promote localized substrate phosphorylation. Nat Commun. 
6:8364. doi:10.1038/ncomms9364. 
Bancroft, J., P. Auckland, C.P. Samora, and A.D. McAinsh. 2015. Chromosome 
congression is promoted by CENP-Q- and CENP-E-dependent pathways. 
Journal of Cell Science. 128:171–184. doi:10.1242/jcs.163659. 
Bantscheff, M., M. Schirle, G. Sweetman, J. Rick, and B. Kuster. 2007. Quantitative 
mass spectrometry in proteomics: a critical review. Anal Bioanal Chem. 
389:1017–1031. doi:10.1007/s00216-007-1486-6. 
Barr, F.A., and U. Gruneberg. 2007. Cytokinesis: placing and making the final cut. 
Cell. 131:847–860. doi:10.1016/j.cell.2007.11.011. 
Berdougo, E., M.-E. Terret, and P.V. Jallepalli. 2009. Functional dissection of 
mitotic regulators through gene targeting in human somatic cells. Methods Mol. 
Biol. 545:21–37. doi:10.1007/978-1-60327-993-2_2. 
Berg, J.M., L. Stryer, and J.L. Tymoczko. 2015. Stryer Biochemie. Springer-Verlag. 1 
pp. 
Bertoli, C., J.M. Skotheim, and R.A.M. de Bruin. 2013. Control of cell cycle 
transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 14:518–528. 
doi:10.1038/nrm3629. 
Blackburn, K., and M.B. Goshe. 2009. Challenges and strategies for targeted 
7.References 
		158	
phosphorylation site identification and quantification using mass 
spectrometry analysis. Brief Funct Genomic Proteomic. 8:90–103. 
doi:10.1093/bfgp/eln051. 
Boersema, P.J., S. Mohammed, and A.J.R. Heck. 2009. Phosphopeptide 
fragmentation and analysis by mass spectrometry. J Mass Spectrom. 44:861–878. 
doi:10.1002/jms.1599. 
Bolanos-Garcia, V.M., and T.L. Blundell. 2011. BUB1 and BUBR1: multifaceted 
kinases of the cell cycle. Trends in Biochemical Sciences. 36:141–150. 
doi:10.1016/j.tibs.2010.08.004. 
Boyarchuk, Y., A. Salic, M. Dasso, and A. Arnaoutov. 2007. Bub1 is essential for 
assembly of the functional inner centromere. The Journal of Cell Biology. 
176:919–928. doi:10.1083/jcb.200609044. 
Brito, D.A., and C.L. Rieder. 2006. Mitotic checkpoint slippage in humans occurs 
via cyclin B destruction in the presence of an active checkpoint. Current 
Biology. 16:1194–1200. doi:10.1016/j.cub.2006.04.043. 
Brito, D.A., and C.L. Rieder. 2009. The ability to survive mitosis in the presence of 
microtubule poisons differs significantly between human nontransformed 
(RPE-1) and cancer (U2OS, HeLa) cells. Cell Motil. Cytoskeleton. 66:437–447. 
doi:10.1002/cm.20316. 
Buschhorn, B.A., G. Petzold, M. Galova, P. Dube, C. Kraft, F. Herzog, H. Stark, and 
J.-M. Peters. 2011. Substrate binding on the APC/C occurs between the 
coactivator Cdh1 and the processivity factor Doc1. Nat. Struct. Mol. Biol. 18:6–
13. doi:10.1038/nsmb.1979. 
Campbell, C.S., and A. Desai. 2013. Tension sensing by Aurora B kinase is 
independent of survivin-based centromere localization. Nature. 497:118–121. 
doi:10.1038/nature12057. 
Carmena, M., M. Wheelock, H. Funabiki, and W.C. Earnshaw. 2012. The 
chromosomal passenger complex (CPC): from easy rider to the godfather of 
mitosis. Nat. Rev. Mol. Cell Biol. 13:789–803. doi:10.1038/nrm3474. 
Carpenter, A.E., T.R. Jones, M.R. Lamprecht, C. Clarke, I.H. Kang, O. Friman, D.A. 
Guertin, J.H. Chang, R.A. Lindquist, J. Moffat, P. Golland, and D.M. Sabatini. 
2006. CellProfiler: image analysis software for identifying and quantifying cell 
phenotypes. Genome Biol. 7:R100. doi:10.1186/gb-2006-7-10-r100. 
Chang, L., and D. Barford. 2014. Insights into the anaphase-promoting complex: a 
molecular machine that regulates mitosis. Curr. Opin. Struct. Biol. 29:1–9. 
doi:10.1016/j.sbi.2014.08.003. 
7.References 
		159	
Chao, W.C.H., K. Kulkarni, Z. Zhang, E.H. Kong, and D. Barford. 2012. Structure 
of the mitotic checkpoint complex. Nature. 484:208–213. 
doi:10.1038/nature10896. 
Cheeseman, I.M., and A. Desai. 2008. Molecular architecture of the kinetochore-
microtubule interface. Nat. Rev. Mol. Cell Biol. 9:33–46. doi:10.1038/nrm2310. 
Cheeseman, I.M., J.S. Chappie, E.M. Wilson-Kubalek, and A. Desai. 2006. The 
conserved KMN network constitutes the core microtubule-binding site of the 
kinetochore. Cell. 127:983–997. doi:10.1016/j.cell.2006.09.039. 
Chen, J.-G., and S.B. Horwitz. 2002. Differential mitotic responses to microtubule-
stabilizing and -destabilizing drugs. Cancer Research. 62:1935–1938. 
Chen, X., S. Wei, Y. Ji, X. Guo, and F. Yang. 2015. Quantitative proteomics using 
SILAC: Principles, applications, and developments. Proteomics. 15:3175–3192. 
doi:10.1002/pmic.201500108. 
Ciferri, C., S. Pasqualato, E. Screpanti, G. Varetti, S. Santaguida, G. Dos Reis, A. 
Maiolica, J. Polka, J.G. De Luca, P. De Wulf, M. Salek, J. Rappsilber, C.A. 
Moores, E.D. Salmon, and A. Musacchio. 2008. Implications for kinetochore-
microtubule attachment from the structure of an engineered Ndc80 complex. 
Cell. 133:427–439. doi:10.1016/j.cell.2008.03.020. 
Cleveland, D.W., Y. Mao, and K.F. Sullivan. 2003. Centromeres and kinetochores: 
from epigenetics to mitotic checkpoint signaling. Cell. 112:407–421. 
Cohen, P. 2002. The origins of protein phosphorylation. Nature Cell Biology. 
4:E127–30. doi:10.1038/ncb0502-e127. 
Collin, P., O. Nashchekina, R. Walker, and J. Pines. 2013. The spindle assembly 
checkpoint works like a rheostat rather than a toggle switch. Nature Cell 
Biology. 15:1378–1385. doi:10.1038/ncb2855. 
Colombo, R., M. Caldarelli, M. Mennecozzi, M.L. Giorgini, F. Sola, P. Cappella, C. 
Perrera, S.R. Depaolini, L. Rusconi, U. Cucchi, N. Avanzi, J.A. Bertrand, R.T. 
Bossi, E. Pesenti, A. Galvani, A. Isacchi, F. Colotta, D. Donati, and J. Moll. 2010. 
Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an 
inhibitor of MPS1 kinase. Cancer Research. 70:10255–10264. doi:10.1158/0008-
5472.CAN-10-2101. 
Cooper, G.M., and R.E. Hausman. 2013. The Cell. Sinauer Associates Incorporated. 
1 pp. 
CSLS, The University of Tokyo. 2011. A comprehensive approach to life science. 
http://csls-text.c.u-tokyo.ac.jpactive.html. 
7.References 
		160	
da Fonseca, P.C.A., E.H. Kong, Z. Zhang, A. Schreiber, M.A. Williams, E.P. Morris, 
and D. Barford. 2011. Structures of APC/C(Cdh1) with substrates identify 
Cdh1 and Apc10 as the D-box co-receptor. Nature. 470:274–278. 
doi:10.1038/nature09625. 
Davenport, J., L.D. Harris, and R. Goorha. 2006. Spindle checkpoint function 
requires Mad2-dependent Cdc20 binding to the Mad3 homology domain of 
BubR1. Experimental Cell Research. 312:1831–1842. 
doi:10.1016/j.yexcr.2006.02.018. 
De Antoni, A., C.G. Pearson, D. Cimini, J.C. Canman, V. Sala, L. Nezi, M. Mapelli, 
L. Sironi, M. Faretta, E.D. Salmon, and A. Musacchio. 2005. The Mad1/Mad2 
complex as a template for Mad2 activation in the spindle assembly checkpoint. 
Current Biology. 15:214–225. doi:10.1016/j.cub.2005.01.038. 
De Antoni, A., S. Maffini, S. Knapp, A. Musacchio, and S. Santaguida. 2012. A 
small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora 
B. The Journal of Cell Biology. 199:269–284. doi:10.1083/jcb.201205119. 
DeLuca, J.G., W.E. Gall, C. Ciferri, D. Cimini, A. Musacchio, and E.D. Salmon. 
2006. Kinetochore microtubule dynamics and attachment stability are 
regulated by Hec1. Cell. 127:969–982. doi:10.1016/j.cell.2006.09.047. 
Dephoure, N., K.L. Gould, S.P. Gygi, and D.R. Kellogg. 2013. Mapping and 
analysis of phosphorylation sites: a quick guide for cell biologists. Mol. Biol. 
Cell. 24:535–542. doi:10.1091/mbc.E12-09-0677. 
Dick, A.E., and D.W. Gerlich. 2013. Kinetic framework of spindle assembly 
checkpoint signalling. Nature Cell Biology. 15:1370–1377. doi:10.1038/ncb2842. 
Ditchfield, C., V.L. Johnson, A. Tighe, R. Ellston, C. Haworth, T. Johnson, A. 
Mortlock, N. Keen, and S.S. Taylor. 2003. Aurora B couples chromosome 
alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to 
kinetochores. The Journal of Cell Biology. 161:267–280. doi:10.1083/jcb.200208091. 
Domon, B., and R. Aebersold. 2010. Options and considerations when selecting a 
quantitative proteomics strategy. Nat. Biotechnol. 28:710–721. 
doi:10.1038/nbt.1661. 
Donzelli, M., and G.F. Draetta. 2003. Regulating mammalian checkpoints through 
Cdc25 inactivation. EMBO Rep. 4:671–677. doi:10.1038/sj.embor.embor887. 
Dou, Z., C. von Schubert, R. Körner, A. Santamaria, S. Elowe, and E.A. Nigg. 2011. 
Quantitative mass spectrometry analysis reveals similar substrate consensus 
motif for human Mps1 kinase and Plk1. PLoS ONE. 6:e18793. 
doi:10.1371/journal.pone.0018793. 
7.References 
		161	
Du, J., A.E. Kelly, H. Funabiki, and D.J. Patel. 2012. Structural basis for recognition 
of H3T3ph and Smac/DIABLO N-terminal peptides by human Survivin. 
Structure. 20:185–195. doi:10.1016/j.str.2011.12.001. 
Elbashir, S.M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. 
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured 
mammalian cells. Nature. 411:494–498. doi:10.1038/35078107. 
Elia, A.E.H., L.C. Cantley, and M.B. Yaffe. 2003. Proteomic screen finds pSer/pThr-
binding domain localizing Plk1 to mitotic substrates. Science. 299:1228–1231. 
doi:10.1126/science.1079079. 
Elmore, S. 2007. Apoptosis: a review of programmed cell death. Toxicol Pathol. 
35:495–516. doi:10.1080/01926230701320337. 
Elowe, S. 2011. Bub1 and BubR1: at the interface between chromosome attachment 
and the spindle checkpoint. Molecular and Cellular Biology. 31:3085–3093. 
doi:10.1128/MCB.05326-11. 
Emanuele, M.J., W. Lan, M. Jwa, S.A. Miller, C.S.M. Chan, and P.T. Stukenberg. 
2008. Aurora B kinase and protein phosphatase 1 have opposing roles in 
modulating kinetochore assembly. The Journal of Cell Biology. 181:241–254. 
doi:10.1083/jcb.200710019. 
Espeut, J., P. Lara-Gonzalez, M. Sassine, A.K. Shiau, A. Desai, and A. Abrieu. 2015. 
Natural Loss of Mps1 Kinase in Nematodes Uncovers a Role for Polo-like 
Kinase 1 in Spindle Checkpoint Initiation. Cell Rep. 
doi:10.1016/j.celrep.2015.05.039. 
Fang, G. 2002. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit 
anaphase-promoting complex. Mol. Biol. Cell. 13:755–766. doi:10.1091/mbc.01-
09-0437. 
Farr, K.A., and M.A. Hoyt. 1998. Bub1p kinase activates the Saccharomyces 
cerevisiae spindle assembly checkpoint. Molecular and Cellular Biology. 18:2738–
2747. 
Fava, L.L., M. Kaulich, E.A. Nigg, and A. Santamaria. 2011. Probing the in vivo 
function of Mad1:C-Mad2 in the spindle assembly checkpoint. The EMBO 
Journal. 30:3322–3336. doi:10.1038/emboj.2011.239. 
Fernius, J., and K.G. Hardwick. 2007. Bub1 kinase targets Sgo1 to ensure efficient 
chromosome biorientation in budding yeast mitosis. PLoS Genet. 3:e213. 
doi:10.1371/journal.pgen.0030213. 
Figueroa-Masot, X.A., M. Hetman, M.J. Higgins, N. Kokot, and Z. Xia. 2001. Taxol 
7.References 
		162	
induces apoptosis in cortical neurons by a mechanism independent of Bcl-2 
phosphorylation. J. Neurosci. 21:4657–4667. 
Fíla, J., and D. Honys. 2012. Enrichment techniques employed in 
phosphoproteomics. Amino Acids. 43:1025–1047. doi:10.1007/s00726-011-1111-z. 
Foley, E.A., and T.M. Kapoor. 2013. Microtubule attachment and spindle assembly 
checkpoint signalling at the kinetochore. Nat. Rev. Mol. Cell Biol. 14:25–37. 
doi:10.1038/nrm3494. 
Foley, E.A., M. Maldonado, and T.M. Kapoor. 2011. Formation of stable 
attachments between kinetochores and microtubules depends on the B56-
PP2A phosphatase. Nature Cell Biology. 13:1265–1271. doi:10.1038/ncb2327. 
Fuller, B.G., M.A. Lampson, E.A. Foley, S. Rosasco-Nitcher, K.V. Le, P. 
Tobelmann, D.L. Brautigan, P.T. Stukenberg, and T.M. Kapoor. 2008. Midzone 
activation of aurora B in anaphase produces an intracellular phosphorylation 
gradient. Nature. 453:1132–1136. doi:10.1038/nature06923. 
Funabiki, H., and D.J. Wynne. 2013. Making an effective switch at the kinetochore 
by phosphorylation and dephosphorylation. Chromosoma. 122:135–158. 
doi:10.1007/s00412-013-0401-5. 
Gallien, S., E. Duriez, C. Crone, M. Kellmann, T. Moehring, and B. Domon. 2012. 
Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. 
Mol. Cell Proteomics. 11:1709–1723. doi:10.1074/mcp.O112.019802. 
Gandhi, R., P.J. Gillespie, and T. Hirano. 2006. Human Wapl is a cohesin-binding 
protein that promotes sister-chromatid resolution in mitotic prophase. Current 
Biology. 16:2406–2417. doi:10.1016/j.cub.2006.10.061. 
Gascoigne, K.E., and S.S. Taylor. 2008. Cancer cells display profound intra- and 
interline variation following prolonged exposure to antimitotic drugs. Cancer 
Cell. 14:111–122. doi:10.1016/j.ccr.2008.07.002. 
Gascoigne, K.E., and S.S. Taylor. 2009. How do anti-mitotic drugs kill cancer cells? 
Journal of Cell Science. 122:2579–2585. doi:10.1242/jcs.039719. 
Gassmann, R., A.J. Holland, D. Varma, X. Wan, F. Civril, D.W. Cleveland, K. 
Oegema, E.D. Salmon, and A. Desai. 2010. Removal of Spindly from 
microtubule-attached kinetochores controls spindle checkpoint silencing in 
human cells. Genes & Development. 24:957–971. doi:10.1101/gad.1886810. 
Gillet, L.C., P. Navarro, S. Tate, H. Röst, N. Selevsek, L. Reiter, R. Bonner, and R. 
Aebersold. 2012. Targeted data extraction of the MS/MS spectra generated by 
data-independent acquisition: a new concept for consistent and accurate 
7.References 
		163	
proteome analysis. Mol. Cell Proteomics. 11:O111.016717–O111.016717. 
doi:10.1074/mcp.O111.016717. 
Gillette, M.A., and S.A. Carr. 2013. Quantitative analysis of peptides and proteins 
in biomedicine by targeted mass spectrometry. Nature Methods. 10:28–34. 
doi:10.1038/nmeth.2309. 
Gohard, F.H., D.J. St-Cyr, M. Tyers, and W.C. Earnshaw. 2014. Targeting the 
INCENP IN-box-Aurora B interaction to inhibit CPC activity in vivo. Open 
Biol. 4:140163–140163. doi:10.1098/rsob.140163. 
Gregan, J., S. Polakova, L. Zhang, I.M. Tolić-Nørrelykke, and D. Cimini. 2011. 
Merotelic kinetochore attachment: causes and effects. Trends in Cell Biology. 
21:374–381. doi:10.1016/j.tcb.2011.01.003. 
Gruber, S., C.H. Haering, and K. Nasmyth. 2003. Chromosomal cohesin forms a 
ring. Cell. 112:765–777. 
Guimaraes, G.J., Y. Dong, B.F. McEwen, and J.G. DeLuca. 2008. Kinetochore-
microtubule attachment relies on the disordered N-terminal tail domain of 
Hec1. Current Biology. 18:1778–1784. doi:10.1016/j.cub.2008.08.012. 
Guo, Y., C. Kim, and Y. Mao. 2013. New insights into the mechanism for 
chromosome alignment in metaphase. Int Rev Cell Mol Biol. 303:237–262. 
doi:10.1016/B978-0-12-407697-6.00006-4. 
Haarhuis, J.H.I., A.M.O. Elbatsh, and B.D. Rowland. 2014. Cohesin and Its 
Regulation: On the Logic of X-Shaped Chromosomes. Developmental Cell. 31:7–
18. 
Haering, C.H., A.-M. Farcas, P. Arumugam, J. Metson, and K. Nasmyth. 2008. The 
cohesin ring concatenates sister DNA molecules. Nature. 454:297–301. 
doi:10.1038/nature07098. 
Haering, C.H., J. Löwe, A. Hochwagen, and K. Nasmyth. 2002. Molecular 
architecture of SMC proteins and the yeast cohesin complex. Molecular Cell. 
9:773–788. 
Hanisch, A., A. Wehner, E.A. Nigg, and H.H.W. Silljé. 2006a. Different Plk1 
functions show distinct dependencies on Polo-Box domain-mediated 
targeting. Mol. Biol. Cell. 17:448–459. doi:10.1091/mbc.E05-08-0801. 
Hanisch, A., H.H.W. Silljé, and E.A. Nigg. 2006b. Timely anaphase onset requires a 
novel spindle and kinetochore complex comprising Ska1 and Ska2. The EMBO 
Journal. 25:5504–5515. doi:10.1038/sj.emboj.7601426. 
7.References 
		164	
Hardwick, K.G., R.C. Johnston, D.L. Smith, and A.W. Murray. 2000. MAD3 
encodes a novel component of the spindle checkpoint which interacts with 
Bub3p, Cdc20p, and Mad2p. The Journal of Cell Biology. 148:871–882. 
Hartwell, L.H., and T.A. Weinert. 1989. Checkpoints: controls that ensure the 
order of cell cycle events. Science. 
Hauf, S., I.C. Waizenegger, and J.M. Peters. 2001. Cohesin cleavage by separase 
required for anaphase and cytokinesis in human cells. Science. 293:1320–1323. 
doi:10.1126/science.1061376. 
Hauf, S., R.W. Cole, S. LaTerra, C. Zimmer, G. Schnapp, R. Walter, A. Heckel, J. 
van Meel, C.L. Rieder, and J.-M. Peters. 2003. The small molecule Hesperadin 
reveals a role for Aurora B in correcting kinetochore-microtubule attachment 
and in maintaining the spindle assembly checkpoint. The Journal of Cell Biology. 
161:281–294. doi:10.1083/jcb.200208092. 
Heald, R., R. Tournebize, T. Blank, R. Sandaltzopoulos, P. Becker, A. Hyman, and 
E. Karsenti. 1996. Self-organization of microtubules into bipolar spindles 
around artificial chromosomes in Xenopus egg extracts. Nature. 382:420–425. 
doi:10.1038/382420a0. 
Hewitt, L., A. Tighe, S. Santaguida, A.M. White, C.D. Jones, A. Musacchio, S. 
Green, and S.S. Taylor. 2010. Sustained Mps1 activity is required in mitosis to 
recruit O-Mad2 to the Mad1-C-Mad2 core complex. The Journal of Cell Biology. 
190:25–34. doi:10.1083/jcb.201002133. 
Hirota, T., J.J. Lipp, B.-H. Toh, and J.-M. Peters. 2005. Histone H3 serine 10 
phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. 
Nature. 438:1176–1180. doi:10.1038/nature04254. 
Hitchcock, M., A. Mengel, A. Richter, H. Briem, K. Eis, V. Pütter, G. Siemeister, S. 
Prechtl, A.E. Fernandez-Montalvan, C. Stegmann, S. Holton, M.J. Gnoth, and 
C. Preusse. 2013. Substituted benzylpyrazoles WO2013092512. 
Holland, A.J., and D.W. Cleveland. 2009. Boveri revisited: chromosomal 
instability, aneuploidy and tumorigenesis. Nat. Rev. Mol. Cell Biol. 10:478–487. 
doi:10.1038/nrm2718. 
Honda, R., R. Körner, and E.A. Nigg. 2003. Exploring the functional interactions 
between Aurora B, INCENP, and survivin in mitosis. Mol. Biol. Cell. 14:3325–
3341. doi:10.1091/mbc.E02-11-0769. 
Howell, B.J., B. Moree, E.M. Farrar, S. Stewart, G. Fang, and E.D. Salmon. 2004. 
Spindle checkpoint protein dynamics at kinetochores in living cells. Current 
Biology. 14:953–964. doi:10.1016/j.cub.2004.05.053.
7.References 
		165	
Howell, B.J., B.F. McEwen, J.C. Canman, D.B. Hoffman, E.M. Farrar, C.L. Rieder, 
and E.D. Salmon. 2001. Cytoplasmic dynein/dynactin drives kinetochore 
protein transport to the spindle poles and has a role in mitotic spindle 
checkpoint inactivation. The Journal of Cell Biology. 155:1159–1172. 
doi:10.1083/jcb.200105093. 
Hoyt, M.A., L. Totis, and B.T. Roberts. 1991. S. cerevisiae genes required for cell 
cycle arrest in response to loss of microtubule function. Cell. 66:507–517. 
Hsu, J.Y., Z.W. Sun, X. Li, M. Reuben, K. Tatchell, D.K. Bishop, J.M. Grushcow, C.J. 
Brame, J.A. Caldwell, D.F. Hunt, R. Lin, M.M. Smith, and C.D. Allis. 2000. 
Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and 
Glc7/PP1 phosphatase in budding yeast and nematodes. Cell. 102:279–291. 
Ibarrola, N., D.E. Kalume, M. Gronborg, A. Iwahori, and A. Pandey. 2003. A 
proteomic approach for quantitation of phosphorylation using stable isotope 
labeling in cell culture. Anal. Chem. 75:6043–6049. doi:10.1021/ac034931f. 
Iemura, K., and K. Tanaka. 2015. Chromokinesin Kid and kinetochore kinesin 
CENP-E differentially support chromosome congression without end-on 
attachment to microtubules. Nat Commun. 6:6447. doi:10.1038/ncomms7447. 
Ikui, A.E., C.-P.H. Yang, T. Matsumoto, and S.B. Horwitz. 2005. Low 
concentrations of taxol cause mitotic delay followed by premature dissociation 
of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, 
leading to aneuploidy. Cell Cycle. 4:1385–1388. 
Ivanov, D., and K. Nasmyth. 2005. A topological interaction between cohesin rings 
and a circular minichromosome. Cell. 122:849–860. 
doi:10.1016/j.cell.2005.07.018. 
Jablonski, S.A., G.K. Chan, C.A. Cooke, W.C. Earnshaw, and T.J. Yen. 1998. The 
hBUB1 and hBUBR1 kinases sequentially assemble onto kinetochores during 
prophase with hBUBR1 concentrating at the kinetochore plates in mitosis. 
Chromosoma. 107:386–396. 
Jaffe, J.D., H. Keshishian, B. Chang, T.A. Addona, M.A. Gillette, and S.A. Carr. 
2008. Accurate inclusion mass screening: a bridge from unbiased discovery to 
targeted assay development for biomarker verification. Mol. Cell Proteomics. 
7:1952–1962. doi:10.1074/mcp.M800218-MCP200. 
Janssen, A., G.J.P.L. Kops, and R.H. Medema. 2009. Elevating the frequency of 
chromosome mis-segregation as a strategy to kill tumor cells. Proc. Natl. Acad. 
Sci. U.S.A. 106:19108–19113. doi:10.1073/pnas.0904343106. 
Jeganathan, K., L. Malureanu, D.J. Baker, S.C. Abraham, and J.M. van Deursen. 
7.References 
		166	
2007. Bub1 mediates cell death in response to chromosome missegregation and 
acts to suppress spontaneous tumorigenesis. The Journal of Cell Biology. 
179:255–267. doi:10.1083/jcb.200706015. 
Jelluma, N., A.B. Brenkman, N.J.F. van den Broek, C.W.A. Cruijsen, M.H.J. van 
Osch, S.M.A. Lens, R.H. Medema, and G.J.P.L. Kops. 2008. Mps1 
phosphorylates Borealin to control Aurora B activity and chromosome 
alignment. Cell. 132:233–246. doi:10.1016/j.cell.2007.11.046. 
Jelluma, N., T.B. Dansen, T. Sliedrecht, N.P. Kwiatkowski, and G.J.P.L. Kops. 2010. 
Release of Mps1 from kinetochores is crucial for timely anaphase onset. The 
Journal of Cell Biology. 191:281–290. doi:10.1083/jcb.201003038. 
Jemaà, M., L. Galluzzi, O. Kepp, L. Senovilla, M. Brands, U. Boemer, M. Koppitz, 
P. Lienau, S. Prechtl, V. Schulze, G. Siemeister, A.M. Wengner, D. Mumberg, 
K. Ziegelbauer, A. Abrieu, M. Castedo, I. Vitale, and G. Kroemer. 2013. 
Characterization of novel MPS1 inhibitors with preclinical anticancer activity. 
Cell Death Differ. 20:1532–1545. doi:10.1038/cdd.2013.105. 
Jia, L., B. Li, R.T. Warrington, X. Hao, S. Wang, and H. Yu. 2011. Defining 
pathways of spindle checkpoint silencing: functional redundancy between 
Cdc20 ubiquitination and p31(comet). Mol. Biol. Cell. 22:4227–4235. 
doi:10.1091/mbc.E11-05-0389. 
Johnson, V.L., M.I.F. Scott, S.V. Holt, D. Hussein, and S.S. Taylor. 2004. Bub1 is 
required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, 
and chromosome congression. Journal of Cell Science. 117:1577–1589. 
doi:10.1242/jcs.01006. 
Kang, J., M. Yang, B. Li, W. Qi, C. Zhang, K.M. Shokat, D.R. Tomchick, M. 
Machius, and H. Yu. 2008. Structure and substrate recruitment of the human 
spindle checkpoint kinase Bub1. Molecular Cell. 32:394–405. 
doi:10.1016/j.molcel.2008.09.017. 
Kapoor, T.M., M.A. Lampson, P. Hergert, L. Cameron, D. Cimini, E.D. Salmon, 
B.F. McEwen, and A. Khodjakov. 2006. Chromosomes can congress to the 
metaphase plate before biorientation. Science. 311:388–391. 
doi:10.1126/science.1122142. 
Kapoor, T.M., T.U. Mayer, M.L. Coughlin, and T.J. Mitchison. 2000. Probing 
spindle assembly mechanisms with monastrol, a small molecule inhibitor of 
the mitotic kinesin, Eg5. The Journal of Cell Biology. 150:975–988. 
doi:10.1038/35036012. 
Kawashima, S.A., T. Tsukahara, M. Langegger, S. Hauf, T.S. Kitajima, and Y. 
7.References 
		167	
Watanabe. 2007. Shugoshin enables tension-generating attachment of 
kinetochores by loading Aurora to centromeres. Genes & Development. 21:420–
435. doi:10.1101/gad.1497307. 
Kawashima, S.A., Y. Yamagishi, T. Honda, K.-I. Ishiguro, and Y. Watanabe. 2010. 
Phosphorylation of H2A by Bub1 prevents chromosomal instability through 
localizing shugoshin. Science. 327:172–177. doi:10.1126/science.1180189. 
Kelly, A.E., C. Ghenoiu, J.Z. Xue, C. Zierhut, H. Kimura, and H. Funabiki. 2010. 
Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic 
kinase Aurora B. Science. 330:235–239. doi:10.1126/science.1189505. 
Kim, Y., A.J. Holland, W. Lan, and D.W. Cleveland. 2010. Aurora kinases and 
protein phosphatase 1 mediate chromosome congression through regulation of 
CENP-E. Cell. 142:444–455. doi:10.1016/j.cell.2010.06.039. 
Kirschner, M.W., and T. Mitchison. 1986. Microtubule dynamics. Nature. 324:621–
621. doi:10.1038/324621a0. 
Kishi, K., M.A.T.M. van Vugt, K.-I. Okamoto, Y. Hayashi, and M.B. Yaffe. 2009. 
Functional dynamics of Polo-like kinase 1 at the centrosome. Molecular and 
Cellular Biology. 29:3134–3150. doi:10.1128/MCB.01663-08. 
Kitajima, T.S., S. Hauf, M. Ohsugi, T. Yamamoto, and Y. Watanabe. 2005. Human 
Bub1 defines the persistent cohesion site along the mitotic chromosome by 
affecting Shugoshin localization. Current Biology. 15:353–359. 
doi:10.1016/j.cub.2004.12.044. 
Kitajima, T.S., T. Sakuno, K.-I. Ishiguro, S.-I. Iemura, T. Natsume, S.A. Kawashima, 
and Y. Watanabe. 2006. Shugoshin collaborates with protein phosphatase 2A 
to protect cohesin. Nature. 441:46–52. doi:10.1038/nature04663. 
Kiyomitsu, T., H. Murakami, and M. Yanagida. 2011. Protein interaction domain 
mapping of human kinetochore protein Blinkin reveals a consensus motif for 
binding of spindle assembly checkpoint proteins Bub1 and BubR1. Molecular 
and Cellular Biology. 31:998–1011. doi:10.1128/MCB.00815-10. 
Klebig, C., D. Korinth, and P. Meraldi. 2009. Bub1 regulates chromosome 
segregation in a kinetochore-independent manner. The Journal of Cell Biology. 
185:841–858. doi:10.1083/jcb.200902128. 
Klein, U.R., E.A. Nigg, and U. Gruneberg. 2006. Centromere targeting of the 
chromosomal passenger complex requires a ternary subcomplex of Borealin, 
Survivin, and the N-terminal domain of INCENP. Mol. Biol. Cell. 17:2547–2558. 
doi:10.1091/mbc.E05-12-1133. 
7.References 
		168	
Knowlton, A.L., W. Lan, and P.T. Stukenberg. 2006. Aurora B is enriched at 
merotelic attachment sites, where it regulates MCAK. Current Biology. 16:1705–
1710. doi:10.1016/j.cub.2006.07.057. 
Kolodner, R.D., D.W. Cleveland, and C.D. Putnam. 2011. Cancer. Aneuploidy 
drives a mutator phenotype in cancer. Science. 333:942–943. 
doi:10.1126/science.1211154. 
Kops, G.J.P.L., A.T. Saurin, and P. Meraldi. 2010. Finding the middle ground: how 
kinetochores power chromosome congression. Cell. Mol. Life Sci. 67:2145–2161. 
doi:10.1007/s00018-010-0321-y. 
Kops, G.J.P.L., D.R. Foltz, and D.W. Cleveland. 2004. Lethality to human cancer 
cells through massive chromosome loss by inhibition of the mitotic checkpoint. 
Proc. Natl. Acad. Sci. U.S.A. 101:8699–8704. doi:10.1073/pnas.0401142101. 
Krenn, V., A. Wehenkel, X. Li, S. Santaguida, and A. Musacchio. 2012. Structural 
analysis reveals features of the spindle checkpoint kinase Bub1-kinetochore 
subunit Knl1 interaction. The Journal of Cell Biology. 196:451–467. 
doi:10.1083/jcb.201110013. 
Krenn, V., K. Overlack, I. Primorac, S. van Gerwen, and A. Musacchio. 2014. KI 
motifs of human Knl1 enhance assembly of comprehensive spindle checkpoint 
complexes around MELT repeats. Curr. Biol. 24:29–39. 
doi:10.1016/j.cub.2013.11.046. 
Kruse, T., G. Zhang, M.S.Y. Larsen, T. Lischetti, W. Streicher, T. Kragh Nielsen, 
S.P. Bjørn, and J. Nilsson. 2013. Direct binding between BubR1 and B56-PP2A 
phosphatase complexes regulate mitotic progression. Journal of Cell Science. 
126:1086–1092. doi:10.1242/jcs.122481. 
Kueng, S., B. Hegemann, B.H. Peters, J.J. Lipp, A. Schleiffer, K. Mechtler, and J.-M. 
Peters. 2006. Wapl controls the dynamic association of cohesin with chromatin. 
Cell. 127:955–967. doi:10.1016/j.cell.2006.09.040. 
Kulukian, A., J.S. Han, and D.W. Cleveland. 2009. Unattached kinetochores 
catalyze production of an anaphase inhibitor that requires a Mad2 template to 
prime Cdc20 for BubR1 binding. Developmental Cell. 16:105–117. 
doi:10.1016/j.devcel.2008.11.005. 
Kusakabe, K.-I., N. Ide, Y. Daigo, T. Itoh, T. Yamamoto, H. Hashizume, K. Nozu, 
H. Yoshida, G. Tadano, S. Tagashira, K. Higashino, Y. Okano, Y. Sato, M. 
Inoue, M. Iguchi, T. Kanazawa, Y. Ishioka, K. Dohi, Y. Kido, S. Sakamoto, S. 
Ando, M. Maeda, M. Higaki, Y. Baba, and Y. Nakamura. 2015. Discovery of 
imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 
7.References 
		169	
(TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. J. Med. 
Chem. 58:1760–1775. doi:10.1021/jm501599u. 
Lampson, M.A., and I.M. Cheeseman. 2011. Sensing centromere tension: Aurora B 
and the regulation of kinetochore function. Trends in Cell Biology. 21:133–140. 
doi:10.1016/j.tcb.2010.10.007. 
Lampson, M.A., K. Renduchitala, A. Khodjakov, and T.M. Kapoor. 2004. 
Correcting improper chromosome-spindle attachments during cell division. 
Nature Cell Biology. 6:232–237. doi:10.1038/ncb1102. 
Lan, W., and D.W. Cleveland. 2010. A chemical tool box defines mitotic and 
interphase roles for Mps1 kinase. The Journal of Cell Biology. 190:21–24. 
doi:10.1083/jcb.201006080. 
Lan, W., X. Zhang, S.L. Kline-Smith, S.E. Rosasco, G.A. Barrett-Wilt, J. 
Shabanowitz, D.F. Hunt, C.E. Walczak, and P.T. Stukenberg. 2004. Aurora B 
phosphorylates centromeric MCAK and regulates its localization and 
microtubule depolymerization activity. Current Biology. 14:273–286. 
doi:10.1016/j.cub.2004.01.055. 
Lange, V., P. Picotti, B. Domon, and R. Aebersold. 2008. Selected reaction 
monitoring for quantitative proteomics: a tutorial. Molecular Systems Biology. 
4:222. doi:10.1038/msb.2008.61. 
Lara-Gonzalez, P., and S.S. Taylor. 2012. Cohesion fatigue explains why 
pharmacological inhibition of the APC/C induces a spindle checkpoint-
dependent mitotic arrest. PLoS ONE. 7:e49041. 
doi:10.1371/journal.pone.0049041. 
Lara-Gonzalez, P., F.G. Westhorpe, and S.S. Taylor. 2012. The spindle assembly 
checkpoint. Curr. Biol. 22:R966–80. doi:10.1016/j.cub.2012.10.006. 
Larsen, M.R., T.E. Thingholm, O.N. Jensen, P. Roepstorff, and T.J.D. Jørgensen. 
2005. Highly selective enrichment of phosphorylated peptides from peptide 
mixtures using titanium dioxide microcolumns. Mol. Cell Proteomics. 4:873–886. 
doi:10.1074/mcp.T500007-MCP200. 
Larsen, N.A., and S.C. Harrison. 2004. Crystal structure of the spindle assembly 
checkpoint protein Bub3. J. Mol. Biol. 344:885–892. 
doi:10.1016/j.jmb.2004.09.094. 
Larsen, N.A., J. Al-Bassam, R.R. Wei, and S.C. Harrison. 2007. Structural analysis 
of Bub3 interactions in the mitotic spindle checkpoint. Proc. Natl. Acad. Sci. 
U.S.A. 104:1201–1206. doi:10.1073/pnas.0610358104. 
7.References 
		170	
Lee, E.A., M.K. Keutmann, M.L. Dowling, E. Harris, G. Chan, and G.D. Kao. 2004. 
Inactivation of the mitotic checkpoint as a determinant of the efficacy of 
microtubule-targeted drugs in killing human cancer cells. Mol. Cancer Ther. 
3:661–669. 
Lenart, P., M. Petronczki, M. Steegmaier, B. Di Fiore, J.J. Lipp, M. Hoffmann, W.J. 
Rettig, N. Kraut, and J.-M. Peters. 2007. The small-molecule inhibitor BI 2536 
reveals novel insights into mitotic roles of polo-like kinase 1. Current Biology. 
17:304–315. doi:10.1016/j.cub.2006.12.046. 
Li, H.Y., D. Wirtz, and Y. Zheng. 2003. A mechanism of coupling RCC1 mobility to 
RanGTP production on the chromatin in vivo. The Journal of Cell Biology. 
160:635–644. doi:10.1083/jcb.200211004. 
Li, R., and A.W. Murray. 1991. Feedback control of mitosis in budding yeast. Cell. 
66:519–531. 
Li, X., and R.B. Nicklas. 1995. Mitotic forces control a cell-cycle checkpoint. Nature. 
373:630–632. doi:10.1038/373630a0. 
Lin, Z., L. Jia, D.R. Tomchick, X. Luo, and H. Yu. 2014. Substrate-specific activation 
of the mitotic kinase Bub1 through intramolecular autophosphorylation and 
kinetochore targeting. Structure. 22:1616–1627. doi:10.1016/j.str.2014.08.020. 
Liu, D., G. Vader, M.J.M. Vromans, M.A. Lampson, and S.M.A. Lens. 2009. 
Sensing chromosome bi-orientation by spatial separation of aurora B kinase 
from kinetochore substrates. Science. 323:1350–1353. 
doi:10.1126/science.1167000. 
Liu, D., M. Vleugel, C.B. Backer, T. Hori, T. Fukagawa, I.M. Cheeseman, and M.A. 
Lampson. 2010. Regulated targeting of protein phosphatase 1 to the outer 
kinetochore by KNL1 opposes Aurora B kinase. The Journal of Cell Biology. 
188:809–820. doi:10.1083/jcb.201001006. 
Liu, H., L. Jia, and H. Yu. 2013a. Phospho-H2A and cohesin specify distinct 
tension-regulated Sgo1 pools at kinetochores and inner centromeres. Curr. Biol. 
23:1927–1933. doi:10.1016/j.cub.2013.07.078. 
Liu, H., Q. Qu, R. Warrington, A. Rice, N. Cheng, and H. Yu. 2015. Mitotic 
Transcription Installs Sgo1 at Centromeres to Coordinate Chromosome 
Segregation. Molecular Cell. 59:426–436. doi:10.1016/j.molcel.2015.06.018. 
Liu, H., S. Rankin, and H. Yu. 2013b. Phosphorylation-enabled binding of SGO1-
PP2A to cohesin protects sororin and centromeric cohesion during mitosis. 
Nature Cell Biology. 15:40–49. doi:10.1038/ncb2637. 
7.References 
		171	
Liu, S.-T., G.K.T. Chan, J.C. Hittle, G. Fujii, E. Lees, and T.J. Yen. 2003. Human 
MPS1 kinase is required for mitotic arrest induced by the loss of CENP-E from 
kinetochores. Mol. Biol. Cell. 14:1638–1651. doi:10.1091/mbc.02-05-0074. 
Liu, X., and M. Winey. 2012. The MPS1 family of protein kinases. Annu. Rev. 
Biochem. 81:561–585. doi:10.1146/annurev-biochem-061611-090435. 
Lodish, H., A. Berk, C.A. Kaiser, M. Krieger, M.P. Scott, A. Bretscher, H. Ploegh, 
and P. Matsudaira. 2012. Molecular Cell Biology. Macmillan Higher 
Education. 
London, N., and S. Biggins. 2014. Mad1 kinetochore recruitment by Mps1-
mediated phosphorylation of Bub1 signals the spindle checkpoint. Genes & 
Development. 28:140–152. doi:10.1101/gad.233700.113. 
London, N., S. Ceto, J.A. Ranish, and S. Biggins. 2012. Phosphoregulation of 
Spc105 by Mps1 and PP1 regulates Bub1 localization to kinetochores. Curr. 
Biol. 22:900–906. doi:10.1016/j.cub.2012.03.052. 
Losada, A. 2014. Cohesin in cancer: chromosome segregation and beyond. Nat. 
Rev. Cancer. 14:389–393. doi:10.1038/nrc3743. 
Maciejowski, J., K.A. George, M.-E. Terret, C. Zhang, K.M. Shokat, and P.V. 
Jallepalli. 2010. Mps1 directs the assembly of Cdc20 inhibitory complexes 
during interphase and mitosis to control M phase timing and spindle 
checkpoint signaling. The Journal of Cell Biology. 190:89–100. 
doi:10.1083/jcb.201001050. 
Maia, A.R.R., J. de Man, U. Boon, A. Janssen, J.-Y. Song, M. Omerzu, J.G. 
Sterrenburg, M.B.W. Prinsen, N. Willemsen-Seegers, J.A.D.M. de Roos, A.M. 
van Doornmalen, J.C.M. Uitdehaag, G.J.P.L. Kops, J. Jonkers, R.C. Buijsman, 
G.J.R. Zaman, and R.H. Medema. 2015. Inhibition of the spindle assembly 
checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative 
breast cancer model. Ann. Oncol. mdv293. doi:10.1093/annonc/mdv293. 
Malhotra, V., and M.C. Perry. 2003. Classical chemotherapy: mechanisms, 
toxicities and the therapeutic window. Cancer Biol. Ther. 2:S2–4. 
Malumbres, M., and M. Barbacid. 2009. Cell cycle, CDKs and cancer: a changing 
paradigm. Nat. Rev. Cancer. 9:153–166. doi:10.1038/nrc2602. 
Mapelli, M., F.V. Filipp, G. Rancati, L. Massimiliano, L. Nezi, G. Stier, R.S. Hagan, 
S. Confalonieri, S. Piatti, M. Sattler, and A. Musacchio. 2006. Determinants of 
conformational dimerization of Mad2 and its inhibition by p31comet. The 
EMBO Journal. 25:1273–1284. doi:10.1038/sj.emboj.7601033. 
7.References 
		172	
Mapelli, M., L. Massimiliano, S. Santaguida, and A. Musacchio. 2007. The Mad2 
conformational dimer: structure and implications for the spindle assembly 
checkpoint. Cell. 131:730–743. doi:10.1016/j.cell.2007.08.049. 
Martinez, R., A. Blasina, J.F. Hallin, W. Hu, I. Rymer, J. Fan, R.L. Hoffman, S. 
Murphy, M. Marx, G. Yanochko, D. Trajkovic, D. Dinh, S. Timofeevski, Z. Zhu, 
P. Sun, P.B. Lappin, and B.W. Murray. 2015. Mitotic Checkpoint Kinase Mps1 
Has a Role in Normal Physiology which Impacts Clinical Utility. PLoS ONE. 
10:e0138616. doi:10.1371/journal.pone.0138616. 
McEwen, B.F., G.K. Chan, B. Zubrowski, M.S. Savoian, M.T. Sauer, and T.J. Yen. 
2001. CENP-E is essential for reliable bioriented spindle attachment, but 
chromosome alignment can be achieved via redundant mechanisms in 
mammalian cells. Mol. Biol. Cell. 12:2776–2789. 
Meraldi, P., and P.K. Sorger. 2005. A dual role for Bub1 in the spindle checkpoint 
and chromosome congression. The EMBO Journal. 24:1621–1633. 
doi:10.1038/sj.emboj.7600641. 
Meraldi, P., V.M. Draviam, and P.K. Sorger. 2004. Timing and checkpoints in the 
regulation of mitotic progression. Developmental Cell. 7:45–60. 
doi:10.1016/j.devcel.2004.06.006. 
Michalski, A., J. Cox, and M. Mann. 2011. More than 100,000 detectable peptide 
species elute in single shotgun proteomics runs but the majority is inaccessible 
to data-dependent LC-MS/MS. J. Proteome Res. 10:1785–1793. 
doi:10.1021/pr101060v. 
Michel, L., E. Diaz-Rodriguez, G. Narayan, E. Hernando, V.V.V.S. Murty, and R. 
Benezra. 2004. Complete loss of the tumor suppressor MAD2 causes 
premature cyclin B degradation and mitotic failure in human somatic cells. 
Proc. Natl. Acad. Sci. U.S.A. 101:4459–4464. doi:10.1073/pnas.0306069101. 
Morgan, D.O. 2007. The Cell Cycle: Principles of Control. New Science Press Ltd., 
London. 
Morrow, C.J., A. Tighe, V.L. Johnson, M.I.F. Scott, C. Ditchfield, and S.S. Taylor. 
2005. Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of 
APC/CCdc20. Journal of Cell Science. 118:3639–3652. doi:10.1242/jcs.02487. 
Moyle, M.W., T. Kim, N. Hattersley, J. Espeut, D.K. Cheerambathur, K. Oegema, 
and A. Desai. 2014. A Bub1-Mad1 interaction targets the Mad1-Mad2 complex 
to unattached kinetochores to initiate the spindle checkpoint. The Journal of Cell 
Biology. 204:647–657. doi:10.1083/jcb.201311015. 
Musacchio, A. 2011. Spindle assembly checkpoint: the third decade. Philos. Trans. 
7.References 
		173	
R. Soc. Lond., B, Biol. Sci. 366:3595–3604. doi:10.1098/rstb.2011.0072. 
Musacchio, A., and E.D. Salmon. 2007. The spindle-assembly checkpoint in space 
and time. Nat. Rev. Mol. Cell Biol. 8:379–393. doi:10.1038/nrm2163. 
Musacchio, A., and K.G. Hardwick. 2002. The spindle checkpoint: structural 
insights into dynamic signalling. Nat. Rev. Mol. Cell Biol. 3:731–741. 
doi:10.1038/nrm929. 
Nagahara, H., R.R. Latek, S.A. Ezhevsky, and S.F. Dowdy. 1999. 2-D 
phosphopeptide mapping. Methods Mol. Biol. 112:271–279. 
Nasmyth, K. 2001. A prize for proliferation. Cell. 107:689–701. 
Nasmyth, K., and C.H. Haering. 2009. Cohesin: its roles and mechanisms. Annu. 
Rev. Genet. 43:525–558. doi:10.1146/annurev-genet-102108-134233. 
Nasmyth, K., J.M. Peters, and F. Uhlmann. 2000. Splitting the chromosome: cutting 
the ties that bind sister chromatids. Science. 288:1379–1385. 
Nezi, L., and A. Musacchio. 2009. Sister chromatid tension and the spindle 
assembly checkpoint. Curr. Opin. Cell Biol. 21:785–795. 
doi:10.1016/j.ceb.2009.09.007. 
Nigg, E.A. 2001. Mitotic kinases as regulators of cell division and its checkpoints. 
Nat. Rev. Mol. Cell Biol. 2:21–32. doi:10.1038/35048096. 
Nijenhuis, W., E. von Castelmur, D. Littler, V. De Marco, E. Tromer, M. Vleugel, 
M.H.J. van Osch, B. Snel, A. Perrakis, and G.J.P.L. Kops. 2013. A TPR domain-
containing N-terminal module of MPS1 is required for its kinetochore 
localization by Aurora B. The Journal of Cell Biology. 201:217–231. 
doi:10.1083/jcb.201210033. 
Nilsson, J., M. Yekezare, J. Minshull, and J. Pines. 2008. The APC/C maintains the 
spindle assembly checkpoint by targeting Cdc20 for destruction. Nature Cell 
Biology. 10:1411–1420. doi:10.1038/ncb1799. 
Nishiyama, T., M.M. Sykora, P.J. Huis in 't Veld, K. Mechtler, and J.-M. Peters. 
2013. Aurora B and Cdk1 mediate Wapl activation and release of acetylated 
cohesin from chromosomes by phosphorylating Sororin. Proc. Natl. Acad. Sci. 
U.S.A. 110:13404–13409. doi:10.1073/pnas.1305020110. 
Nishiyama, T., R. Ladurner, J. Schmitz, E. Kreidl, A. Schleiffer, V. Bhaskara, M. 
Bando, K. Shirahige, A.A. Hyman, K. Mechtler, and J.-M. Peters. 2010. Sororin 
mediates sister chromatid cohesion by antagonizing Wapl. Cell. 143:737–749. 
doi:10.1016/j.cell.2010.10.031. 
7.References 
		174	
Nyati, S., K. Schinske-Sebolt, S. Pitchiaya, K. Chekhovskiy, A. Chator, N. 
Chaudhry, J. Dosch, M.E. Van Dort, S. Varambally, C. Kumar-Sinha, M.K. 
Nyati, D. Ray, N.G. Walter, H. Yu, B.D. Ross, and A. Rehemtulla. 2015. The 
kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signaling. Sci 
Signal. 8:ra1–ra1. doi:10.1126/scisignal.2005379. 
Olsen, J.V., B. Macek, O. Lange, A. Makarov, S. Horning, and M. Mann. 2007. 
Higher-energy C-trap dissociation for peptide modification analysis. Nature 
Methods. 4:709–712. doi:10.1038/nmeth1060. 
Ong, S.-E., L.J. Foster, and M. Mann. 2003. Mass spectrometric-based approaches 
in quantitative proteomics. Methods. 29:124–130. 
Overlack, K., I. Primorac, M. Vleugel, V. Krenn, S. Maffini, I. Hoffmann, G.J.P.L. 
Kops, and A. Musacchio. 2015. A molecular basis for the differential roles of 
Bub1 and BubR1 in the spindle assembly checkpoint. eLife. 4:e05269. 
doi:10.7554/eLife.05269. 
Ozlu, N., B. Akten, W. Timm, N. Haseley, H. Steen, and J.A.J. Steen. 2010. 
Phosphoproteomics. Wiley Interdiscip Rev Syst Biol Med. 2:255–276. 
doi:10.1002/wsbm.41. 
Palumbo, A.M., J.J. Tepe, and G.E. Reid. 2008. Mechanistic insights into the 
multistage gas-phase fragmentation behavior of phosphoserine- and 
phosphothreonine-containing peptides. J. Proteome Res. 7:771–779. 
doi:10.1021/pr0705136. 
Paweletz, N. 2001. Walther Flemming: pioneer of mitosis research. 2. Nature 
Publishing Group. 4 pp. 
Perdiguero, E., and A.R. Nebreda. 2004. Regulation of Cdc25C activity during the 
meiotic G2/M transition. Cell Cycle. 3:733–737. 
Perera, D., and S.S. Taylor. 2010. Sgo1 establishes the centromeric cohesion 
protection mechanism in G2 before subsequent Bub1-dependent recruitment 
in mitosis. Journal of Cell Science. 123:653–659. doi:10.1242/jcs.059501. 
Perera, D., V. Tilston, J.A. Hopwood, M. Barchi, R.P. Boot-Handford, and S.S. 
Taylor. 2007. Bub1 maintains centromeric cohesion by activation of the spindle 
checkpoint. Developmental Cell. 13:566–579. doi:10.1016/j.devcel.2007.08.008. 
Peters, J.-M., and T. Nishiyama. 2012. Sister chromatid cohesion. Cold Spring Harb 
Perspect Biol. 4:a011130–a011130. doi:10.1101/cshperspect.a011130. 
Peters, J.M. 1999. Subunits and substrates of the anaphase-promoting complex. 
Experimental Cell Research. 248:339–349. doi:10.1006/excr.1999.4443. 
7.References 
		175	
Peterson, A.C., J.D. Russell, D.J. Bailey, M.S. Westphall, and J.J. Coon. 2012. 
Parallel reaction monitoring for high resolution and high mass accuracy 
quantitative, targeted proteomics. Mol. Cell Proteomics. 11:1475–1488. 
doi:10.1074/mcp.O112.020131. 
Petronczki, M., P. Lenart, and J.-M. Peters. 2008. Polo on the Rise-from Mitotic 
Entry to Cytokinesis with Plk1. Developmental Cell. 14:646–659. 
doi:10.1016/j.devcel.2008.04.014. 
Picotti, P., B. Bodenmiller, L.N. Mueller, B. Domon, and R. Aebersold. 2009. Full 
Dynamic Range Proteome Analysis of S. cerevisiae by Targeted Proteomics. 
Cell. 138:795–806. doi:10.1016/j.cell.2009.05.051. 
Pines, J. 2006. Mitosis: a matter of getting rid of the right protein at the right time. 
Trends in Cell Biology. 16:55–63. doi:10.1016/j.tcb.2005.11.006. 
Pines, J. 2011. Cubism and the cell cycle: the many faces of the APC/C. Nat. Rev. 
Mol. Cell Biol. 12:427–438. doi:10.1038/nrm3132. 
Pines, J., and C.L. Rieder. 2001. Re-staging mitosis: a contemporary view of mitotic 
progression. Nature Cell Biology. 3:E3–6. doi:10.1038/35050676. 
Pinsky, B.A., and S. Biggins. 2005. The spindle checkpoint: tension versus 
attachment. Trends in Cell Biology. 15:486–493. doi:10.1016/j.tcb.2005.07.005. 
Primorac, I., J.R. Weir, E. Chiroli, F. Gross, I. Hoffmann, S. van Gerwen, A. 
Ciliberto, and A. Musacchio. 2013. Bub3 reads phosphorylated MELT repeats 
to promote spindle assembly checkpoint signaling. eLife. 2:e01030. 
doi:10.7554/eLife.01030. 
Putkey, F.R., T. Cramer, M.K. Morphew, A.D. Silk, R.S. Johnson, J.R. McIntosh, 
and D.W. Cleveland. 2002. Unstable kinetochore-microtubule capture and 
chromosomal instability following deletion of CENP-E. Developmental Cell. 
3:351–365. 
Qi, W., and H. Yu. 2007. KEN-box-dependent degradation of the Bub1 spindle 
checkpoint kinase by the anaphase-promoting complex/cyclosome. J. Biol. 
Chem. 282:3672–3679. doi:10.1074/jbc.M609376200. 
Ricke, R.M., and J.M. van Deursen. 2011. Aurora B hyperactivation by Bub1 
overexpression promotes chromosome missegregation. Cell Cycle. 10:3645–
3651. doi:10.4161/cc.10.21.18156. 
Ricke, R.M., K.B. Jeganathan, L. Malureanu, A.M. Harrison, and J.M. van Deursen. 
2012. Bub1 kinase activity drives error correction and mitotic checkpoint 
control but not tumor suppression. The Journal of Cell Biology. 199:931–949. 
7.References 
		176	
doi:10.1083/jcb.201205115. 
Riedel, C.G., V.L. Katis, Y. Katou, S. Mori, T. Itoh, W. Helmhart, M. Galova, M. 
Petronczki, J. Gregan, B. Cetin, I. Mudrak, E. Ogris, K. Mechtler, L. Pelletier, F. 
Buchholz, K. Shirahige, and K. Nasmyth. 2006. Protein phosphatase 2A 
protects centromeric sister chromatid cohesion during meiosis I. Nature. 
441:53–61. doi:10.1038/nature04664. 
Rieder, C.L., R.W. Cole, A. Khodjakov, and G. Sluder. 1995. The checkpoint 
delaying anaphase in response to chromosome monoorientation is mediated 
by an inhibitory signal produced by unattached kinetochores. The Journal of 
Cell Biology. 130:941–948. 
Rischitor, P.E., K.M. May, and K.G. Hardwick. 2007. Bub1 is a fission yeast 
kinetochore scaffold protein, and is sufficient to recruit other spindle 
checkpoint proteins to ectopic sites on chromosomes. PLoS ONE. 2:e1342. 
doi:10.1371/journal.pone.0001342. 
Roberts, B.T., K.A. Farr, and M.A. Hoyt. 1994. The Saccharomyces cerevisiae 
checkpoint gene BUB1 encodes a novel protein kinase. Molecular and Cellular 
Biology. 14:8282–8291. 
Rodriguez-Bravo, V., J. Maciejowski, J. Corona, H.K. Buch, P. Collin, M.T. 
Kanemaki, J.V. Shah, and P.V. Jallepalli. 2014. Nuclear pores protect genome 
integrity by assembling a premitotic and Mad1-dependent anaphase inhibitor. 
Cell. 156:1017–1031. doi:10.1016/j.cell.2014.01.010. 
Rogers, L.D., and L.J. Foster. 2009. Phosphoproteomics—finally fulfilling the 
promise? Molecular BioSystems. 5:1122–1129. doi:10.1039/B905580K. 
Sacristan, C., and G.J.P.L. Kops. 2015. Joined at the hip: kinetochores, 
microtubules, and spindle assembly checkpoint signaling. Trends in Cell 
Biology. 25:21–28. doi:10.1016/j.tcb.2014.08.006. 
Salmela, A.-L., and M.J. Kallio. 2013. Mitosis as an anti-cancer drug target. 
Chromosoma. 122:431–449. doi:10.1007/s00412-013-0419-8. 
Sandhu, C., J.A. Hewel, G. Badis, S. Talukder, J. Liu, T.R. Hughes, and A. Emili. 
2008. Evaluation of data-dependent versus targeted shotgun proteomic 
approaches for monitoring transcription factor expression in breast cancer. J. 
Proteome Res. 7:1529–1541. doi:10.1021/pr700836q. 
Santaguida, S., A. Tighe, A.M. D'Alise, S.S. Taylor, and A. Musacchio. 2010. 
Dissecting the role of MPS1 in chromosome biorientation and the spindle 
checkpoint through the small molecule inhibitor reversine. The Journal of Cell 
Biology. 190:73–87. doi:10.1083/jcb.201001036. 
7.References 
		177	
Santaguida, S., and A. Musacchio. 2009. The life and miracles of kinetochores. The 
EMBO Journal. 28:2511–2531. doi:10.1038/emboj.2009.173. 
Santaguida, S., C. Vernieri, F. Villa, A. Ciliberto, and A. Musacchio. 2011. Evidence 
that Aurora B is implicated in spindle checkpoint signalling independently of 
error correction. The EMBO Journal. 30:1508–1519. doi:10.1038/emboj.2011.70. 
Santamaria, A., B. Wang, S. Elowe, R. Malik, F. Zhang, M. Bauer, A. Schmidt, 
H.H.W. Silljé, R. Körner, and E.A. Nigg. 2011. The Plk1-dependent 
phosphoproteome of the early mitotic spindle. Mol. Cell Proteomics. 
10:M110.004457–M110.004457. doi:10.1074/mcp.M110.004457. 
Santamaria, A., R. Neef, U. Eberspächer, K. Eis, M. Husemann, D. Mumberg, S. 
Prechtl, V. Schulze, G. Siemeister, L. Wortmann, F.A. Barr, and E.A. Nigg. 
2007. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions 
of Plk1 in early and late stages of mitosis. Mol. Biol. Cell. 18:4024–4036. 
doi:10.1091/mbc.E07-05-0517. 
Saurin, A.T., M.S. van der Waal, R.H. Medema, S.M.A. Lens, and G.J.P.L. Kops. 
2011. Aurora B potentiates Mps1 activation to ensure rapid checkpoint 
establishment at the onset of mitosis. Nat Commun. 2:316. 
doi:10.1038/ncomms1319. 
Savitski, M.M., F. Fischer, T. Mathieson, G. Sweetman, M. Lang, and M. 
Bantscheff. 2010. Targeted data acquisition for improved reproducibility and 
robustness of proteomic mass spectrometry assays. J. Am. Soc. Mass Spectrom. 
21:1668–1679. doi:10.1016/j.jasms.2010.01.012. 
Schaar, B.T., G.K. Chan, P. Maddox, E.D. Salmon, and T.J. Yen. 1997. CENP-E 
function at kinetochores is essential for chromosome alignment. The Journal of 
Cell Biology. 139:1373–1382. 
Schmidt, A., M. Claassen, and R. Aebersold. 2009. Directed mass spectrometry: 
towards hypothesis-driven proteomics. Curr Opin Chem Biol. 13:510–517. 
doi:10.1016/j.cbpa.2009.08.016. 
Schmidt, A., N. Gehlenborg, B. Bodenmiller, L.N. Mueller, D. Campbell, M. 
Mueller, R. Aebersold, and B. Domon. 2008. An integrated, directed mass 
spectrometric approach for in-depth characterization of complex peptide 
mixtures. Mol. Cell Proteomics. 7:2138–2150. doi:10.1074/mcp.M700498-MCP200. 
Schmit, T.L., and N. Ahmad. 2007. Regulation of mitosis via mitotic kinases: new 
opportunities for cancer management. Mol. Cancer Ther. 6:1920–1931. 
doi:10.1158/1535-7163.MCT-06-0781. 
Schmitz, J., E. Watrin, P. Lenart, K. Mechtler, and J.-M. Peters. 2007. Sororin Is 
7.References 
		178	
Required for Stable Binding of Cohesin to Chromatin and for Sister Chromatid 
Cohesion in Interphase. Current Biology. 17:630–636. 
doi:10.1016/j.cub.2007.02.029. 
Scholey, J.M., I. Brust-Mascher, and A. Mogilner. 2003. Cell division. Nature. 
422:746–752. doi:10.1038/nature01599. 
Schubert, O.T., L.C. Gillet, B.C. Collins, P. Navarro, G. Rosenberger, W.E. Wolski, 
H. Lam, D. Amodei, P. Mallick, B. MacLean, and R. Aebersold. 2015a. Building 
high-quality assay libraries for targeted analysis of SWATH MS data. Nat 
Protoc. 10:426–441. doi:10.1038/nprot.2015.015. 
Schubert, von, C., and E.A. Nigg. 2013. Polo-like kinases. Curr. Biol. 23:R225–7. 
doi:10.1016/j.cub.2013.01.066. 
Schubert, von, C., F. Cubizolles, J.M. Bracher, T. Sliedrecht, G.J.P.L. Kops, and E.A. 
Nigg. 2015b. Plk1 and Mps1 Cooperatively Regulate the Spindle Assembly 
Checkpoint in Human Cells. Cell Rep. doi:10.1016/j.celrep.2015.06.007. 
SCIEX. 2012. MS/MS ALL with SWATH Acquisition. 
https://www.youtube.comwatchvVZAZtAqEbg. 
Sebastian, B., A. Kakizuka, and T. Hunter. 1993. Cdc25M2 activation of cyclin-
dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. 
Proc. Natl. Acad. Sci. U.S.A. 90:3521–3524. doi:10.1073/pnas.90.8.3521. 
Sharp-Baker, H., and R.H. Chen. 2001. Spindle checkpoint protein Bub1 is 
required for kinetochore localization of Mad1, Mad2, Bub3, and CENP-E, 
independently of its kinase activity. The Journal of Cell Biology. 153:1239–1250. 
Shepperd, L.A., J.C. Meadows, A.M. Sochaj, T.C. Lancaster, J. Zou, G.J. Buttrick, J. 
Rappsilber, K.G. Hardwick, and J.B.A. Millar. 2012. Phosphodependent 
recruitment of Bub1 and Bub3 to Spc7/KNL1 by Mph1 kinase maintains the 
spindle checkpoint. Curr. Biol. 22:891–899. doi:10.1016/j.cub.2012.03.051. 
Sherrod, S.D., M.V. Myers, M. Li, J.S. Myers, K.L. Carpenter, B. MacLean, M.J. 
MacCoss, D.C. Liebler, and A.-J.L. Ham. 2012. Label-free quantitation of 
protein modifications by pseudo selected reaction monitoring with internal 
reference peptides. J. Proteome Res. 11:3467–3479. doi:10.1021/pr201240a. 
Silljé, H.H.W., S. Nagel, R. Körner, and E.A. Nigg. 2006. HURP is a Ran-importin 
beta-regulated protein that stabilizes kinetochore microtubules in the vicinity 
of chromosomes. Current Biology. 16:731–742. doi:10.1016/j.cub.2006.02.070. 
Skotheim, J.M., S. Di Talia, E.D. Siggia, and F.R. Cross. 2008. Positive feedback of 
G1 cyclins ensures coherent cell cycle entry. Nature. 454:291–296. 
7.References 
		179	
doi:10.1038/nature07118. 
Sliedrecht, T., C. Zhang, K.M. Shokat, and G.J.P.L. Kops. 2010. Chemical genetic 
inhibition of Mps1 in stable human cell lines reveals novel aspects of Mps1 
function in mitosis. PLoS ONE. 5:e10251. doi:10.1371/journal.pone.0010251. 
Steen, H., J.A. Jebanathirajah, J. Rush, N. Morrice, and M.W. Kirschner. 2006. 
Phosphorylation analysis by mass spectrometry: myths, facts, and the 
consequences for qualitative and quantitative measurements. Mol. Cell 
Proteomics. 5:172–181. doi:10.1074/mcp.M500135-MCP200. 
Stucke, V.M., H.H.W. Silljé, L. Arnaud, and E.A. Nigg. 2002. Human Mps1 kinase 
is required for the spindle assembly checkpoint but not for centrosome 
duplication. The EMBO Journal. 21:1723–1732. doi:10.1093/emboj/21.7.1723. 
Sudakin, V., G.K. Chan, and T.J. Yen. 2001. Checkpoint inhibition of the APC/C in 
HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. The 
Journal of Cell Biology. 154:925–936. doi:10.1083/jcb.200102093. 
Suijkerbuijk, S.J.E., M. Vleugel, A. Teixeira, and G.J.P.L. Kops. 2012a. Integration 
of kinase and phosphatase activities by BUBR1 ensures formation of stable 
kinetochore-microtubule attachments. Developmental Cell. 23:745–755. 
doi:10.1016/j.devcel.2012.09.005. 
Suijkerbuijk, S.J.E., T.J.P. van Dam, G.E. Karagöz, E. von Castelmur, N.C. Hubner, 
A.M.S. Duarte, M. Vleugel, A. Perrakis, S.G.D. Rüdiger, B. Snel, and G.J.P.L. 
Kops. 2012b. The vertebrate mitotic checkpoint protein BUBR1 is an unusual 
pseudokinase. Developmental Cell. 22:1321–1329. 
doi:10.1016/j.devcel.2012.03.009. 
Sumara, I., E. Vorlaufer, P.T. Stukenberg, O. Kelm, N. Redemann, E.A. Nigg, and 
J.-M. Peters. 2002. The dissociation of cohesin from chromosomes in prophase 
is regulated by Polo-like kinase. Molecular Cell. 9:515–525. 
Tang, Z., H. Shu, D. Oncel, S. Chen, and H. Yu. 2004a. Phosphorylation of Cdc20 
by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle 
checkpoint. Molecular Cell. 16:387–397. doi:10.1016/j.molcel.2004.09.031. 
Tang, Z., H. Shu, W. Qi, N.A. Mahmood, M.C. Mumby, and H. Yu. 2006. PP2A is 
required for centromeric localization of Sgo1 and proper chromosome 
segregation. Developmental Cell. 10:575–585. doi:10.1016/j.devcel.2006.03.010. 
Tang, Z., Y. Sun, S.E. Harley, H. Zou, and H. Yu. 2004b. Human Bub1 protects 
centromeric sister-chromatid cohesion through Shugoshin during mitosis. 
Proc. Natl. Acad. Sci. U.S.A. 101:18012–18017. doi:10.1073/pnas.0408600102. 
7.References 
		180	
Tanno, Y., T.S. Kitajima, T. Honda, Y. Ando, K.-I. Ishiguro, and Y. Watanabe. 2010. 
Phosphorylation of mammalian Sgo2 by Aurora B recruits PP2A and MCAK 
to centromeres. Genes & Development. 24:2169–2179. doi:10.1101/gad.1945310. 
Tannous, B.A., M. Kerami, P.M. Van der Stoop, N. Kwiatkowski, J. Wang, W. 
Zhou, A.F. Kessler, G. Lewandrowski, L. Hiddingh, N. Sol, T. Lagerweij, L. 
Wedekind, J.M. Niers, M. Barazas, R.J.A. Nilsson, D. Geerts, P.C. De Witt 
Hamer, C. Hagemann, W.P. Vandertop, O. Van Tellingen, D.P. Noske, N.S. 
Gray, and T. Würdinger. 2013. Effects of the selective MPS1 inhibitor MPS1-
IN-3 on glioblastoma sensitivity to antimitotic drugs. J. Natl. Cancer Inst. 
105:1322–1331. doi:10.1093/jnci/djt168. 
Tanudji, M., J. Shoemaker, L. L'Italien, L. Russell, G. Chin, and X.M. Schebye. 2004. 
Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to 
missegregation of chromosomes after a mitotic delay. Mol. Biol. Cell. 15:3771–
3781. doi:10.1091/mbc.E03-07-0482. 
Tao, Y., C. Leteur, J. Calderaro, F. Girdler, P. Zhang, V. Frascogna, M. Varna, P. 
Opolon, M. Castedo, J. Bourhis, G. Kroemer, and E. Deutsch. 2009. The aurora 
B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation 
and induces mitotic catastrophe. Cell Cycle. 8:3172–3181. 
Tardif, K.D., A. Rogers, J. Cassiano, B.L. Roth, D.M. Cimbora, R. McKinnon, A. 
Peterson, T.B. Douce, R. Robinson, I. Dorweiler, T. Davis, M.A. Hess, K. 
Ostanin, D.I. Papac, V. Baichwal, I. McAlexander, J.A. Willardsen, M. 
Saunders, H. Christophe, D.V. Kumar, D.A. Wettstein, R.O. Carlson, and B.L. 
Williams. 2011. Characterization of the cellular and antitumor effects of MPI-
0479605, a small-molecule inhibitor of the mitotic kinase Mps1. Mol. Cancer 
Ther. 10:2267–2275. doi:10.1158/1535-7163.MCT-11-0453. 
Taylor, S., and J.-M. Peters. 2008. Polo and Aurora kinases—lessons derived from 
chemical biology. Curr. Opin. Cell Biol. 20:77–84. doi:10.1016/j.ceb.2007.11.008. 
Taylor, S.S., and F. McKeon. 1997. Kinetochore localization of murine Bub1 is 
required for normal mitotic timing and checkpoint response to spindle 
damage. Cell. 89:727–735. 
Taylor, S.S., E. Ha, and F. McKeon. 1998. The human homologue of Bub3 is 
required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein 
kinase. The Journal of Cell Biology. 142:1–11. 
Thingholm, T.E., and M.R. Larsen. 2009. The use of titanium dioxide micro-
columns to selectively isolate phosphopeptides from proteolytic digests. 
Methods Mol. Biol. 527:57–66– xi. doi:10.1007/978-1-60327-834-8_5. 
7.References 
		181	
Tighe, A., O. Staples, and S. Taylor. 2008. Mps1 kinase activity restrains anaphase 
during an unperturbed mitosis and targets Mad2 to kinetochores. The Journal 
of Cell Biology. 181:893–901. doi:10.1083/jcb.200712028. 
Trost, B., and A. Kusalik. 2011. Computational prediction of eukaryotic 
phosphorylation sites. Bioinformatics. 27:2927–2935. 
doi:10.1093/bioinformatics/btr525. 
Tsukahara, T., Y. Tanno, and Y. Watanabe. 2010. Phosphorylation of the CPC by 
Cdk1 promotes chromosome bi-orientation. Nature. 467:719–723. 
doi:10.1038/nature09390. 
Ulintz, P.J., A.K. Yocum, B. Bodenmiller, R. Aebersold, P.C. Andrews, and A.I. 
Nesvizhskii. 2009. Comparison of MS(2)-only, MSA, and MS(2)/MS(3) 
methodologies for phosphopeptide identification. J. Proteome Res. 8:887–899. 
doi:10.1021/pr800535h. 
van der Geer, P., and T. Hunter. 1994. Phosphopeptide mapping and 
phosphoamino acid analysis by electrophoresis and chromatography on thin-
layer cellulose plates. Electrophoresis. 15:544–554. 
van der Waal, M.S., A.T. Saurin, M.J.M. Vromans, M. Vleugel, C. Wurzenberger, 
D.W. Gerlich, R.H. Medema, G.J.P.L. Kops, and S.M.A. Lens. 2012. Mps1 
promotes rapid centromere accumulation of Aurora B. Nature Publishing 
Group. 13:847–854. doi:10.1038/embor.2012.93. 
Vassilev, L.T., C. Tovar, S. Chen, D. Knezevic, X. Zhao, H. Sun, D.C. Heimbrook, 
and L. Chen. 2006. Selective small-molecule inhibitor reveals critical mitotic 
functions of human CDK1. Proc. Natl. Acad. Sci. U.S.A. 103:10660–10665. 
doi:10.1073/pnas.0600447103. 
Vermeulen, K., D.R. Van Bockstaele, and Z.N. Berneman. 2003. The cell cycle: a 
review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 
36:131–149. 
Villén, J., S.A. Beausoleil, and S.P. Gygi. 2008. Evaluation of the utility of neutral-
loss-dependent MS3 strategies in large-scale phosphorylation analysis. 
Proteomics. 8:4444–4452. doi:10.1002/pmic.200800283. 
Vitale, I., L. Galluzzi, M. Castedo, and G. Kroemer. 2011. Mitotic catastrophe: a 
mechanism for avoiding genomic instability. Nat. Rev. Mol. Cell Biol. 12:385–
392. doi:10.1038/nrm3115. 
Vleugel, M., E. Hoogendoorn, B. Snel, and G.J.P.L. Kops. 2012. Evolution and 
function of the mitotic checkpoint. Developmental Cell. 23:239–250. 
doi:10.1016/j.devcel.2012.06.013. 
7.References 
		182	
Vleugel, M., E. Tromer, M. Omerzu, V. Groenewold, W. Nijenhuis, B. Snel, and 
G.J.P.L. Kops. 2013. Arrayed BUB recruitment modules in the kinetochore 
scaffold KNL1 promote accurate chromosome segregation. The Journal of Cell 
Biology. 203:943–955. doi:10.1083/jcb.201307016. 
Waizenegger, I.C., S. Hauf, A. Meinke, and J.M. Peters. 2000. Two distinct 
pathways remove mammalian cohesin from chromosome arms in prophase 
and from centromeres in anaphase. Cell. 103:399–410. 
Walczak, C.E., S. Cai, and A. Khodjakov. 2010. Mechanisms of chromosome 
behaviour during mitosis. Nat. Rev. Mol. Cell Biol. 11:91–102. 
doi:10.1038/nrm2832. 
Wang, F., J. Dai, J.R. Daum, E. Niedzialkowska, B. Banerjee, P.T. Stukenberg, G.J. 
Gorbsky, and J.M.G. Higgins. 2010. Histone H3 Thr-3 phosphorylation by 
Haspin positions Aurora B at centromeres in mitosis. Science. 330:231–235. 
doi:10.1126/science.1189435. 
Wang, F., N.P. Ulyanova, M.S. van der Waal, D. Patnaik, S.M.A. Lens, and J.M.G. 
Higgins. 2011. A positive feedback loop involving Haspin and Aurora B 
promotes CPC accumulation at centromeres in mitosis. Curr. Biol. 21:1061–
1069. doi:10.1016/j.cub.2011.05.016. 
Warren, C.D., D.M. Brady, R.C. Johnston, J.S. Hanna, K.G. Hardwick, and F.A. 
Spencer. 2002. Distinct chromosome segregation roles for spindle checkpoint 
proteins. Mol. Biol. Cell. 13:3029–3041. doi:10.1091/mbc.E02-04-0203. 
Weaver, B.A.A., and D.W. Cleveland. 2006. Does aneuploidy cause cancer? Curr. 
Opin. Cell Biol. 18:658–667. doi:10.1016/j.ceb.2006.10.002. 
Westhorpe, F.G., A. Tighe, P. Lara-Gonzalez, and S.S. Taylor. 2011. p31comet-
mediated extraction of Mad2 from the MCC promotes efficient mitotic exit. 
Journal of Cell Science. 124:3905–3916. doi:10.1242/jcs.093286. 
Windecker, H., M. Langegger, S. Heinrich, and S. Hauf. 2009. Bub1 and Bub3 
promote the conversion from monopolar to bipolar chromosome attachment 
independently of shugoshin. Nature Publishing Group. 10:1022–1028. 
doi:10.1038/embor.2009.183. 
Wollman, R., E.N. Cytrynbaum, J.T. Jones, T. Meyer, J.M. Scholey, and A. 
Mogilner. 2005. Efficient chromosome capture requires a bias in the “search-
and-capture” process during mitotic-spindle assembly. Current Biology. 15:828–
832. doi:10.1016/j.cub.2005.03.019. 
Wong, J.W.H., and G. Cagney. 2010. An overview of label-free quantitation 
methods in proteomics by mass spectrometry. Methods Mol. Biol. 604:273–283. 
7.References 
		183	
doi:10.1007/978-1-60761-444-9_18. 
Wurzenberger, C., and D.W. Gerlich. 2011. Phosphatases: providing safe passage 
through mitotic exit. Nat. Rev. Mol. Cell Biol. 12:469–482. doi:10.1038/nrm3149. 
Xu, P., E.A. Raetz, M. Kitagawa, D.M. Virshup, and S.H. Lee. 2013. BUBR1 recruits 
PP2A via the B56 family of targeting subunits to promote chromosome 
congression. Biol Open. 2:479–486. doi:10.1242/bio.20134051. 
Yamagishi, Y., C.-H. Yang, Y. Tanno, and Y. Watanabe. 2012. MPS1/Mph1 
phosphorylates the kinetochore protein KNL1/Spc7 to recruit SAC 
components. Nature Cell Biology. 14:746–752. doi:10.1038/ncb2515. 
Yamagishi, Y., T. Honda, Y. Tanno, and Y. Watanabe. 2010. Two histone marks 
establish the inner centromere and chromosome bi-orientation. Science. 
330:239–243. doi:10.1126/science.1194498. 
Yamaguchi, S., A. Decottignies, and P. Nurse. 2003. Function of Cdc2p-dependent 
Bub1p phosphorylation and Bub1p kinase activity in the mitotic and meiotic 
spindle checkpoint. The EMBO Journal. 22:1075–1087. 
doi:10.1093/emboj/cdg100. 
Yang, C., H. Wang, Y. Xu, K.L. Brinkman, H. Ishiyama, S.T.C. Wong, and B. Xu. 
2012. The kinetochore protein Bub1 participates in the DNA damage response. 
DNA Repair (Amst.). 11:185–191. doi:10.1016/j.dnarep.2011.10.018. 
Yang, Z., A.E. Kenny, D.A. Brito, and C.L. Rieder. 2009. Cells satisfy the mitotic 
checkpoint in Taxol, and do so faster in concentrations that stabilize syntelic 
attachments. The Journal of Cell Biology. 186:675–684. doi:10.1083/jcb.200906150. 
Yang, Z., U.S. Tulu, P. Wadsworth, and C.L. Rieder. 2007. Kinetochore dynein is 
required for chromosome motion and congression independent of the spindle 
checkpoint. Current Biology. 17:973–980. doi:10.1016/j.cub.2007.04.056. 
Yue, Z., A. Carvalho, Z. Xu, X. Yuan, S. Cardinale, S. Ribeiro, F. Lai, H. Ogawa, E. 
Gudmundsdottir, R. Gassmann, C.G. Morrison, S. Ruchaud, and W.C. 
Earnshaw. 2008. Deconstructing Survivin: comprehensive genetic analysis of 
Survivin function by conditional knockout in a vertebrate cell line. The Journal 
of Cell Biology. 183:279–296. doi:10.1083/jcb.200806118. 
Zeitlin, S.G., R.D. Shelby, and K.F. Sullivan. 2001. CENP-A is phosphorylated by 
Aurora B kinase and plays an unexpected role in completion of cytokinesis. 
The Journal of Cell Biology. 155:1147–1157. doi:10.1083/jcb.200108125. 
Zhang, G., T. Lischetti, and J. Nilsson. 2014. A minimal number of MELT repeats 
supports all the functions of KNL1 in chromosome segregation. Journal of Cell 
7.References 
		184	
Science. 127:871–884. doi:10.1242/jcs.139725. 
Zhang, J., X. Shi, Y. Li, B.-J. Kim, J. Jia, Z. Huang, T. Yang, X. Fu, S.Y. Jung, Y. 
Wang, P. Zhang, S.-T. Kim, X. Pan, and J. Qin. 2008. Acetylation of Smc3 by 
Eco1 is required for S phase sister chromatid cohesion in both human and 
yeast. Molecular Cell. 31:143–151. doi:10.1016/j.molcel.2008.06.006. 
Zhang, X., W. Lan, S.C. Ems-McClung, P.T. Stukenberg, and C.E. Walczak. 2007. 
Aurora B phosphorylates multiple sites on mitotic centromere-associated 
kinesin to spatially and temporally regulate its function. Mol. Biol. Cell. 
18:3264–3276. doi:10.1091/mbc.E07-01-0086. 
Zi, J., S. Zhang, R. Zhou, B. Zhou, S. Xu, G. Hou, F. Tan, B. Wen, Q. Wang, L. Lin, 
and S. Liu. 2014. Expansion of the ion library for mining SWATH-MS data 
through fractionation proteomics. Anal. Chem. 86:7242–7246. 
doi:10.1021/ac501828a. 
 
 		185	
Curriculum Vitae 
Anna Pauline Baron 
 
 
Email anna.baron@gmx.ch 
Date of birth March 6th, 1987 
Nationality German 
 
 
 
Professional Experience 
 
03/2012 – 12/2015 Researcher in the field of cell biology 
Biozentrum, University of Basel, Switzerland, Laboratory of Prof. Dr. 
Erich A. Nigg 
– Field of research:  molecular biology and cell biology 
– understanding of cell proliferation regulatory mechanisms, 
essential processes deregulated in cancer, with a particular 
focus on chromosome segregation 
 
2010-2011 Research Fellow (Postgraduate) 
Biozentrum, University of Basel, Switzerland, Laboratory of Prof. Dr. 
Erich A. Nigg 
− Field of research:  molecular biology and cell biology 
− introduction into the analysis of the cell proteome using mass 
spectrometry 
   
 
Education 
 
05/2012 – 12/2015 Doctor of Philosophy in Cell Biology 
 Fellowships for Excellence International PhD Program 
 Biozentrum, University of Basel, Switzerland 
Thesis Title: On the Regulation of Chromosome Segregation in Human 
Cells – Implications of Bub1 Kinase Inhibition During Cell Division 
 
 
09/2010 – 11/2011 Master of Science in Cell Biology 
 Biozentrum, University of Basel, Switzerland 
Thesis Title: Elucidating the role of Mad1 Phosphorylation in the 
context of the spindle assembly checkpoint  
 
10/2006 – 07/2009 Bachelor of Science in Biology, Major in Molecular Biology 
 University of Basel, Switzerland 
 
09/2003-07/2006  German University Entrance Qualification, Abitur 
 Ernährungswissenschaftliches Gymnasium, Lörrach, Germany         
 Focus on biochemistry, physiology and molecular biology  
 
 
 
 		186	
Extracurricular Activities 
 
05/2012 – 07/2015 PhD Student Representative board member 
 Secretary of PhD Student Representative board 
 Organization of PhD Talk series 
 
02/2015 Project-Management – An introduction 
 2-day course by SPOL AG 
 
05/2015 Project Management 
3-day course organized by RUPPLI + PARTNER AG and Advanced 
Studies of the University of Basel 
 
06/2013 – 06/2014 Fellowships for Excellence Symposium 2014 
 Basel, Switzerland 
 Organizing Committee Member 
 
2012 Swiss Proteomics Society – PhD Student Symposium 2012 
 Basel, Switzerland 
  Organizing Committee Member 
 
 
Award & Scholarship 
 
2012 – 2015 Selected Fellow of the Fellowships for Excellence International PhD 
Program - providing support in terms of travel grants, access to 
scientific and soft skill workshops and salary  
 
Publications 
 
2015 Baron AP., von Schubert C., Cubizolles F., Siemeister G., Hitchcock M., 
Mengel A., Schr.der J., Fernández-Montalvan A., von Nussbaum F., 
Mumberg D., Nigg EA. Probing the catalytic functions of Bub1 kinase using 
the small molecule inhibitors BAY-320 and BAY-524. – Under revision in 
eLife 
 
2015 Bauer M.*, Ahrné E.*, Baron A.P.*, Glatter T., Fava L.L., Santamaria, S., 
Nigg E.A., Schmidt A. Assessment of current mass spectrometric workflows 
for the quantification of low abundant proteins and phosphorylation sites. – 
Data in Brief 
 *These authors contributed equally to this work 
 
2014 Bauer M.*, Ahrné E.*, Baron A.P.*, Glatter T., Fava L.L., Santamaria, S., 
Nigg E.A., Schmidt A. Evaluation of data-dependent and data-independent 
mass spectrometric workflows for sensitive quantification of proteins and 
phosphorylation sites. – Journal of Proteome Research  
 *These authors contributed equally to this work 
 
 
 
 
 	187	
Acknowledgements 
 
This work would not have been possible without the guidance, help and 
support of several individuals, who in one way or another contributed in the 
preparation and completion of this study. 
I would like to thank Prof. Erich Nigg for giving me the opportunity to be a 
member of his laboratory and to work in such a stimulating research context. I 
also thank him for his guidance, input, patience and the freedom he gave me in 
conducting scientific research. 
I am grateful to Prof. Christoph Handschin and Prof. Michel Steinmetz for 
taking part in my PhD Advisory Committee and for their input.  
Very special thanks go to Dr. Conrad von Schubert. You have been a great 
supervisor and a constant source of help. Thank you for all your help while 
preparing the Bub1 manuscript. To all the past and present members of the lab, 
especially the ‘mitosis lab’: Ana Amaro-Meyer, Cristina Viganó, Patrick Redli, 
Conrad von Schubert and Anna Santamaria. Thanks for sharing all the challenges 
that have been faced while working with the ‘spindle assembly checkpoint’ and all 
the discussions we have had. Also to the other members of the lab: Elena Nigg, 
Dominik Schnerch, Christian Arquint, Anna-Maria Gabryjonczyk, Fabien 
Cubizolles, Olivier Ganier, Agathe Morand, Nadine Iberl, Lukas Cajanek, Manuel 
Bauer and Katharina Sonnen. It was a pleasure to work with all of you. 
Thanks to all the members of the Proteomics Core Facility, especially 
Alexander Schmidt. Thanks for all the data analysis and for your patient 
explanations. It was much appreciated.  
Moreover, I am grateful to the Fellowships for Excellence program and the 
Werner von Siemens Foundation for funding and for providing so many 
opportunities to network. 
I would also thank all people at BAYER Pharma AG that were involved in 
the -Bub1 inhibitor project-, especially Dr. Gerhard Siemeister for a successful 
 	188	
collaboration. 
My dearest gratitude goes to my family and friends. I would like to thank my 
parents, my sister Agi, Timon, Ilaria, Stefan, Loïc, Anjana, Anna, Daniele, Vanja, 
Pavlina and Mario. You have been a constant source of support and 
encouragement throughout my studies. Thank you for all the fun moments, for 
sharing the ‘ups and downs’ of a PhD life and for your confidence in me! You are 
great! 
  
 	189	
 
